<SEC-DOCUMENT>0000947871-20-000458.txt : 20200513
<SEC-HEADER>0000947871-20-000458.hdr.sgml : 20200513
<ACCEPTANCE-DATETIME>20200513170147
ACCESSION NUMBER:		0000947871-20-000458
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20200511
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200513
DATE AS OF CHANGE:		20200513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			QUEST DIAGNOSTICS INC
		CENTRAL INDEX KEY:			0001022079
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				161387862
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12215
		FILM NUMBER:		20874021

	BUSINESS ADDRESS:	
		STREET 1:		500 PLAZA DRIVE
		CITY:			SECAUCUS
		STATE:			NJ
		ZIP:			07094
		BUSINESS PHONE:		9735202700

	MAIL ADDRESS:	
		STREET 1:		500 PLAZA DRIVE
		CITY:			SECAUCUS
		STATE:			NJ
		ZIP:			07094

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CORNING CLINICAL LABORATORIES INC
		DATE OF NAME CHANGE:	19960903
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ss173511_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:DGX="http://DGX/20200511">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" /></head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_035_DGX_DGX_20200511 -->
<!-- Field: Set; Name: xdx; ID: xdx_049_20200511_20200511 -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0001022079 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body>
<div style="display: none">
<ix:header>
  <ix:hidden>
    <ix:nonNumeric contextRef="From2020-05-11to2020-05-11" name="dei:EntityCentralIndexKey">0001022079</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-05-11to2020-05-11" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    </ix:hidden>
  <ix:references>
    <link:schemaRef xlink:href="dgx-20200511.xsd" xlink:type="simple" />
    </ix:references>
  <ix:resources>
    <xbrli:context id="From2020-05-11to2020-05-11">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-11</xbrli:startDate>
        <xbrli:endDate>2020-05-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    </ix:resources>
  </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; font-size: 1pt; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WASHINGTON, DC 20549</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 100%; font: 10pt Times New Roman, Times, Serif; padding: 1.1pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_905_edei--DocumentType_c20200511__20200511_zKPsc5brXsNg"><ix:nonNumeric contextRef="From2020-05-11to2020-05-11" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 100%; font: 10pt Times New Roman, Times, Serif; padding: 1.1pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT PURSUANT TO SECTION 13
OR 15(d) OF</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>THE SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report</b> (Date of Earliest
Event Reported)<b>: <span id="xdx_903_edei--DocumentPeriodEndDate_c20200511__20200511_znXMGd166oi5"><ix:nonNumeric contextRef="From2020-05-11to2020-05-11" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">May 11, 2020</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 100%; font: 10pt Times New Roman, Times, Serif; padding: 1.1pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0pt; text-align: center"><b><span id="xdx_90B_edei--EntityRegistrantName_c20200511__20200511_zFPqyXRUst0k"><ix:nonNumeric contextRef="From2020-05-11to2020-05-11" name="dei:EntityRegistrantName">Quest Diagnostics Incorporated</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in
Its Charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 100%; font: 10pt Times New Roman, Times, Serif; padding: 1.1pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0pt; text-align: center"><b><span id="xdx_90F_edei--EntityIncorporationStateCountryCode_c20200511__20200511_zgDvPbwwEZze"><ix:nonNumeric contextRef="From2020-05-11to2020-05-11" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of incorporation)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="padding: 1.1pt; width: 39%; text-align: center"><b><span id="xdx_90A_edei--EntityFileNumber_c20200511__20200511_zRTBnhg3ZnOh"><ix:nonNumeric contextRef="From2020-05-11to2020-05-11" name="dei:EntityFileNumber">001-12215</ix:nonNumeric></span></b></td>
    <td style="padding: 1.1pt; width: 20%">&#160;</td>
    <td style="padding: 1.1pt; width: 41%; text-align: center"><b><span id="xdx_90A_edei--EntityTaxIdentificationNumber_c20200511__20200511_zJFbaXNxSnR4"><ix:nonNumeric contextRef="From2020-05-11to2020-05-11" name="dei:EntityTaxIdentificationNumber">16-1387862</ix:nonNumeric></span></b></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 1.1pt; text-align: center">(Commission File Number)</td>
    <td style="padding: 1.1pt">&#160;</td>
    <td style="padding: 1.1pt; text-align: center">(I.R.S. Employer Identification No.)</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 1.1pt">&#160;</td>
    <td style="padding: 1.1pt">&#160;</td>
    <td style="padding: 1.1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.45pt; text-align: center"><b><span id="xdx_90E_edei--EntityAddressAddressLine1_c20200511__20200511_z4K5bTpXfph9"><ix:nonNumeric contextRef="From2020-05-11to2020-05-11" name="dei:EntityAddressAddressLine1">500 Plaza Drive</ix:nonNumeric></span></b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.1pt; text-align: center"><b><span id="xdx_908_edei--EntityAddressCityOrTown_c20200511__20200511_zUurIPlhek9e"><ix:nonNumeric contextRef="From2020-05-11to2020-05-11" name="dei:EntityAddressCityOrTown">Secaucus</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressStateOrProvince_c20200511__20200511_z1XCbZ0f5Wu7"><ix:nonNumeric contextRef="From2020-05-11to2020-05-11" name="dei:EntityAddressStateOrProvince">NJ</ix:nonNumeric></span></b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.1pt; text-align: center"></p></td>
    <td style="padding: 1.1pt">&#160;</td>
    <td style="padding-right: 1.45pt; padding-left: 1.45pt; text-align: center"><b><span id="xdx_90F_edei--EntityAddressPostalZipCode_c20200511__20200511_zobe5RB5sY52"><ix:nonNumeric contextRef="From2020-05-11to2020-05-11" name="dei:EntityAddressPostalZipCode">07094</ix:nonNumeric></span></b></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 1.1pt; text-align: center">&#160;</td>
    <td style="padding: 1.1pt">&#160;</td>
    <td style="padding: 1.1pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 1.1pt; text-align: center">(Address of principal executive offices)</td>
    <td style="padding: 1.1pt">&#160;</td>
    <td style="padding: 1.1pt; text-align: center">(Zip Code)</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 1.1pt">&#160;</td>
    <td style="padding: 1.1pt">&#160;</td>
    <td style="padding: 1.1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="padding: 1.1pt; text-align: center"><b><span id="xdx_90A_edei--CityAreaCode_c20200511__20200511_zHBb2gle3o96"><ix:nonNumeric contextRef="From2020-05-11to2020-05-11" name="dei:CityAreaCode">(973)</ix:nonNumeric></span> <span id="xdx_90E_edei--LocalPhoneNumber_c20200511__20200511_zqRZ77NO081i"><ix:nonNumeric contextRef="From2020-05-11to2020-05-11" name="dei:LocalPhoneNumber">520-2700</ix:nonNumeric></span></b></td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="padding: 1.1pt; text-align: center">(Registrant&#8217;s telephone number, including area code)</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 100%; padding: 1.1pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_901_edei--WrittenCommunications_c20200511__20200511_zoPK8BHL42Ec"><ix:nonNumeric contextRef="From2020-05-11to2020-05-11" format="ixt:booleanfalse" name="dei:WrittenCommunications">o</ix:nonNumeric></span></span> Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_90B_edei--SolicitingMaterial_c20200511__20200511_zMC7Q1b9H4sc"><ix:nonNumeric contextRef="From2020-05-11to2020-05-11" format="ixt:booleanfalse" name="dei:SolicitingMaterial">o</ix:nonNumeric></span></span> Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_905_edei--PreCommencementTenderOffer_c20200511__20200511_zJvYI9uw7ouf"><ix:nonNumeric contextRef="From2020-05-11to2020-05-11" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">o</ix:nonNumeric></span></span> Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_90B_edei--PreCommencementIssuerTenderOffer_c20200511__20200511_zpqLOmb0SKIb"><ix:nonNumeric contextRef="From2020-05-11to2020-05-11" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">o</ix:nonNumeric></span></span> Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border: Black 1pt solid; width: 35%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Title of each class</td>
    <td style="border-top: Black 1pt solid; width: 24%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Trading Symbol(s)</td>
    <td style="border-top: Black 1pt solid; width: 41%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Name of each exchange on which registered</td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span id="xdx_90F_edei--Security12bTitle_c20200511__20200511_zLotceRaA98e"><ix:nonNumeric contextRef="From2020-05-11to2020-05-11" name="dei:Security12bTitle">Common Stock, $0.01 Par Value</ix:nonNumeric></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span id="xdx_909_edei--TradingSymbol_c20200511__20200511_zaUgnkPXxRkk"><ix:nonNumeric contextRef="From2020-05-11to2020-05-11" name="dei:TradingSymbol">DGX</ix:nonNumeric></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span id="xdx_902_edei--SecurityExchangeName_c20200511__20200511_zvaAztTvOlY9"><ix:nonNumeric contextRef="From2020-05-11to2020-05-11" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">New York Stock Exchange</ix:nonNumeric></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.55in">Emerging growth company <span style="font-family: Wingdings"><span id="xdx_906_edei--EntityEmergingGrowthCompany_c20200511__20200511_z3LLp6BEpJV8"><ix:nonNumeric contextRef="From2020-05-11to2020-05-11" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">o</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings">o</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">&#160;</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1.01 Entry into a Material Definitive Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 13, 2020, Quest Diagnostics Incorporated (the &#8220;Company&#8221;)
issued $550,000,000 aggregate principal amount of 2.800% senior notes due 2031 (the &#8220;Notes&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company will pay interest on the Notes on June 30 and December
30 of each year, beginning on December 30, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Notes will mature on June 30, 2031. The Notes will be the
senior unsecured obligations of the Company and will rank equally with the Company&#8217;s other and future senior unsecured obligations.
The Notes will not be entitled to the benefit of any sinking fund.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Notes were issued pursuant to an indenture dated as of
June 27, 2001 among the Company, the guarantors (as defined therein) and The Bank of New York Mellon, as trustee (the
&#8220;Trustee&#8221;), as supplemented from time to time, and as further supplemented by a twenty-first supplemental
indenture dated as of May 13, 2020 between the Company and the Trustee (collectively, the &#8220;Indenture&#8221;). The
Indenture contains covenants that, among other things, will limit the ability of (i) the Company and any subsidiary
guarantors to create certain liens and enter into certain sale and leaseback transactions and (ii) the Company to
consolidate, merge or transfer all or substantially all of the Company&#8217;s assets  on a consolidated basis and incur indebtedness at non-guarantor subsidiaries. The Indenture provides for customary events of default. Upon a change of control
triggering event (as defined in the Indenture), the Company will be required to make an offer to purchase the Notes at a
price equal to 101% of their principal amount plus accrued and unpaid interest to, but excluding, the date of repurchase.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing description of the Indenture does not purport
to be complete and is qualified in its entirety by reference to the text of the applicable agreements, each of which is included
as an exhibit to this Current Report on Form 8-K and incorporated by reference herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A copy of the opinion of Shearman &#38; Sterling LLP, counsel
to the Company, relating to the legality of the Notes is filed as Exhibit 5.1 to this Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 8.01 Other Events</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 11, 2020, the Company issued a press release announcing
the pricing of a public offering of $550 million aggregate principal amount of the Notes under the Company&#8217;s shelf registration
statement. A copy of the press release, dated May 11, 2020, is attached to this Current Report on Form 8-K as Exhibit 99.1 and
is incorporated by reference into this Current Report on Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the offering of the Notes, on May 11, 2020,
the Company entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Goldman Sachs &#38; Co. LLC,
J.P. Morgan Securities LLC and Mizuho Securities USA LLC on behalf of themselves and the other underwriters named therein. The
Underwriting Agreement is attached to this Current Report on Form 8-K as Exhibit 1.1 and is incorporated by reference into this
Current Report on Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item&#160;9.01 Financial Statements and Exhibits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 9%; padding-right: 5.75pt; padding-bottom: 0.1in; padding-left: 5.75pt">&#160;</td>
    <td style="width: 10%; padding-right: 5.75pt; padding-bottom: 10pt; padding-left: 5.75pt; text-align: right"><b><span style="text-decoration: underline">Exhibit</span></b></td>
    <td style="width: 81%; padding-right: 5.75pt; padding-bottom: 0.1in; padding-left: 12.6pt"><b><span style="text-decoration: underline">Description</span></b></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.75pt; padding-bottom: 0.1in; padding-left: 5.75pt">&#160;</td>
    <td style="padding-right: 5.75pt; padding-bottom: 0.1in; padding-left: 5.75pt"><a href="ss173511_ex0101.htm">1.1</a>*</td>
    <td style="padding-right: 5.75pt; padding-bottom: 0.1in; padding-left: 12.6pt"><a href="ss173511_ex0101.htm">Underwriting Agreement, dated May 11, 2020</a></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.75pt; padding-bottom: 0.1in; padding-left: 5.75pt">&#160;</td>
    <td style="padding-right: 5.75pt; padding-bottom: 0.1in; padding-left: 5.75pt"><a href="http://www.sec.gov/Archives/edgar/data/1022079/000094787101500290/ex4-3_062801.txt">4.1</a></td>
    <td style="padding-right: 5.75pt; padding-bottom: 0.1in; padding-left: 12.6pt"><span style="font-family: inherit,serif"><a href="http://www.sec.gov/Archives/edgar/data/1022079/000094787101500290/ex4-3_062801.txt">Indenture dated as of June 27, 2001, among the Company, the Subsidiary Guarantors and the Trustee (filed as an Exhibit to the Company&#8217;s current report on Form 8-K (Date of Report: June 27, 2001) and incorporated herein by reference)</a></span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.75pt; padding-bottom: 0.1in; padding-left: 5.75pt">&#160;</td>
    <td style="padding-right: 5.75pt; padding-bottom: 0.1in; padding-left: 5.75pt"><a href="ss173511_ex0402.htm">4.2</a>*</td>
    <td style="padding-right: 5.75pt; padding-bottom: 0.1in; padding-left: 12.6pt"><span style="font-family: inherit,serif"><a href="ss173511_ex0402.htm">Twenty-First Supplemental Indenture, dated as of May 13, 2020, between the Company and the Trustee</a></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">&#160;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="padding-right: 5.75pt; padding-bottom: 0.1in; padding-left: 5.75pt; width: 9%">&#160;</td>
    <td style="padding-right: 5.75pt; padding-bottom: 0.1in; padding-left: 5.75pt; width: 10%"><a href="ss173511_ex0402.htm">4.3</a>*</td>
    <td style="padding-right: 5.75pt; padding-bottom: 0.1in; padding-left: 12.6pt; width: 81%"><a href="ss173511_ex0402.htm">Form of the Company&#8217;s 2.800% Senior Note due 2031 (incorporated by reference from Exhibit A to Exhibit 4.2 hereof</a>)</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.75pt; padding-bottom: 0.1in; padding-left: 5.75pt">&#160;</td>
    <td style="padding-right: 5.75pt; padding-bottom: 0.1in; padding-left: 5.75pt"><a href="ss173511_ex0501.htm">5.1</a>*</td>
    <td style="padding-right: 5.75pt; padding-bottom: 0.1in; padding-left: 12.6pt"><a href="ss173511_ex0501.htm">Opinion of Shearman &#38; Sterling LLP, counsel to the Company</a></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.75pt; padding-bottom: 0.1in; padding-left: 5.75pt">&#160;</td>
    <td style="padding-right: 5.75pt; padding-bottom: 0.1in; padding-left: 5.75pt"><a href="ss173511_ex0501.htm">23.1</a>*</td>
    <td style="padding-right: 5.75pt; padding-bottom: 0.1in; padding-left: 12.6pt"><a href="ss173511_ex0501.htm">Consent of Shearman &#38; Sterling LLP (included in Exhibit 5.1)</a></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.75pt; padding-bottom: 0.1in; padding-left: 5.75pt">&#160;</td>
    <td style="padding-right: 5.75pt; padding-bottom: 0.1in; padding-left: 5.75pt"><a href="ss173511_ex9901.htm">99.1</a>*</td>
    <td style="padding-right: 5.75pt; padding-bottom: 0.1in; padding-left: 12.6pt"><a href="ss173511_ex9901.htm">Press Release issued by the Company, dated May 11, 2020, announcing pricing of notes</a></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.75pt; padding-bottom: 0.1in; padding-left: 5.75pt">&#160;</td>
    <td style="padding-right: 5.75pt; padding-bottom: 0.1in; padding-left: 5.75pt">104*</td>
    <td style="padding-right: 5.75pt; padding-bottom: 0.1in; padding-left: 12.6pt">The cover page from this current report on Form 8-K, formatted in Inline XBRL.</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* &#160;&#160;&#160;&#160;&#160;&#160;&#160;Filed herewith.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">&#160;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Signature</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 243.35pt; text-indent: -27.35pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      <tr style="vertical-align: top">
<td>&#160;</td><td colspan="2">May 13, 2020</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td><td colspan="2">QUEST DIAGNOSTICS INCORPORATED</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: top">
<td style="width: 216pt"></td><td style="width: 27.35pt">By:</td><td><span style="text-decoration: underline">/s/ William J. O&#8217;Shaughnessy, Jr.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#9;</span><br />
William J. O&#8217;Shaughnessy, Jr.</td></tr>                                             <tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td>Deputy General Counsel and Corporate Secretary</td></tr>
</table>

<p style="font: 10pt inherit,serif; margin: 0pt 0 0pt 243.35pt; text-indent: 0pt"></p>

<p style="font: 10pt inherit,serif; margin: 0pt 0 0pt 243.35pt; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KgkAQhZ/Adxj2WnLVuvEyKYksQiS6XXKMJd2R2e3vkXrLNiUaBoaZc745QoSioLXukOG0rEqosR865RAqbJHRnNE78s02Az8rvGjrWBk3rj8wJ8+gZxazVPn76Lxri00GchHFaZRIkPMsSeGwE8FXz8m0ukHjtOpAmQYOTANrdIpf04daPclQ/xqTjshWk8kgnslJfkMi4wT2dFcP4quFssxFEI4ViILpNnxjbtZRD6sOe59lJ/TfwQfZ9UkT -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ss173511_ex0101.htm
<DESCRIPTION>UNDERWRITING AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 1.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXECUTION VERSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">QUEST DIAGNOSTICS INCORPORATED<BR>
(a Delaware corporation)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">$550,000,000 2.800% Senior Notes due 2031</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNDERWRITING AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: May 11, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Table of Contents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><U>Page</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%; text-align: left; text-indent: -0.5in; padding-top: 12pt; padding-bottom: 12pt; padding-left: 0.5in">SECTION 1.&nbsp;&nbsp;&nbsp;<U>Representations and Warranties</U></TD>
    <TD STYLE="width: 10%; text-align: right; padding-top: 12pt; padding-bottom: 12pt">3</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(a)&nbsp;&nbsp;&nbsp;<I>Representations and Warranties by the Company</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">3</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(b)&nbsp;&nbsp;&nbsp;<I>Officer&#8217;s Certificates</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">13</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 12pt; padding-bottom: 12pt; padding-left: 0.5in">SECTION 2.&nbsp;&nbsp;&nbsp;<U>Sale and Delivery to Underwriters; Closing</U></TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 12pt">14</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(a)&nbsp;&nbsp;&nbsp;<I>Notes</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">14</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(b)&nbsp;&nbsp;&nbsp;<I>Public Offering</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">14</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(c)&nbsp;&nbsp;&nbsp;<I>Payment</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">14</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(d)&nbsp;&nbsp;&nbsp;<I>Denominations; Registration</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">14</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 12pt; padding-bottom: 12pt; padding-left: 0.5in">SECTION 3.&nbsp;&nbsp;&nbsp;<U>Covenants of the Company</U></TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 12pt">14</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(a)&nbsp;&nbsp;&nbsp;<I>Delivery of Registration Statement, Time of Sale Prospectus and Prospectus</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">14</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(b)&nbsp;&nbsp;&nbsp;<I>Amendments and Supplements</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">15</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(c)&nbsp;&nbsp;&nbsp;<I>Free Writing Prospectus</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">15</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(d)&nbsp;&nbsp;&nbsp;<I>Free Writing Prospectus (Underwriter)</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">15</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(e)&nbsp;&nbsp;&nbsp;<I>Amend or Supplement Time of Sale Prospectus</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">15</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(f)&nbsp;&nbsp;&nbsp;<I>Amend or Supplement Prospectus</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">15</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(g)&nbsp;&nbsp;&nbsp;<I>Blue Sky Qualifications</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">16</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(h)&nbsp;&nbsp;&nbsp;<I>Rule 158</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">16</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(i)&nbsp;&nbsp;&nbsp;<I>Use of Proceeds</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">16</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(j)&nbsp;&nbsp;&nbsp;<I>Restriction on Sale of Notes</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">16</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(k)&nbsp;&nbsp;&nbsp;<I>Final Term Sheet</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">16</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(l)&nbsp;&nbsp;&nbsp;<I>Reporting Requirements</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">17</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(m)&nbsp;&nbsp;&nbsp;<I>DTC Clearance</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">17</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 12pt; padding-bottom: 12pt; padding-left: 0.5in">SECTION 4.&nbsp;&nbsp;&nbsp;<U>Payment of Expenses</U></TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 12pt">17</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(a)&nbsp;&nbsp;&nbsp;<I>Expenses</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">17</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(b)&nbsp;&nbsp;&nbsp;<I>Termination of Agreement</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">17</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 12pt; padding-bottom: 12pt; padding-left: 0.5in">SECTION 5.&nbsp;&nbsp;&nbsp;<U>Conditions of Underwriters&#8217; Obligations</U></TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 12pt">17</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(a)&nbsp;&nbsp;&nbsp;<I>Opinion of Counsel for the Company</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">18</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(b)&nbsp;&nbsp;&nbsp;<I>Opinion of Deputy General Counsel of the Company</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">18</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(c)&nbsp;&nbsp;&nbsp;<I>Opinion of Counsel for the Underwriters</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">18</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(d)&nbsp;&nbsp;&nbsp;<I>Officers&#8217; Certificate</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">18</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(e)&nbsp;&nbsp;&nbsp;<I>Prospectus, Final Term Sheet and Free Writing Prospectus</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">18</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(f)&nbsp;&nbsp;&nbsp;<I>Comfort Letters</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">19</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(g)&nbsp;&nbsp;&nbsp;<I>Maintenance of Rating</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">19</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(h)&nbsp;&nbsp;&nbsp;<I>Twenty-First Supplemental Indenture</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">19</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(i)&nbsp;&nbsp;&nbsp;<I>Additional Documents</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">19</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in; width: 90%">(j)&nbsp;&nbsp;&nbsp;<I>Termination of Agreement</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt; width: 10%">19</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 12pt; padding-bottom: 12pt; padding-left: 0.5in">SECTION 6.&nbsp;&nbsp;&nbsp;<U>Covenants of the Underwriters</U></TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 12pt">20</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 12pt; padding-bottom: 12pt; padding-left: 0.5in">SECTION 7.&nbsp;&nbsp;&nbsp;<U>Indemnification</U></TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 12pt">20</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(a)&nbsp;&nbsp;&nbsp;<I>Indemnification of the Underwriters</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">20</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(b)&nbsp;&nbsp;&nbsp;<I>Indemnification of Company, Directors and Officers</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">20</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(c)&nbsp;&nbsp;&nbsp;<I>Actions against Parties; Notification</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">21</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(d)&nbsp;&nbsp;&nbsp;<I>Settlement without Consent if Failure to Reimburse</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">21</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 12pt; padding-bottom: 12pt; padding-left: 0.5in">SECTION 8.&nbsp;&nbsp;&nbsp;<U>Contribution</U></TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 12pt">22</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 12pt; padding-bottom: 12pt; padding-left: 0.5in">SECTION 9.&nbsp;&nbsp;&nbsp;<U>Representations, Warranties and Agreements to Survive Delivery</U></TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 12pt">23</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 12pt; padding-bottom: 12pt; padding-left: 0.5in">SECTION 10.&nbsp;&nbsp;&nbsp;<U>Termination of Agreement</U></TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 12pt">23</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(a)&nbsp;&nbsp;&nbsp;<I>Termination; General</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">23</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(b)&nbsp;&nbsp;&nbsp;<I>Liabilities</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">23</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 12pt; padding-bottom: 12pt; padding-left: 0.5in">SECTION 11.&nbsp;&nbsp;&nbsp;<U>Default by One or More of the Underwriters</U></TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 12pt">24</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 12pt; padding-bottom: 12pt; padding-left: 0.5in">SECTION 12.&nbsp;&nbsp;&nbsp;<U>Default by the Company</U></TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 12pt">24</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 12pt; padding-bottom: 12pt; padding-left: 0.5in">SECTION 13.&nbsp;&nbsp;&nbsp;<U>Notices</U></TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 12pt">24</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 12pt; padding-bottom: 12pt; padding-left: 0.5in">SECTION 14.&nbsp;&nbsp;&nbsp;<U>Parties</U></TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 12pt">25</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 12pt; padding-bottom: 12pt; padding-left: 0.5in">SECTION 15.&nbsp;&nbsp;&nbsp;<U>Governing Law and Time</U></TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 12pt">25</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 12pt; padding-bottom: 12pt; padding-left: 0.5in">SECTION 16.&nbsp;&nbsp;&nbsp;<U>Effect of Headings</U></TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 12pt">25</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 12pt; padding-bottom: 12pt; padding-left: 0.5in">SECTION 17.&nbsp;&nbsp;&nbsp;<U>Partial Unenforceability</U></TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 12pt">25</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 12pt; padding-bottom: 12pt; padding-left: 0.5in">SECTION 18.&nbsp;&nbsp;&nbsp;<U>No Advisory or Fiduciary Responsibility</U></TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 12pt">25</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 12pt; padding-bottom: 12pt; padding-left: 0.5in">SECTION 19.&nbsp;&nbsp;&nbsp;<U>Recognition of the U.S. Special Resolution Regimes</U></TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 12pt">26</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 12pt; padding-bottom: 12pt; padding-left: 0.5in">SECTION 20.&nbsp;&nbsp;&nbsp;<U>General Provisions</U></TD>
    <TD STYLE="text-align: right; padding-top: 12pt; padding-bottom: 12pt">27</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(a)&nbsp;&nbsp;&nbsp;<I>General</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">27</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(b)&nbsp;&nbsp;&nbsp;<I>USA Patriot Act</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">27</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">Schedule A</TD>
    <TD STYLE="width: 5%; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">-</TD>
    <TD STYLE="width: 80%; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">Underwriters</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">Schedule B</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">-</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">Time of Sale Prospectus</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">Schedule C-1</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">-</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">Purchase Price</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">Schedule C-2</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">-</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">Final Term Sheet</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">Schedule D</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">-</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">Subsidiaries</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">Exhibit A</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">-</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">Form of Opinion of Shearman &amp; Sterling LLP</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">Exhibit B</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">-</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">Form of Opinion of Deputy General Counsel of the Company</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">QUEST DIAGNOSTICS INCORPORATED<BR>
(a Delaware corporation)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">$550,000,000 2.800% Senior Notes due 2031</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>UNDERWRITING AGREEMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">May 11, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">GOLDMAN SACHS &amp; CO. LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">J.P. MORGAN SECURITIES LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">MIZUHO SECURITIES USA LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><BR>
c/o GOLDMAN SACHS &amp; CO. LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">200 West Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10282</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c/o J.P. MORGAN SECURITIES LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">383 Madison Ave., 3<SUP>rd</SUP> Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10179</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c/o MIZUHO SECURITIES USA LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">320 Park Avenue, 12<SUP>th</SUP> Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Quest Diagnostics
Incorporated, a Delaware corporation (the &#8220;Company&#8221;) confirms its agreement with Goldman Sachs &amp; Co. LLC (&#8220;Goldman
Sachs&#8221;), J.P. Morgan Securities LLC (&#8220;JPMorgan&#8221;), Mizuho Securities USA LLC (&#8220;Mizuho&#8221;) and each of
the other underwriters named in Schedule A hereto (collectively, the &#8220;Underwriters,&#8221; which term shall also include
any underwriter substituted as hereinafter provided in Section&nbsp;11 hereof), for whom Goldman Sachs, JPMorgan and Mizuho are
acting as representatives (in such capacity, the &#8220;Representatives&#8221;), with respect to the issue and sale by the Company
and the purchase by the Underwriters, acting severally and not jointly, of the respective principal amounts set forth in said Schedule&nbsp;A
of $550,000,000 aggregate principal amount of the Company&#8217;s 2.800% Senior Notes due 2031 (the &#8220;Notes&#8221;). The Notes
are to be issued pursuant to an indenture dated as of June 27, 2001 (the &#8220;Base Indenture&#8221;) among the Company, the Subsidiary
Guarantors party thereto, as guarantors, and The Bank of New York Mellon Trust Company, N.A., as successor trustee to The Bank
of New York (the &#8220;Trustee&#8221;), as supplemented by a first supplemental indenture, dated as of June 27, 2001, among the
Company, as issuer, the Initial Subsidiary Guarantors party thereto and the Trustee, as further supplemented by a second supplemental
indenture, dated as of November 26, 2001, among the Company, the Subsidiary Guarantors party thereto and the Trustee, as further
supplemented by a third supplemental indenture, dated as of April 4, 2002, among the Company, the additional Subsidiary</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Guarantors
party thereto and the Trustee, as further supplemented by a fourth supplemental indenture, dated as of March 19, 2003, among the
Company, the additional Subsidiary Guarantors party thereto and the Trustee, as further supplemented by a fifth supplemental indenture,
dated as of April 16, 2004, among the Company, the additional Subsidiary Guarantor party thereto and the Trustee, as further supplemented
by a sixth supplemental indenture, dated as of October 31, 2005, among the Company, the Subsidiary Guarantors party thereto and
the Trustee, as further supplemented by a seventh supplemental indenture, dated as of November 31, 2005, among the Company, the
Subsidiary Guarantors party thereto and the Trustee, as further supplemented by an eighth supplemental indenture, dated as of July
31, 2006, among the Company, the Subsidiary Guarantors party thereto and the Trustee, as further supplemented by a ninth supplemental
indenture, dated as of September 30, 2006, among the Company, the Subsidiary Guarantors party thereto and the Trustee, as further
supplemented by a tenth supplemental indenture, dated as of June 22, 2007, among the Company, the Subsidiary Guarantors party thereto
and the Trustee, as further supplemented by an eleventh supplemental indenture, dated as of June 22, 2007, among the Company, the
additional Subsidiary Guarantors party thereto and the Trustee, as further supplemented by a twelfth supplemental indenture, dated
as of June 25, 2007, among the Company, the additional Subsidiary Guarantors party thereto and the Trustee, as further supplemented
by a thirteenth supplemental indenture, dated as of November 17, 2009, among the Company, the Subsidiary Guarantors party thereto
and the Trustee, as further supplemented by a fourteenth supplemental indenture, dated as of March 24, 2011, among the Company,
the additional Subsidiary Guarantors party thereto and the Trustee, as further supplemented by a fifteenth supplemental indenture,
dated as of November 30, 2011, among the Company, the additional Subsidiary Guarantors party thereto and the Trustee, as further
supplemented by a sixteenth supplemental indenture dated as of March 17, 2014, between the Company and the Trustee, as further
supplemented by a seventeenth supplemental indenture, dated as of March 10, 2015, between the Company and the Trustee, as further
supplemented by an eighteenth supplemental indenture dated as of May 23, 2016, between the Company and the Trustee, as further
supplemented by a nineteenth supplemental indenture dated as of March 12, 2019, between the Company and the Trustee, as further
supplemented by a twentieth supplemental indenture dated as of December 16, 2019, between the Company and the Trustee and as to
be further supplemented by a twenty-first supplemental indenture to be dated May 13, 2020 between the Company and the Trustee (the
&#8220;Twenty-First Supplemental Indenture&#8221;); the Base Indenture together with all such supplements, the &#8220;Indenture&#8221;.
The Notes will be issued only in book-entry form in the name of Cede &amp; Co., as nominee of The Depository Trust Company (the
&#8220;Depositary&#8221;) pursuant to a letter of representations, dated October 27, 2005 (the &#8220;DTC Agreement&#8221;), between
the Company and the Depositary.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has
filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;) a registration statement, including a prospectus,
(the file number of which is 333-232138) on Form S-3, relating to securities (the &#8220;Shelf Securities&#8221;), including the
Notes, to be issued from time to time by the Company. The registration statement as amended to the date of this Agreement, including
the information (if any) deemed to be part of the registration statement at the time of effectiveness pursuant to Rule 430A or
Rule 430B under the Securities Act of 1933, as amended (the &#8220;1933 Act&#8221;), is hereinafter referred to as the &#8220;Registration
Statement&#8221;, and the related prospectus covering the Shelf Securities dated June 14, 2019 is hereinafter referred to as the
&#8220;Basic Prospectus&#8221;. The Basic Prospectus, as supplemented by the prospectus supplement specifically relating to the
Notes in the form first used to confirm sales of the Notes (or in the form first made</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">available to the Underwriters by the Company
to meet requests of purchasers pursuant to Rule 173 under the 1933 Act) is hereinafter referred to as the &#8220;Prospectus&#8221;,
and the term &#8220;preliminary prospectus&#8221; means any preliminary form of the Prospectus. For purposes of this Agreement,
&#8220;free writing prospectus&#8221; has the meaning set forth in Rule 405 under the 1933 Act and &#8220;Time of Sale Prospectus&#8221;
means the preliminary prospectus identified in Schedule B hereto together with the free writing prospectuses, if any, each identified
in Schedule B hereto. As used herein, the terms &#8220;Registration Statement&#8221;, &#8220;Basic Prospectus&#8221;, &#8220;preliminary
prospectus&#8221;, &#8220;Time of Sale Prospectus&#8221; and &#8220;Prospectus&#8221; shall include the documents, if any, incorporated
by reference therein. The terms &#8220;supplement&#8221;, &#8220;amendment&#8221; and &#8220;amend&#8221; as used herein with respect
to the Registration Statement, the Basic Prospectus, the Time of Sale Prospectus, any preliminary prospectus or free writing prospectus
shall include all documents subsequently filed by the Company with the Commission pursuant to the Securities Exchange Act of 1934,
as amended (the &#8220;1934 Act&#8221;), that are deemed to be incorporated by reference therein.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All references
in this Agreement to financial statements and schedules and other information which is &#8220;contained&#8221;, &#8220;included&#8221;,
&#8220;stated&#8221;, &#8220;described&#8221; or &#8220;disclosed&#8221; in the Registration Statement, the Basic Prospectus, the
Time of Sale Prospectus, any preliminary prospectus or free writing prospectus (or other references of like import) shall be deemed
to mean and include all such financial statements and schedules and other information which are incorporated by reference in the
Registration Statement, the Basic Prospectus, the Time of Sale Prospectus, any preliminary prospectus or free writing prospectus,
as the case may be.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<U>Representations
and Warranties</U>.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Representations
and Warranties by the Company</I>. The Company represents and warrants to each Underwriter as of the date hereof and as of the
Closing Time referred to in Section 2(c) hereof (unless otherwise specified), and agrees with each Underwriter, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Registration Statement has become effective, no stop order suspending the effectiveness of the Registration Statement is in effect
and no proceedings for such purpose are pending before or threatened by the Commission. The Company is a well-known seasoned issuer
(as defined in Rule 405 under the 1933 Act), eligible to use the Registration Statement as an automatic shelf registration statement
and the Company has not received notice that the Commission objects to the use of the Registration Statement as an automatic shelf
registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>(A)
The Registration Statement, when it became effective, did not contain, and as amended or supplemented, if applicable, will not
contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to
make the statements therein not misleading, (B) the Registration Statement as of the date hereof does not contain any untrue statement
of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not
misleading, (C) the Registration Statement and the Prospectus comply, and as amended or supplemented, if applicable, will comply
in all material respects with the 1933 Act and the applicable rules and regulations of the Commission thereunder, (D) the Time
of Sale Prospectus does not, and at the time of each sale of the Notes in connection with the offering when the Prospectus is not
yet available to prospective purchasers and at the</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Closing Time, the Time of Sale Prospectus, as then amended or supplemented by
the Company, if applicable, will not, contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements therein, in the light of the circumstances under which they were made, not misleading, (E) each electronic
road show related to the offering of the Notes, if any, when considered together with the Time of Sale Prospectus, does not contain
any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light
of the circumstances under which they were made, not misleading and (F) the Prospectus does not contain and, as amended or supplemented,
if applicable, will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements therein, in the light of the circumstances under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">The
representations and warranties in this subsection shall not apply to statements in or omissions from the Registration Statement,
the Time of Sale Prospectus or the Prospectus made in reliance upon and in conformity with information furnished to the Company
in writing by any Underwriter through the Representatives expressly for use therein.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 85.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Incorporated
Documents</U>. The documents incorporated or deemed to be incorporated by reference in the Time of Sale Prospectus or the Prospectus,
at the time they were or hereafter are filed with the Commission, complied and will comply in all material respects with the requirements
of the 1934 Act and the rules and regulations of the Commission thereunder (the &#8220;1934 Act Regulations&#8221;), and, when
read together with the other information in the Time of Sale Prospectus or the Prospectus at its date and at the Closing Time,
did not and will not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary to make the statements therein not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Company is not an &#8220;ineligible issuer&#8221; in connection with the offering pursuant to Rules 164, 405 and 433 under the
1933 Act. Any free writing prospectus that the Company is required to file pursuant to Rule 433(d) under the 1933 Act has been,
or will be, filed with the Commission in accordance with the requirements of the 1933 Act and the applicable rules and regulations
of the Commission thereunder. Each free writing prospectus that the Company has filed, or is required to file, pursuant to Rule
433(d) under the 1933 Act or that was prepared by or behalf of or used or referred to by the Company complies or will comply in
all material respects with the requirements of the 1933 Act and the applicable rules and regulations of the Commission thereunder.
Except for the free writing prospectuses, if any, identified in Schedule B hereto, and electronic road shows each furnished to
you before first use, the Company has not prepared, used or referred to, and will not, without your prior consent, prepare, use
or refer to, any free writing prospectus. Any issuer free writing prospectus as defined in Rule 433(h) under the 1933 Act, as of
its issue date and at all subsequent times through the completion of the public offer and sale of the Notes, did not, does not
and will not include any information that conflicted, conflicts or will conflict with the information contained in the Registration
Statement, the Time of Sale Prospectus or the Prospectus, including any document incorporated by reference therein and any preliminary
or other prospectus deemed to be a part thereof that has not been superseded or modified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Independent
Accountants</U>. PricewaterhouseCoopers LLP, which audited the annual financial statements incorporated by reference in the Time
of Sale Prospectus and the Prospectus, are independent registered public accountants with respect to the Company, in any case,
as required by the 1933 Act, the rules and regulations of the Commission under the 1933 Act, the 1934 Act and the 1934 Act Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Financial
Statements</U>. The financial statements of the Company included or incorporated by reference in the Time of Sale Prospectus and
the Prospectus, together with the related schedule and notes, present fairly (A) the financial position of the Company and its
Subsidiaries (as defined below) on a consolidated basis at the dates indicated and (B) the statements of operations, stockholders&#8217;
equity and cash flows of the Company and its Subsidiaries on a consolidated basis for the periods specified. Such financial statements
have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) applied
on a consistent basis throughout the periods involved. The supporting schedules relating to the Company, if any, included in the
Time of Sale Prospectus and the Prospectus present fairly in accordance with GAAP the information required to be stated therein.
The summary financial information of the Company included in the Time of Sale Prospectus and the Prospectus present fairly the
information shown therein and have been compiled on a basis consistent with that of the audited or unaudited financial statements
of the Company, as applicable, included in the Time of Sale Prospectus and the Prospectus. The interactive data in eXtensible Business
Reporting Language included or incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus
fairly present the information called for in all material respects and have been prepared in all material respects in accordance
with the Commission&#8217;s rules and guidelines applicable thereto. There are no historical or pro forma financial statements
of the Company or any of its Subsidiaries or any acquired entities which are required by the 1933 Act to be disclosed in the Registration
Statement, the Time of Sale Prospectus or the Prospectus which are not so disclosed in the Registration Statement, the Time of
Sale Prospectus and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>No
Material Adverse Change in Business</U>. Since the respective dates as of which information is given in the Time of Sale Prospectus,
except as otherwise stated therein or contemplated thereby, (A)&nbsp;there has been no material adverse change in the business,
financial condition, operations, cash flow or business prospects of the Company and its Subsidiaries, considered as one enterprise,
whether or not arising in the ordinary course of business (a &#8220;Material Adverse Effect&#8221;), and (B)&nbsp;there have been
no transactions entered into by the Company or any of its Subsidiaries, other than those described or contemplated by the Time
of Sale Prospectus or in the ordinary course of business, which are material with respect to the Company and its Subsidiaries considered
as one enterprise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(viii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Good
Standing of the Company</U>. The Company has been duly organized and is validly existing as a corporation in good standing under
the laws of the State of Delaware and has corporate power and authority to own, lease and operate its properties and to conduct
its business as described in the Time of Sale Prospectus and the Prospectus and to enter into and perform its obligations under
this Agreement, the Indenture and the Notes; and the Company is duly qualified as a foreign corporation to transact business and
is in good standing in each other jurisdiction in which such qualification is required,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">whether by reason of the ownership or leasing
of property or the conduct of business, except where the failure so to qualify or to be in good standing would not result in a
Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(ix)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Good
Standing of Subsidiaries</U>. Each subsidiary of the Company (each a &#8220;Subsidiary&#8221; and collectively the &#8220;Subsidiaries&#8221;)&nbsp;has
been duly organized and is validly existing as a corporation, partnership or limited liability company, as the case may be, in
good standing under the laws of the jurisdiction of its incorporation or existence, has corporate or partnership power and authority
to own, lease and operate its properties and to conduct its business as described in the Time of Sale Prospectus and the Prospectus
and is duly qualified as a foreign corporation or partnership to transact business and is in good standing in each jurisdiction
in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business,
except where the failure so to qualify or to be in good standing would not result in a Material Adverse Effect. Except as otherwise
disclosed in the Time of Sale Prospectus and the Prospectus, all of the outstanding capital stock or partnership interests of each
Subsidiary have been duly authorized and validly issued or created, are fully paid and non-assessable and except as described in
Schedule D are owned by the Company, directly or through the Subsidiaries, free and clear of any security interest, mortgage, pledge,
lien, encumbrance, claim or equity; none of the outstanding shares of capital stock or partnership interests of the Subsidiaries
was issued in violation of any preemptive or similar rights arising by operation of law, or under the charter, by-laws or other
charter documents of any Subsidiary or under any agreement to which the Company or any Subsidiary is a party. All of the Subsidiaries
of the Company are listed on Schedule D attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Authorization
of this Agreement</U>. This Agreement has been duly authorized, executed and delivered by, and will be a valid and binding agreement
of, the Company, enforceable in accordance with its terms, except as the enforcement thereof may be limited by bankruptcy, insolvency
(including, without limitation, all laws relating to fraudulent transfers), reorganization, moratorium or similar laws affecting
enforcement of creditors&#8217; rights generally and except as enforcement thereof is subject to general principles of equity (regardless
of whether enforcement is considered in a proceeding in equity or at law).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Qualification,
Authorization and Description of the Indenture</U>. The Indenture has been duly qualified under the Trust Indenture of 1939, as
amended. The Base Indenture and each supplemental indenture thereto have all been duly authorized, executed and delivered by the
Company (and each of the Subsidiaries party thereto, as applicable) and constitute valid and binding agreements of the Company
(and each of the Subsidiaries party thereto, as applicable), enforceable against the Company (and each of the Subsidiaries party
thereto, as applicable) in accordance with their terms, except as the enforcement thereof may be limited by bankruptcy, insolvency
(including, without limitation, all laws relating to fraudulent transfers), reorganization, moratorium or similar laws affecting
enforcement of creditors&#8217; rights generally and except as enforcement thereof is subject to general principles of equity (regardless
of whether enforcement is considered in a proceeding in equity or at law). The Twenty-First Supplemental Indenture has been duly
authorized by the Company and, when duly executed and delivered by the Company,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">will constitute a valid and binding agreement of
the Company, enforceable against the Company in accordance with its terms, except as the enforcement thereof may be limited by
bankruptcy, insolvency (including, without limitation, all laws relating to fraudulent transfers), reorganization, moratorium or
similar laws affecting enforcement of creditors&#8217; rights generally and except as enforcement thereof is subject to general
principles of equity (regardless of whether enforcement is considered in a proceeding in equity or at law).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Authorization
of the Notes</U>. The Notes to be purchased by the Underwriters from the Company have been duly authorized for issuance and sale
to the Underwriters pursuant to this Agreement and, at the Closing Time, will have been duly executed by the Company and, when
authenticated, issued and delivered in the manner provided for in the Indenture and delivered against payment of the purchase price
therefor as provided in this Agreement, will constitute valid and binding obligations of the Company, enforceable against the Company
in accordance with their terms, except as the enforcement thereof may be limited by bankruptcy, insolvency (including, without
limitation, all laws relating to fraudulent transfers), reorganization, moratorium or similar laws affecting enforcement of creditors&#8217;
rights generally and except as enforcement thereof is subject to general principles of equity (regardless of whether enforcement
is considered in a proceeding in equity or at law), and will be in the form contemplated by, and entitled to the benefits of, the
Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xiii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Description
of the Notes and the Indenture</U>. The description of the Notes and the Indenture set forth in the Time of Sale Prospectus and
the Prospectus are correct and complete in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xiv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Non-Guarantor
Subsidiaries</U>. Except as otherwise disclosed in the Time of Sale Prospectus and the Prospectus, no Subsidiary (A) is a guarantor
of any Indebtedness (as defined in the Indenture) of the Company that, when taken together with any other outstanding Indebtedness
of the Company that is guaranteed by its Subsidiaries that are not Subsidiary Guarantors (as defined in the Indenture), exceeds
$50 million in the aggregate at any time, or (B) has incurred any Indebtedness that is not permitted pursuant to Section 1011 of
the Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Absence
of Defaults and Conflicts</U>. Neither the Company nor any of the Subsidiaries is in violation of its charter or by-laws or in
default in the performance or observance of any obligation, agreement, covenant or condition contained in any contract, indenture,
mortgage, deed of trust, loan or credit agreement, note, lease or other agreement or instrument to which the Company or any of
the Subsidiaries is a party or by which any of them may be bound, or to which any of the property or assets of the Company or any
of the Subsidiaries is subject (collectively, &#8220;Agreements and Instruments&#8221;)&nbsp;or has violated or is in violation
of any of the laws, rules and regulations administered by the United States Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;),
the United States Food and Drug Administration (the &#8220;FDA&#8221;), the Substance Abuse and Mental Health Services Administration
(the &#8220;SAMHSA&#8221;) and by the Drug Enforcement Administration (the &#8220;DEA&#8221;), or any other applicable law, statute,
rule, regulation, judgment, order, writ or decree of any government, government instrumentality or court, domestic or foreign,
having jurisdiction over the Company or any of the Subsidiaries or any of their assets or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">properties, except in each case for such
defaults or violations that have been disclosed or that would not singly or in the aggregate result in a Material Adverse Effect.
The execution, delivery and performance of this Agreement, the Indenture, the Notes and any other agreement or instrument entered
into or issued or to be entered into or issued by the Company in connection with the consummation of the transactions contemplated
by this Agreement herein and in the Time of Sale Prospectus and the Prospectus (including the issuance and sale of the Notes, the
use of the proceeds from the sale of the Notes as described in the Time of Sale Prospectus and the Prospectus under the caption
&#8220;Use of Proceeds&#8221;) and compliance by the Company with its obligations under this Agreement, the Indenture and the Notes
have been duly authorized by all necessary corporate action and do not and will not, whether with or without the giving of notice
or passage of time or both, conflict with or constitute a breach of, or a default under, or result in the creation or imposition
of any lien, charge or encumbrance upon any property or assets of the Company or any of the Subsidiaries pursuant to, the Agreements
and Instruments (except for such conflicts, breaches or defaults or liens, charges or encumbrances that, singly or in the aggregate,
would not result in a Material Adverse Effect), nor will such action result in any violation of the provisions of the charter or
by&#45;laws of the Company or any of the Subsidiaries or any applicable law, statute, rule, regulation, judgment, order, writ or
decree of any government, government instrumentality or court, domestic or foreign, having jurisdiction over the Company or any
of the Subsidiaries or any of their assets, properties or operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xvi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Absence
of Labor Disputes</U>. No labor dispute with the employees of the Company or any of the Subsidiaries exists or, to the knowledge
of the Company, is imminent, which may reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xvii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Absence
of Proceedings</U>. Except as disclosed in the Time of Sale Prospectus and the Prospectus or in the documents incorporated by reference
thereto, there is not pending or, to the knowledge of the Company, threatened any action, suit, proceeding, inquiry or investigation,
to which the Company or any Subsidiary is a party, or to which the property of the Company or any Subsidiary is subject, before
or brought by any domestic or foreign court or governmental agency or body, affecting (A) the possession by any of them of any
Governmental Authorization (as defined herein) currently held by any them, (B) the accreditation of any of their respective laboratories
with the College of American Pathologists (&#8220;CAP&#8221;), (C) any of their qualification to perform services for and receive
reimbursement from, Medicaid, Medicare or TRICARE (D) any of their ability to conduct their clinical testing business in any state
or (E) any of them in any other way, which in the case of any of the foregoing, might reasonably be expected to result in a Material
Adverse Effect, or which might reasonably be expected to materially and adversely affect the properties or assets of the Company
and the Subsidiaries considered as one enterprise or the consummation of the transactions contemplated in this Agreement or the
performance by the Company of its obligations hereunder or under the Indenture or the Notes. The aggregate of all pending legal
or governmental proceedings to which the Company or any Subsidiary thereof is a party or of which any of their respective property
or assets is the subject which are not described in the Time of Sale Prospectus and the Prospectus or in the documents incorporated
by reference thereto, including ordinary routine litigation incidental to the business, could not reasonably be expected to result
in a</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Material Adverse Effect. All of the descriptions set forth in the Time of Sale Prospectus and the Prospectus or in the documents
incorporated by reference thereto, of the legal and governmental proceedings by or before any court, governmental agency or body
are true and accurate in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xviii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Accuracy
of Exhibits</U>. There are no contracts or documents which are required to be described in the Time of Sale Prospectus and the
Prospectus or the documents incorporated by reference therein or to be filed as exhibits to the Registration Statement which have
not been so described and filed as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xix)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Possession
of Intellectual Property</U>. The Company and the Subsidiaries own, possess or license, or can acquire on reasonable terms, adequate
patents, patent rights, licenses, inventions, copyrights, know-how (including trade secrets and other unpatented and/or unpatentable
proprietary or confidential information, systems or procedures), trademarks, service marks, trade names or other intellectual property
(collectively, &#8220;Intellectual Property&#8221;)&nbsp;necessary to carry on the business now operated by them, and neither the
Company nor any of the Subsidiaries has received any notice or is otherwise aware of any infringement of or conflict with asserted
rights of others with respect to any Intellectual Property (including Intellectual Property which is licensed)&nbsp;or of any facts
or circumstances which would render any Intellectual Property invalid or inadequate to protect the interest of the Company or any
of the Subsidiaries therein, and which infringement or conflict or invalidity or inadequacy, singly or in the aggregate, would
reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xx)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Absence
of Further Requirements</U>. No filing with, or authorization, approval, consent, license, order, registration, qualification or
decree of, any court or governmental authority or agency is necessary or required (i) for the performance by the Company of its
obligations hereunder, (ii) in connection with the offering, issuance or sale of the Notes under this Agreement or the consummation
of the transactions contemplated by this Agreement or (iii) for the due execution, delivery or performance by the Company of this
Agreement, the Indenture, the Notes or any other agreement or instrument entered into or issued or to be entered into or issued
by the Company or any of the Subsidiaries in connection with the consummation of the transactions contemplated herein and in the
Time of Sale Prospectus and the Prospectus (including the issuance and sale of the Notes and the use of proceeds from the sale
of the Notes as described in the Time of Sale Prospectus and the Prospectus under the caption &#8220;Use of Proceeds&#8221;), except
such as have been already obtained or as may be required under state securities laws and except such where the failure to obtain
would not result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xxi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Possession
of Licenses, Provider Agreements and Permits</U>. The Company and the Subsidiaries possess all governmental permits, licenses,
provider numbers and agreements, approvals, consents, certificates and other authorizations required (i) under the Medicare, Medicaid
and TRICARE programs, (ii) under the Clinical Laboratories Improvement Act of 1967, as amended (the &#8220;CLIA&#8221;), (iii)
by the SAMHSA and (iv) as otherwise necessary to conduct the business now operated by them respectively, issued by CMS, the FDA,
the SAMHSA and each other appropriate federal, state, local or foreign regulatory agencies or bodies including, but not limited
to, any foreign regulatory</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">authorities performing functions similar to their respective functions (&#8220;Governmental Authorizations&#8221;)
except where failure to obtain such Governmental Authorizations would not, singly or in the aggregate, result in a Material Adverse
Effect; the Company and the Subsidiaries are in compliance with the terms and conditions of all such Governmental Authorizations
and with the rules and regulations of the regulatory authorities and governing bodies having jurisdiction with respect thereto,
except where the failure so to comply would not, singly or in the aggregate, have a Material Adverse Effect; all of the Governmental
Authorizations are valid and in full force and effect, except when the invalidity of such Governmental Authorizations or the failure
of such Governmental Authorizations to be in full force and effect would not have a Material Adverse Effect; and, except as disclosed
in the Time of Sale Prospectus and the Prospectus or in the documents incorporated by reference thereto, neither the Company nor
any of the Subsidiaries has received any notice of proceedings relating to the revocation or modification of any such Governmental
Authorizations, nor are there, to the knowledge of the Company, any pending or threatened actions, suits, claims or proceedings
against the Company or any Subsidiary before any court, governmental agency or body including, but not limited to, CMS, the FDA
and the SAMHSA or otherwise that would reasonably be expected to limit, revoke, cancel, suspend or cause not to be renewed any
Governmental Authorizations, in each case, which, singly or in the aggregate, would result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xxii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Licensing
and Accreditation of Laboratories</U>. All of the regional laboratories of the Company and the Subsidiaries are eligible for accreditation
by CAP and are so accredited, and all of the laboratories of the Company and the Subsidiaries are in compliance, in all material
respects, with the standards required by CLIA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xxiii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Title
to Property</U>. The Company and the Subsidiaries have valid title to all real property owned by the Company and the Subsidiaries
and good title to all other properties owned by them, in each case, free and clear of all mortgages, pledges, liens, security interests,
claims, restrictions or encumbrances of any kind except such as (a)&nbsp;are described in the Time of Sale Prospectus and the Prospectus
and reflected in the financial statements included therein or (b)&nbsp;do not, singly or in the aggregate, materially affect the
value of such property and do not interfere with the use made and proposed to be made of such property by the Company or any of
the Subsidiaries; and all of the leases and subleases material to the business of the Company and the Subsidiaries, considered
as one enterprise, and under which the Company or any of the Subsidiaries holds properties described in the Time of Sale Prospectus
and the Prospectus, are in full force and effect. Except as described in the Time of Sale Prospectus and the Prospectus, neither
the Company nor any of the Subsidiaries has any notice of any claim of any sort that has been asserted by anyone adverse to the
rights of the Company or any of the Subsidiaries under any of the leases or subleases mentioned above, or affecting or questioning
the rights of the Company or any Subsidiary to the continued possession of the leased or subleased premises under any such lease
or sublease, which, singly or in the aggregate, would result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xxiv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Insurance</U>.
The Company and the Subsidiaries carry or are entitled to the benefits of insurance, including, without limitation, professional
liability insurance, with</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">financially sound and reputable insurers, in such amounts, containing such deductibles and covering such
risks as is reasonable and prudent in the view of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xxv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Environmental
Laws</U>. Except for such matters as would not, singly or in the aggregate, result in a Material Adverse Effect, (A)&nbsp;neither
the Company nor any of the Subsidiaries is in violation of any federal, state, local or foreign statute, law, rule, regulation,
ordinance, code, policy or rule of common law or any judicial or administrative interpretation thereof, including any judicial
or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the environment (including,
without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without
limitation, laws and regulations relating to the release or threatened release of chemicals, pollutants, contaminants, wastes,
toxic substances, hazardous substances, medical specimens, petroleum or petroleum products or nuclear or radioactive material (collectively,
&#8220;Hazardous Materials&#8221;) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport
or handling of Hazardous Materials (collectively, &#8220;Environmental Laws&#8221;), (B)&nbsp;the Company and the Subsidiaries
have all permits, licenses, authorizations and approvals currently required for their respective businesses under any applicable
Environmental Laws and are each in compliance with their requirements, (C)&nbsp;there are no pending or threatened administrative,
regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation, investigation
or proceedings relating to any Environmental Law against the Company or any of the Subsidiaries and (D)&nbsp;there are no events,
facts or circumstances that might reasonably be expected to form the basis of any liability or obligation of the Company or any
of the Subsidiaries, including, without limitation, any order, decree, plan or agreement requiring clean-up or remediation, or
any action, suit or proceeding by any private party or governmental body or agency, against or affecting the Company or any of
the Subsidiaries relating to any Hazardous Materials or Environmental Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xxvi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Registration
Rights</U>. Except as disclosed in the Time of Sale Prospectus and the Prospectus or the documents incorporated by reference therein,
there are no holders of securities (debt or equity) of the Company, or holders of rights (including, without limitation, preemptive
rights), warrants or options to obtain securities of the Company, who have the right to request the Company to register securities
held by them under the 1933 Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xxvii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Compliance
with Sarbanes-Oxley</U>. There is not and, since the end of the period covered by the annual financial statements incorporated
by reference in the Time of Sale Prospectus and the Prospectus, there has not been any failure on the part of the Company and its
Subsidiaries and their respective officers and directors to comply with the applicable provisions of the Sarbanes-Oxley Act of
2002 (the &#8220;Sarbanes-Oxley Act&#8221;, which term, as used herein, includes the rules and regulations of the Commission promulgated
thereunder).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xxviii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Accounting
Controls</U>. The Company and its consolidated Subsidiaries maintain a system of internal accounting controls that is in compliance
with the Sarbanes-Oxley Act and is sufficient to provide reasonable assurances that (A)&nbsp;transactions are</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">executed in accordance
with management&#8217;s general or specific authorization; (B)&nbsp;transactions are recorded as necessary to permit preparation
of financial statements in conformity with GAAP and to maintain accountability for assets; (C)&nbsp;access to assets is permitted
only in accordance with management&#8217;s general or specific authorization; and (D)&nbsp;the recorded accountability for assets
is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xxix)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Investment
Company Act</U>. The Company is not, and will not be as a result of the sale of the Notes pursuant to this Agreement, an investment
company within the meaning of the Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xxx)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Reporting
Company</U>. The Company is subject to the reporting requirements of Section 13 or Section 15(d) of the 1934 Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xxxi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Related
Party Transactions</U>. All transactions required to be disclosed under Item 404 of Regulation S-K under the 1933 Act have been
disclosed in the Time of Sale Prospectus and the Prospectus or the Company&#8217;s filings with the Commission under the 1934 Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xxxii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>No
Unlawful Payments</U>. Neither the Company nor any of its Subsidiaries nor any director, officer, or employee of the Company or
any of its Subsidiaries nor, to the knowledge of the Company, any agent, affiliate or other person associated with or acting on
behalf of the Company or any of its subsidiaries has (i) used any funds for any unlawful contribution, gift, entertainment or other
unlawful expense relating to political activity; (ii) made or taken an act in furtherance of an offer, promise or authorization
of any direct or indirect unlawful payment or benefit to any foreign or domestic government or regulatory official or employee,
including of any government-owned or controlled entity or of a public international organization, or any person acting in an official
capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political office;
(iii) materially violated or is in material violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended,
or any applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International
Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom, or any other applicable anti-bribery
or anti-corruption laws; or (iv) made, offered, agreed, requested or taken an act in furtherance of any unlawful bribe or other
unlawful benefit, including, without limitation, any rebate, payoff, influence payment, kickback or other unlawful or improper
payment or benefit. The Company and its Subsidiaries have instituted, and maintain and enforce, policies and procedures designed
to promote and ensure compliance with all applicable anti-bribery and anti-corruption laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xxxiii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Compliance
with Money Laundering Laws</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in
compliance in all material respects with applicable financial recordkeeping and reporting requirements, including those of the
Currency and Foreign Transactions Reporting Act of 1970, as amended, the applicable money laundering statutes of all jurisdictions
where the Company or any of its subsidiaries conducts business, the rules and regulations thereunder and any related or similar
rules, regulations or guidelines issued, administered or enforced by any</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">governmental or regulatory agency (collectively, the &#8220;Money
Laundering Laws&#8221;). No action, suit or proceeding by or before any court or governmental or regulatory agency, authority or
body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or,
to the knowledge of the Company, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xxxiv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>No
Conflict with OFAC Laws or Other Sanctions</U>. Neither the Company nor any of its Subsidiaries nor, to the knowledge of the Company,
any director, officer, agent, employee or affiliate of the Company or any of its Subsidiaries is currently subject to any U.S.
sanctions administered by the U.S. Government, including, without limitation, the Office of Foreign Assets Control of the U.S.
Department of the Treasury (&#8220;OFAC&#8221;), or other relevant sanctions authority (collectively, &#8220;Sanctions&#8221;);
and the Company will not knowingly directly or indirectly use the proceeds of the offering, or lend, contribute or otherwise make
available such proceeds, to any subsidiary, joint venture partner or other person or entity, for the purpose of financing the activities
of any person currently subject to any Sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xxxv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Cybersecurity
and Privacy</U>. Except as disclosed in the Time of Sale Prospectus and the Final Prospectus or except as would not, individually
or in the aggregate, have a Material Adverse Effect, (i) the Company and its Subsidiaries are presently, and since the Company&#8217;s
and its Subsidiaries&#8217; inception have been, in compliance with all privacy policies required by applicable laws, contractual
obligations, applicable state, federal and international laws (including without limitation, if and to the extent applicable, the
Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical
Health Act, the European Union General Data Protection Regulation, and the California Consumer Privacy Act), statutes, judgments,
orders, rules and regulations of any court or arbitrator or other governmental or regulatory authority, all as it relates to data
privacy and information security (&#8220;Data Security Obligations&#8221;); (ii) there is no pending, or to the knowledge of the
Company, threatened, action, suit or proceeding by or before any court or governmental agency, authority or body pending or threatened
alleging non-compliance with any Data Security Obligation; (iii) the Company and its Subsidiaries have established and maintained
reasonable data privacy incident response plans consistent with industry standard practices, which are designed to reasonably respond
data security incidents in accordance with the Data Security Obligations; (iv) the Company is taking reasonable steps to comply
with the California Consumer Privacy Act when such act takes effect with respect to the Company and its Subsidiaries; (v) the Company
and its Subsidiaries have taken all reasonable actions to comply with all applicable laws and regulations with respect to all personally
identifiable, confidential or regulated data in all material respects; and (vi) the Company and its Subsidiaries have at all times
made all disclosures to users or customers required by applicable laws and regulatory rules or requirements and no such disclosures
have been in violation of any applicable laws or regulatory rules and requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Officer&#8217;s
Certificates</I>. Any certificate signed by any officer of the Company or any of its Subsidiaries, as the case may be, delivered
to the Representatives or to counsel for the</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Underwriters shall be deemed a representation and warranty by the Company or any of
the Subsidiaries to each Underwriter as to the matters covered thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<U>Sale
and Delivery to Underwriters; Closing</U>.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Notes</I>.
On the basis of the representations and warranties herein contained and subject to the terms and conditions herein set forth, the
Company agrees to sell to each Underwriter, severally and not jointly, and each Underwriter, severally and not jointly, agrees
to purchase from the Company, at the price set forth in Schedule C-1, the aggregate principal amount of Notes set forth in Schedule
A opposite the name of such Underwriter, plus any additional principal amount of Notes which such Underwriter may become obligated
to purchase pursuant to the provisions of Section 11 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Public
Offering</I>. The Company is advised by you that the Underwriters propose to make a public offering of their respective portions
of the Notes as soon after this Agreement has become effective as in your judgment is advisable. The Company is further advised
by you that the Notes are to be offered to the public upon the terms set forth in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Payment</I>.
Payment of the purchase price for, and delivery of certificates for, the Notes shall be made at the offices of Shearman &amp; Sterling
LLP, 599 Lexington Avenue, New York, New York 10022, or at such other place as shall be agreed upon by the Representatives and
the Company at 9:00 A.M. (New York Time)&nbsp;on May 13, 2020 (unless postponed in accordance with the provisions of Section 11),
or such other time not later than ten business days after such date as shall be agreed upon by the Representatives and the Company
(such time and date of payment and delivery being herein called the &#8220;Closing Time&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Payment shall
be made to the Company by wire transfer of immediately available funds to a bank account designated by the Company against delivery
to the Representatives for the respective accounts of the Underwriters of certificates for the Notes to be purchased by them. It
is understood that each Underwriter has authorized the Representatives, for its account, to accept delivery of, receipt for, and
make payment of the purchase price for, the Notes which it has agreed to purchase. Goldman Sachs, JPMorgan and Mizuho, individually
and not as representatives of the Underwriters, may (but shall not be obligated to) make payment of the purchase price for the
Notes to be purchased by any Underwriter whose funds have not been received by the Closing Time, but such payment shall not relieve
such Underwriter from its obligations hereunder.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Denominations;
Registration</I>. Certificates for the Notes shall be in such denominations and registered in the name of Cede &amp; Co., as nominee
of the Depositary, pursuant to the DTC Agreement. The certificates for the Notes will be made available for examination by the
Representatives in The City of New York not later than 9:00&nbsp;A.M. (New York Time) on the business day prior to the Closing
Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<U>Covenants
of the Company</U>. The Company covenants with each Underwriter as follows:</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Delivery
of Registration Statement, Time of Sale Prospectus and Prospectus</I>. The Company, as promptly as possible, will deliver to each
Underwriter, without charge, as many copies of the Registration Statement (including exhibits thereto and documents incorporated
by</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">reference) and will deliver to each Underwriter during the period mentioned in Section 3(e) or 3(f) below, as many copies of
the Time of Sale Prospectus, the Prospectus and any amendments and supplements thereto and any documents incorporated therein by
reference, in each case, as such Underwriter may reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Amendments
and Supplements</I>. The Company will, before amending or supplementing the Registration Statement, the Time of Sale Prospectus
or the Prospectus, furnish to you a copy of each such proposed amendment or supplement and not file any such proposed amendment
or supplement to which you reasonably object and file with the Commission within the applicable period specified in Rule 424(b)
under the 1933 Act any prospectus required to be filed pursuant to such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Free
Writing Prospectus</I>. The Company will furnish to you a copy of each proposed free writing prospectus to be prepared by or on
behalf of, used by, or referred to by the Company and not use or refer to any proposed free writing prospectus to which you reasonably
object.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Free
Writing Prospectus (Underwriter)</I>. The Company will not take any action that would result in an Underwriter or the Company being
required to file with the Commission pursuant to Rule 433(d) under the 1933 Act a free writing prospectus prepared by or on behalf
of the Underwriter that the Underwriter otherwise would not have been required to file thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Amend
or Supplement Time of Sale Prospectus</I>. If the Time of Sale Prospectus is being used to solicit offers to buy the Notes at a
time when the Prospectus is not yet available to prospective purchasers and any event shall occur or condition exist as a result
of which it is necessary to amend or supplement the Time of Sale Prospectus in order to make the statements therein, in the light
of the circumstances, not misleading, or if any event shall occur or condition exist as a result of which the Time of Sale Prospectus
conflicts with the information contained in the Registration Statement then on file, or if, in the opinion of counsel for the Underwriters
or counsel to the Company, it is necessary to amend or supplement the Time of Sale Prospectus to comply with applicable law, the
Company will forthwith prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer
upon request, either amendments or supplements to the Time of Sale Prospectus so that the statements in the Time of Sale Prospectus
as so amended or supplemented will not, in the light of the circumstances when delivered to a prospective purchaser, be misleading
or so that the Time of Sale Prospectus, as amended or supplemented, will no longer conflict with the Registration Statement, or
so that the Time of Sale Prospectus, as amended or supplemented, will comply with applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Amend
or Supplement Prospectus</I>. If, during such period after the first date of the public offering of the Notes, in the opinion of
counsel for the Underwriters or counsel to the Company, the Prospectus (or in lieu thereof the notice referred to in Rule 173(a)
under the 1933 Act) is required by law to be delivered in connection with sales by an Underwriter or dealer, any event shall occur
or condition exist as a result of which it is necessary to amend or supplement the Prospectus in order to make the statements therein,
in the light of the circumstances when the Prospectus (or in lieu thereof the notice referred to in Rule 173(a) under the 1933
Act) is delivered to a purchaser, not misleading, or if, in the opinion of counsel for the Underwriters or counsel to the Company,
it is necessary to amend or supplement the Prospectus to comply with applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">law, the Company will forthwith prepare, file with
the Commission and furnish, at its own expense, to the Underwriters and to the dealers (whose names and addresses you will furnish
to the Company) to which Notes may have been sold by you on behalf of the Underwriters and to any other dealers upon request, either
amendments or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not, in
the light of the circumstances when the Prospectus (or in lieu thereof the notice referred to in Rule 173(a) under the 1933 Act)
is delivered to a purchaser, be misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Blue
Sky Qualifications</I>. The Company will use its reasonable best efforts, in cooperation with the Underwriters, to qualify the
Notes for offering and sale under the applicable securities laws of such states and other jurisdictions (domestic or foreign) as
the Representatives may designate and to maintain such qualifications in effect as long as required for the sale of the Notes;
<I>provided</I>, <I>however</I>, that (i) the Company shall in no event be required to continue in effect any such qualification
for a period of more than 180 days after the Closing Time, (ii) the Company will not be required to qualify as a foreign corporation
or to file a general consent to service of process in any jurisdiction in which they are not so qualified and (iii) the Company
will not be required to subject itself to taxation (other than any nominal amount) in any jurisdiction if not otherwise so subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Rule
158</I>. The Company will timely file such reports pursuant to the 1934 Act as are necessary in order to make generally available
to their securityholders as soon as practicable an earnings statement for the purposes of, and to provide the benefits contemplated
by, the last paragraph of Section 11(a) of the 1933 Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Use
of Proceeds</I>. The Company will use the net proceeds received by them from the sale of the Notes in the manner specified in the
Time of Sale Prospectus and the Prospectus under &#8220;Use of Proceeds&#8221;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Restriction
on Sale of Notes</I>. Except as otherwise contemplated in the Time of Sale Prospectus and the Prospectus, during the period commencing
on the date hereof and ending at the Closing Time, the Company will not, without the prior written consent of the Underwriters,
(i) directly or indirectly, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option
or contract to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of any debt securities or
guarantees of debt securities of the Company or any securities convertible into or exercisable or exchangeable for any debt securities
or guarantees of debt securities of the Company or file any registration statement under the 1933 Act with respect to any of the
foregoing or (ii) enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or
indirectly, the economic consequence of ownership of any debt securities or guarantees of debt securities of the Company, whether
any such swap or transaction described in clause (i) or (ii) above is to be settled by delivery of any debt securities or guarantees
of debt securities of the Company or such other securities, in cash or otherwise. The foregoing sentence shall not apply to the
Notes to be sold hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Final
Term Sheet</I>. The Company will prepare a final term sheet relating to the offering of the Notes, containing only information
that describes the final terms of the Notes or the offering in a form consented to by the Representatives, and will file such final
term sheet within</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">the period required by Rule 433(d)(5)(ii) under the 1933 Act following the date the final terms have been established
for the offering of the Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Reporting
Requirements</I>. The Company, during the period when the Time of Sale Prospectus or the Prospectus is required to be delivered,
will file all documents required to be filed with the Commission pursuant to the 1934 Act within the time periods required by the
1934 Act and the 1934 Act Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>DTC
Clearance</I>. The Company will use all reasonable efforts in cooperation with the Underwriters to permit the Notes to be eligible
for clearance and settlement through The Depository Trust Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<U>Payment
of Expenses</U>.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Expenses</I>.
The Company will pay all expenses incident to the performance of its obligations under this Agreement, including (i)&nbsp;the preparation,
filing and printing of the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, the Prospectus, any
free writing prospectus prepared by or on behalf of, used by, or referred to by the Company (including financial statements and
any schedules or exhibits)&nbsp;and of each amendment or supplement thereto, including the filing fees payable to the Commission
relating to the Notes (within the time required by Rule 456(b)(1), if applicable), and the delivery to the Underwriters of copies
of each, (ii)&nbsp;the preparation, printing and delivery to the Underwriters of this Agreement, the DTC Agreement, the Indenture
and such other documents as may be required in connection with the offering, purchase, sale and delivery of the Notes, (iii)&nbsp;the
preparation, issuance and delivery of the certificates for the Notes to the Underwriters, (iv)&nbsp;the fees and disbursements
of the Company&#8217;s counsel, accountants and other advisors, (v)&nbsp;the qualification of the Notes under securities laws in
accordance with the provisions of Section 3(g)&nbsp;hereof, including filing fees and the reasonable fees and disbursements of
counsel for the Underwriters in connection therewith and in connection with the preparation of any Blue Sky Survey and any supplement
thereto, (vi)&nbsp;the fees and expenses of the Trustee, including the fees and disbursements of counsel for the Trustee in connection
with the Indenture and the Notes, (vii)&nbsp;the filing fees incident to, and the reasonable fees and disbursements of counsel
to the Underwriters in connection with, the review by The Financial Industry Regulatory Authority, Inc. (the &#8220;FINRA&#8221;)
of the terms of the sale of the Notes, if any, (viii) any fees payable in connection with the rating of the Notes and (ix) the
preparation, printing and delivery to the Underwriters of copies of any Blue Sky Survey and any supplement thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Termination
of Agreement</I>. If this Agreement is terminated by the Representatives in accordance with the provisions of Section 5 or Section
10(a)(i), 10(a)(ii)&nbsp;or Section 12&nbsp;hereof, the Company shall reimburse the Underwriters for all of their out-of-pocket
expenses, including the reasonable fees and disbursements of counsel for the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<U>Conditions
of Underwriters&#8217; Obligations</U>. The obligations of the several Underwriters hereunder are subject to the accuracy of the
representations and warranties of the Company contained in Section 1(a) hereof or in certificates of any officer of the Company
delivered pursuant to the provisions hereof, to the performance by the Company of its covenants and other obligations hereunder
and to the following further conditions:</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Opinion
of Counsel for the Company</I>. At the Closing Time, the Representatives shall have received the favorable opinion, dated as of
the Closing Time, of Shearman &amp; Sterling LLP, counsel for the Company, in form and substance reasonably satisfactory to counsel
for the Underwriters, together with signed or reproduced copies of such letters for each of the other Underwriters in substantially
the form set forth in Exhibit A hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Opinion
of Deputy General Counsel of the Company</I>. At the Closing Time, the Representatives shall have received the favorable opinion,
dated as of the Closing Time, of William J. O&#8217;Shaughnessy, Deputy General Counsel of the Company, in form and substance reasonably
satisfactory to counsel for the Underwriters, together with signed or reproduced copies of such letters for each of the other Underwriters
in substantially the form set forth in Exhibit B hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Opinion
of Counsel for the Underwriters</I>. At the Closing Time, the Representatives shall have received the favorable opinion, dated
as of the Closing Time, of Fried, Frank, Harris, Shriver &amp; Jacobson LLP, counsel for the Underwriters, together with signed
or reproduced copies of such letter for each of the other Underwriters. In giving such opinion such counsel may rely, as to all
matters governed by the laws of jurisdictions other than the law of the State of New York and the federal law of the United States
and the General Corporation Law of the State of Delaware, upon the opinions of counsel satisfactory to the Representatives. Such
counsel may also state that, insofar as such opinion involves factual matters, they have relied, to the extent they deem proper,
upon certificates of officers of the Company and the Subsidiaries and certificates of public officials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Officers&#8217;
Certificate</I>. At the Closing Time, (i)&nbsp;the Prospectus, as it may then be amended or supplemented, including the documents
incorporated by reference therein, shall not contain an untrue statement of a material fact or omit to state a material fact necessary
to make the statements therein, in light of the circumstances under which they were made, not misleading; (ii)&nbsp;there shall
not have been, since the respective dates as of which information is given in the Time of Sale Prospectus, any Material Adverse
Effect; (iii)&nbsp;the Company shall have complied with all agreements and satisfied all conditions on its part to be performed
or satisfied at or prior to the Closing Time; and (iv)&nbsp;the representations and warranties of the Company in Section&nbsp;1(a)
shall be accurate and true and correct as though expressly made at and as of the Closing Time. The Representatives shall have received
a certificate of Mark J. Guinan, Executive Vice President and Chief Financial Officer of the Company, and Sandip Patel, Vice President
&amp; Treasurer of the Company, dated as of the Closing Time, to such effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Prospectus,
Final Term Sheet and Free Writing Prospectus</I>. The Prospectus shall have been filed with the Commission pursuant to Rule 424(b)
under the 1933 Act within the applicable time period prescribed for such filing by the rules and regulations under the 1933 Act;
the final term sheet substantially in the form of Schedule C-2 hereto, and any material required to be filed by the Company pursuant
to Rule 433(d) under the 1933 Act, shall have been filed with the Commission within the applicable time periods prescribed for
such filings by Rule 433; no stop order suspending the effectiveness of the Registration Statement or any part thereof shall have
been issued and no proceeding for that purpose shall have been initiated or, to the Company&#8217;s knowledge, threatened by the
Commission and no notice of objection of the Commission to the use of the Registration Statement or any post-effective amendment
thereto pursuant to Rule</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">401(g)(2) under the 1933 Act shall have been received; no stop order suspending or preventing the use
of the Prospectus or any issuer free writing prospectus shall have been initiated or threatened by the Commission; and all requests
for additional information on the part of the Commission shall have been complied with to the Representatives&#8217; reasonable
satisfaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Comfort
Letters</I>. At each of the times of the execution of this Agreement and the Closing Time, the Representatives shall have received
from PricewaterhouseCoopers LLP letters with respect to the Company dated the date hereof or the Closing Time, as the case may
be, in form and substance satisfactory to the Representatives or to counsel for the Underwriters and to PricewaterhouseCoopers
LLP, together with signed or reproduced copies of such letter for each of the other Underwriters, containing statements and information
of the type ordinarily included in accountants&#8217; &#8220;comfort letters&#8221; to Underwriters with respect to the financial
statements and certain financial information of the Company contained in the Registration Statement, the Time of Sale Prospectus
and the Prospectus; <I>provided</I> that the letter delivered at the Closing Time shall use a &#8220;cut-off date&#8221; no more
than three business days prior to the Closing Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Maintenance
of Rating</I>. At the Closing Time, the Notes shall be rated at investment grade by Moody&#8217;s Investors Service, Inc., S&amp;P
Global Ratings and Fitch Ratings, Inc. and the Company shall have delivered to the Representatives a letter dated the Closing Time,
from each such rating agency, or other evidence satisfactory to the Representatives, confirming that the Notes have such ratings;
and since the date of this Agreement, there shall not have occurred a downgrading in, or withdrawal of, the rating assigned to
the Notes or any of the Company&#8217;s other debt securities or debt instruments by any &#8220;nationally recognized statistical
rating organization&#8221; (as that term is defined under Section 3(a)(62) of the 1934 Act), and no such organization shall have
publicly announced that it has under surveillance or review its rating of the Notes or any of the Company&#8217;s other debt securities
or debt instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Twenty-First
Supplemental Indenture</I>. At or prior to the Closing Time, the Company and the Trustee shall have executed and delivered the
Twenty-First Supplemental Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Additional
Documents</I>. At the Closing Time, counsel for the Underwriters shall have been furnished with such documents and opinions as
they may reasonably require (including any consents under any agreements to which the Company is a party) for the purpose of enabling
them to pass upon the issuance and sale of the Notes as herein contemplated, or in order to evidence the accuracy of any of the
representations or warranties, or the fulfillment of any of the conditions, herein contained; and all proceedings taken by the
Company in connection with the issuance and sale of the Notes as herein contemplated shall be satisfactory in form and substance
to the Representatives and counsel for the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Termination
of Agreement</I>. If any condition specified in this Section shall not have been fulfilled when and as required to be fulfilled,
this Agreement may be terminated by the Representatives by notice to the Company at any time at or prior to the Closing Time, and
such termination shall be without liability of any party to any other party except as provided in Section 4 and except that Sections
1, 7, 8 and 9 shall survive any such termination and remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<U>Covenants
of the Underwriters</U>. Each Underwriter severally covenants with the Company not to take any action that would result in the
Company being required to file with the Commission under Rule 433(d) a free writing prospectus prepared by or on behalf of such
Underwriter that otherwise would not be required to be filed by the Company thereunder, but for the action of the Underwriter.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<U>Indemnification</U>.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Indemnification
of the Underwriters</I>. The Company agrees to indemnify and hold harmless each Underwriter, the directors and officers of each
Underwriter, and each person, if any, who controls any Underwriter within the meaning of Section 15 of the 1933 Act or Section
20 of the 1934 Act to the extent and in the manner set forth in clauses (i), (ii) and (iii) below, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>against
any and all loss, liability, claim, damage and expense whatsoever, as incurred, arising out of any untrue statement or alleged
untrue statement of a material fact contained in the Registration Statement or amendment thereof, any preliminary prospectus, the
Time of Sale Prospectus, any issuer free writing prospectus as defined in Rule 433(h) under the 1933 Act, any Company information
that the Company has filed, or is required to file, pursuant to Rule 433(d) under the 1933 Act or the Prospectus or any amendment
or supplement thereto, or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary
in order to make the statements therein, (and other than with respect to the Registration Statement, in light of the circumstances
in which they were made) not misleading;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>against
any and all loss, liability, claim, damage and expense whatsoever, as incurred, to the extent of the aggregate amount paid in settlement
of any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or of any claim
whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission; <I>provided</I>
that (subject to Section 7(d)&nbsp;below)&nbsp;any such settlement is effected with the written consent of the Company; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>against
any and all expense whatsoever, as incurred (including the fees and disbursements of counsel chosen by the Representatives), reasonably
incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental
agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue statement or omission, or any such
alleged untrue statement or omission, to the extent that any such expense is not paid under (i)&nbsp;or (ii)&nbsp;above;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>provided</I>, <I>however</I>, that
this indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising out of any untrue
statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with written information
furnished to the Company by any Underwriter through the Representatives expressly for use therein.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Indemnification
of Company, Directors and Officers</I>. Each Underwriter severally agrees to indemnify and hold harmless the Company, its directors
and officers, and each person, if any, who controls the Company within the meaning of Section 15 of the 1933 Act or Section 20
of the 1934 Act against any and all loss, liability, claim, damage and expense described in the</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">indemnity contained in subsection&nbsp;(a)
of this Section, as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements or omissions,
made in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, any issuer free writing prospectus
or the Prospectus or any amendment or supplement thereto, in reliance upon and in conformity with written information furnished
to the Company by such Underwriter through the Representatives expressly for use therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Actions
against Parties; Notification</I>. Each indemnified party shall give notice as promptly as reasonably practicable to each indemnifying
party of any action commenced against it in respect of which indemnity may be sought hereunder, but failure to so notify an indemnifying
party shall not relieve such indemnifying party from any liability hereunder to the extent it is not materially prejudiced as a
result thereof and in any event shall not relieve it from any liability which it may have otherwise than on account of this indemnity
agreement. In the case of parties indemnified pursuant to Section 7(a) above, counsel to such indemnified parties shall be selected
by the Representatives, and, in the case of parties indemnified pursuant to Section 7(b) above, counsel to such indemnified parties
shall be selected by the Company. An indemnifying party may participate at its own expense in the defense of any such action; <I>provided</I>,
<I>however</I>, that counsel to the indemnifying party shall not (except with the consent of the indemnified party)&nbsp;also be
counsel to the indemnified party. In no event shall the indemnifying parties be liable for fees and expenses of more than one counsel
(in addition to any local counsel)&nbsp;separate from their own counsel for all indemnified parties in connection with any one
action or separate but similar or related actions in the same jurisdiction arising out of the same general allegations or circumstances.
No indemnifying party shall, without the prior written consent of the indemnified parties, settle or compromise or consent to the
entry of any judgment with respect to any litigation, or any investigation or proceeding by any governmental agency or body, commenced
or threatened, or any claim whatsoever in respect of which indemnification or contribution could be sought under this Section 7
or Section 8 hereof (whether or not the indemnified parties are actual or potential parties thereto), unless such settlement, compromise
or consent (i)&nbsp;includes an unconditional release of each indemnified party from all liability arising out of such litigation,
investigation, proceeding or claim and (ii)&nbsp;does not include a statement as to or an admission of fault, culpability or a
failure to act by or on behalf of any indemnified party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Settlement
without Consent if Failure to Reimburse</I>. If at any time an indemnified party shall have requested an indemnifying party to
reimburse the indemnified party for fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any
settlement of the nature contemplated by Section 7(a)(ii)&nbsp;effected without its written consent if (i)&nbsp;such settlement
is entered into more than 60 days after receipt by such indemnifying party of the aforesaid request, (ii)&nbsp;such indemnifying
party shall have received notice of the terms of such settlement at least 45 days prior to such settlement being entered into and
(iii)&nbsp;such indemnifying party shall not have reimbursed such indemnified party for the indemnified party&#8217;s reasonable
fees and expenses of counsel in accordance with such request prior to the date of such settlement. Notwithstanding the immediately
preceding sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified
party for fees and expenses of counsel, an indemnifying party shall not be liable for any settlement effected without its consent
if such indemnifying party (A) reimburses such indemnified party in accordance with such request to the extent it considers such
request to be reasonable and (B) provides written notice to the indemnified party disputing the unpaid balance in good faith and
substantiating the unpaid balance as</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">unreasonable, in each case prior to the date of such settlement, subject to provision of notice
by the indemnified party in accordance with (i) and (ii) above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<U>Contribution</U>.
If the indemnification provided for in Section&nbsp;7 hereof is for any reason unavailable to or insufficient to hold harmless
an indemnified party in respect of any losses, liabilities, claims, damages or expenses referred to therein, then each indemnifying
party shall contribute to the aggregate amount of such losses, liabilities, claims, damages and expenses incurred by such indemnified
party, as incurred, (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company on the
one hand and the Underwriters on the other hand from the offering of the Notes pursuant to this Agreement or (ii)&nbsp;if the allocation
provided by clause&nbsp;(i)&nbsp;is not permitted by applicable law, in such proportion as is appropriate to reflect not only the
relative benefits referred to in clause&nbsp;(i)&nbsp;above but also the relative fault of the Company on the one hand and of the
Underwriters on the other hand in connection with the statements or omissions which resulted in such losses, liabilities, claims,
damages or expenses, as well as any other relevant equitable considerations.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The relative benefits
received by the Company on the one hand and the Underwriters on the other hand in connection with the offering of the Notes pursuant
to this Agreement shall be deemed to be in the same respective proportions as the total net proceeds from the offering of the Notes
pursuant to this Agreement (before deducting expenses)&nbsp;received by the Company and the total discount received by the Underwriters,
in each case as set forth on the cover of the Prospectus bear to the aggregate initial offering prices of the Notes as set forth
on such cover of the Prospectus.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The relative fault
of the Company on the one hand and the Underwriters on the other hand shall be determined by reference to, among other things,
whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact
relates to information supplied by the Company or by the Underwriters, and the parties&#8217; relative intent, knowledge, access
to information and opportunity to correct or prevent such statement or omission.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company and
the Underwriters agree that it would not be just and equitable if contribution pursuant to this Section&nbsp;8 were determined
by pro rata allocation (even if the Underwriters were treated as one entity for such purpose)&nbsp;or by any other method of allocation
which does not take account of the equitable considerations referred to above in this Section 8. The aggregate amount of losses,
liabilities, claims, damages and expenses incurred by an indemnified party and referred to above in this Section 8 shall be deemed
to include any legal or other expenses reasonably incurred by such indemnified party in investigating, preparing or defending against
any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever
based upon any such untrue or alleged untrue statement or omission or alleged omission.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding
the provisions of this Section&nbsp;8, no Underwriter shall be required to contribute any amount in excess of the amount by which
the total price at which the Notes sold by it exceeds the amount of any damages which such Underwriter has otherwise been required
to pay by reason of such untrue or alleged untrue statement or omission or alleged omission.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No person guilty
of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f)&nbsp;of the 1933 Act)&nbsp;shall be entitled to contribution
from any person who was not guilty of such fraudulent misrepresentation.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of
this Section&nbsp;8, (a) each person, if any, who controls an Underwriter within the meaning of Section 15 of the 1933 Act or Section
20 of the 1934 Act shall have the same rights to contribution as such Underwriter and (b) each director of the Company and each
person, if any, who controls the Company, as the case may be, within the meaning of Section 15 of the 1933 Act or Section 20 of
the 1934 Act shall have the same rights to contribution as the Company. The Underwriters&#8217; respective obligations to contribute
pursuant to this Section 8 are several in proportion to the principal amount of Notes set forth opposite their respective names
in Schedule&nbsp;A hereto and not joint.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<U>Representations,
Warranties and Agreements to Survive Delivery</U>. All representations, warranties and agreements contained in this Agreement or
in certificates of officers of the Company or any of the Subsidiaries submitted pursuant hereto shall remain operative and in full
force and effect, regardless of any investigation made by or on behalf of any Underwriter or controlling person, or by or on behalf
of the Company, and shall survive delivery of the Notes to the Underwriters.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<U>Termination
of Agreement</U>.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Termination;
General</I>. The Representatives may terminate this Agreement, by notice to the Company, at any time at or prior to the Closing
Time (i)&nbsp;if there has been, since the time of execution of this Agreement or since the respective dates as of which information
is given in the Time of Sale Prospectus, any material adverse change in the condition (financial or otherwise), earnings, business
affairs or business prospects of the Company and the Subsidiaries considered as one enterprise, whether or not arising in the ordinary
course of business, (ii)&nbsp;if there shall have occurred a downgrading in the rating of the Company&#8217;s debt securities by
any nationally recognized statistical rating organization, or if such rating organization shall have publicly announced that it
has under surveillance or review, with possible negative implications, its rating of the Company&#8217;s debt securities, (iii)
if there has occurred any material adverse change in the financial markets in the United States or the international financial
markets, any outbreak of hostilities or escalation thereof or other calamity or crisis or any change or development involving a
prospective change in national or international political, financial or economic conditions, in each case the effect of which is
such as to make it, in the judgment of the Representatives, impracticable to market the Notes or to enforce contracts for the sale
of the Notes, (iv)&nbsp;if trading in any securities of the Company has been suspended or limited by the Commission or the New
York Stock Exchange, or if trading generally on the New York Stock Exchange or on the NASDAQ Global Select Market has been suspended
or limited, or minimum or maximum prices for trading have been fixed, or maximum ranges for prices have been required, by any of
said exchanges or by such system or by order of the Commission, FINRA or any other governmental authority, or (v)&nbsp;if a banking
moratorium has been declared by either federal or New York authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Liabilities</I>.
If this Agreement is terminated pursuant to this Section, such termination shall be without liability of any party to any other
party except as provided in Section</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4 hereof, and provided further that Sections 1, 7, 8 and 9 shall survive such termination and
remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<U>Default
by One or More of the Underwriters</U>. If one or more of the Underwriters shall fail at the Closing Time to purchase the Notes
which it or they are obligated to purchase under this Agreement (the &#8220;Defaulted Notes&#8221;), the Representatives shall
have the right, but not the obligation, within 24 hours thereafter, to make arrangements for one or more of the non-defaulting
Underwriters, or any other underwriters, to purchase all, but not less than all, of the Defaulted Notes in such amounts as may
be agreed upon and upon the terms herein set forth; if, however, the Representatives shall not have completed such arrangements
within such 24-hour period, then:</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>if
the number of Defaulted Notes does not exceed 10% of the aggregate principal amount of the Notes to be purchased hereunder, each
of the non-defaulting Underwriters shall be obligated, severally and not jointly, to purchase the full amount thereof in the proportions
that their respective obligations hereunder bear to the obligations of all non-defaulting Underwriters, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>if
the number of Defaulted Notes exceeds 10% of the aggregate principal amount of the Notes to be purchased hereunder, this Agreement
shall terminate without liability on the part of any non-defaulting Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No action taken
pursuant to this Section shall relieve any defaulting Underwriters from liability in respect of its default.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of
any such default which does not result in a termination of this Agreement, either (i) the Representatives or (ii) the Company shall
have the right to postpone the Closing Time for a period not exceeding seven days in order to effect any required changes in the
Registration Statement, in the Time of Sale Prospectus, in the Prospectus or in any other documents or arrangements. As used herein,
the term &#8220;Underwriters&#8221; includes any person substituted for an Underwriter under this Section 11.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<U>Default
by the Company</U>. If the Company shall fail at the Closing Time to sell the number of Notes that they are obligated to sell hereunder,
then this Agreement shall terminate without any liability on the part of any non-defaulting party; <I>provided</I>, <I>however</I>,
that the provisions of Sections 1, 4, 7, 8 and 9 shall remain in full force and effect. No action taken pursuant to this Section
shall relieve the Company from liability, if any, in respect of such default.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<U>Notices</U>.
All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed or transmitted
by any standard form of telecommunication. Notices to the Underwriters shall be directed to Goldman Sachs &amp; Co. LLC, 200 West
Street, New York, NY 10282, attention of Registration Department, with a copy to Fried, Frank, Harris, Shriver &amp; Jacobson LLP,
One New York Plaza, New York, New York 10004, attention of Mark S. Hayek, Esq.; J.P. Morgan Securities LLC, 383 Madison Ave., 3rd
Floor, New York, NY 10179, attention of Investment Grade Syndicate Desk, with a copy to Fried, Frank, Harris, Shriver &amp; Jacobson
LLP, One New York Plaza, New York, New York 10004, attention of Mark S. Hayek, Esq.; Mizuho Securities USA LLC, 320 Park Avenue,
12<SUP>th</SUP> Floor, New</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">York, NY 10022, attention of Debt Capital Markets, with a copy to Fried, Frank, Harris, Shriver &amp;
Jacobson LLP, One New York Plaza, New York, New York 10004, attention of Mark S. Hayek, Esq.; and notices to the Company shall
be directed to it at 500 Plaza Drive, Secaucus, NJ 07094 attention of Deputy General Counsel and Corporate Secretary, with a copy
to Shearman &amp; Sterling LLP, 599 Lexington Avenue, New York, New York 10022, attention of Lona Nallengara, Esq.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<U>Parties</U>.
This Agreement shall inure to the benefit of and be binding upon the Underwriters and the Company and their respective successors.
Nothing expressed or mentioned in this Agreement is intended or shall be construed to give any person, firm or corporation, other
than the Underwriters and the Company and their respective successors and the controlling persons and officers and directors referred
to in Sections&nbsp;7 and 8 and their heirs and legal representatives, any legal or equitable right, remedy or claim under or in
respect of this Agreement or any provision herein contained. This Agreement and all conditions and provisions hereof are intended
to be for the sole and exclusive benefit of the Underwriters and the Company and their respective successors, and said controlling
persons and officers and directors and their heirs and legal representatives, and for the benefit of no other person, firm or corporation.
No purchaser of the Notes from any of the Underwriters shall be deemed to be a successor by reason merely of such purchase.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<U>Governing
Law and Time</U>. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT
REGARD TO CONFLICTS OF LAW PRINCIPLES THEREOF. SPECIFIED TIMES OF DAY HEREIN REFER TO NEW YORK CITY TIME.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<U>Effect
of Headings</U>. The Article, Section and subsection headings herein and the Table of Contents are for convenience only and shall
not affect the construction hereof.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<U>Partial
Unenforceability</U>. The invalidity or unenforceability of any section, paragraph or provision of this Agreement shall not affect
the validity or enforceability of any other section, paragraph or provision hereof. If any section, paragraph or provision of this
Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and
only such minor changes) as are necessary to make it valid and enforceable.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<U>No
Advisory or Fiduciary Responsibility</U><I>.</I> The Company acknowledges and agrees that: (i) the purchase and sale of the Notes
pursuant to this Agreement, including the determination of the offering price of the Notes and any related discounts and commissions,
is an arm&#8217;s-length commercial transaction between the Company, on the one hand, and the several Underwriters, on the other
hand, and the Company is capable of evaluating and understanding and understands and accepts the terms, risks and conditions of
the transactions contemplated by this Agreement; (ii) in connection with each transaction contemplated hereby and the process leading
to such transaction each Underwriter is and has been acting solely as a principal and is not the agent or fiduciary of the Company
or its affiliates, stockholders, creditors or employees or any other party; (iii) no Underwriter has assumed or will assume an
advisory or fiduciary responsibility in favor of the Company with respect to any of the transactions contemplated hereby or the
process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company on other matters)
or any other obligation to the Company except the obligations</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">expressly set forth in this Agreement; (iv) the several Underwriters
and their respective affiliates may be engaged in a broad range of transactions that involve interests that differ from those of
the Company and that the several Underwriters have no obligation to disclose any of such interests by virtue of any fiduciary or
advisory relationship; and (v) the Underwriters have not provided any legal, accounting, regulatory or tax advice with respect
to the offering contemplated hereby and the Company has consulted its own legal, accounting, regulatory and tax advisors to the
extent it deemed appropriate. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the
Company may have against the several Underwriters with respect to any breach or alleged breach of fiduciary duty.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<U>Recognition
of the U.S. Special Resolution Regimes</U>.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime,
the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective
to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such
interest and obligation, were governed by the laws of the United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding
under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are
permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime
if this Agreement were governed by the laws of the United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As used in this
Section 19:</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;BHC Act
Affiliate&#8221; has the meaning assigned to the term &#8220;affiliate&#8221; in, and shall be interpreted in accordance with,
12 U.S.C. &sect; 1841(k).</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;Covered
Entity&#8221; means any of the following:</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;a
&#8220;covered entity&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 252.82(b);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>a
&#8220;covered bank&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 47.3(b); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>a
&#8220;covered FSI&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 382.2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;Default
Right&#8221; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &sect;&sect; 252.81,
47.2 or 382.1, as applicable.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;U.S. Special
Resolution Regime&#8221; means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii)
Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 20.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<U>General
Provisions</U>.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>General</I>.
This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written or oral and all
contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. This Agreement may
be executed in two or more counterparts, each one of which shall be an original, with the same effect as if the signatures thereto
and hereto were upon the same instrument. <FONT STYLE="background-color: white">Any signature delivered by a party hereto via facsimile,
electronic&nbsp;mail in &#8220;portable document format&#8221; (.pdf) form or any other electronic&nbsp;transmission shall be deemed
to be an original signature hereto. </FONT>This Agreement may not be amended or modified unless in writing by all of the parties
hereto, and no condition herein (express or implied) may be waived unless waived in writing by each party whom the condition is
meant to benefit. The section headings herein are for the convenience of the parties only and shall not affect the construction
or interpretation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>USA
Patriot Act.</I> In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. 107-56 (signed into law October
26, 2001)), the Underwriters are required to obtain, verify and record information that identifies their respective clients, including
the Company, which information may include the name and address of their respective clients, as well as other information that
will allow the Underwriters to properly identify their respective clients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the foregoing
is in accordance with your understanding of our agreement, please sign and return to the Company a counterpart hereof, whereupon
this instrument, along with all counterparts, will become a binding agreement among the Underwriters and the Company in accordance
with its terms.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Very Truly Yours,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 47%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 10%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 30%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">QUEST DIAGNOSTICS INCORPORATED</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">/s/ Sandip Patel</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Name:</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Sandip Patel </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Title:</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Vice President &amp; Treasurer </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Page to Quest Diagnostics
Incorporated Underwriting Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CONFIRMED AND ACCEPTED,<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;as of the date first above written:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">GOLDMAN SACHS &amp; CO. LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">J.P. MORGAN SECURITIES LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">MIZUHO SECURITIES USA LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By: GOLDMAN SACHS &amp; CO. LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By <U>/s/Adam T. Greene&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Name: Adam T. Greene</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Title: Managing Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By: J.P. MORGAN SECURITIES LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By <U>/s/Robert Bottamedi&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Name: Robert Bottamedi</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Title: Executive Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By: MIZUHO SECURITIES USA LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By <U>/s/Joseph Santaniello&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Name: Joseph Santaniello</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Title: Vice President</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For themselves and the other Underwriters</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">named in Schedule A hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Page to Quest Diagnostics
Incorporated Underwriting Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>SCHEDULE A &#8211; <FONT STYLE="text-transform: uppercase">Underwriters</FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: center"><B>Name of Underwriter</B></TD>
    <TD STYLE="width: 40%; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: center"><B>Principal Amount<BR>
of Notes To Be Purchased</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Goldman Sachs &amp; Co. LLC</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$118,250,000</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">J.P. Morgan Securities LLC</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$118,250,000</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Mizuho Securities USA LLC</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$118,250,000</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Morgan Stanley &amp; Co. LLC</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$49,500,000</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Wells Fargo Securities, LLC</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$49,500,000</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Credit Agricole Securities (USA) Inc.</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$23,375,000</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">MUFG Securities Americas Inc.</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$20,625,000</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Fifth Third Securities, Inc.</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$13,750,000</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">PNC Capital Markets LLC</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$13,750,000</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">BNY Mellon Capital Markets, LLC</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$8,250,000</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">BofA Securities, Inc.</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$8,250,000</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">KeyBanc Capital Markets Inc.</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$8,250,000</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-indent: 22.5pt">Total:</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1.5pt double; padding-right: -0.9pt; padding-bottom: 6pt; text-align: right">$550,000,000</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 29.85pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 29.85pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 29.85pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 29.85pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 29.85pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 29.85pt 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 29.85pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>SCHEDULE B &#8211; TIME OF SALE PROSPECTUS</U></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">1.</TD><TD>Prospectus dated June 14, 2019 relating to the Shelf Securities.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">2.</TD><TD>Preliminary prospectus supplement dated May 11, 2020 relating to the Notes.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">Final Term Sheet for the Notes.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 35; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>SCHEDULE C-1 &#8211; PURCHASE PRICE</U></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The purchase price
for the 2.800% Senior Notes due 2031 is 99.204%.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 36; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;C-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>FINAL TERM SHEET</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Dated May 11, 2020</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$550,000,000</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Quest Diagnostics Incorporated</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$550,000,000 2.800% Senior Notes due
2031</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>Issuer:</B></TD>
    <TD COLSPAN="2" STYLE="padding: 0.05in 5.75pt">Quest Diagnostics Incorporated</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>Trade Date:</B></TD>
    <TD COLSPAN="2" STYLE="padding: 0.05in 5.75pt">May 11, 2020</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>Original Issue Date (Settlement):</B></TD>
    <TD COLSPAN="2" STYLE="padding: 0.05in 5.75pt">May 13, 2020 (T+2)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>Interest Accrual Date:</B></TD>
    <TD COLSPAN="2" STYLE="padding: 0.05in 5.75pt">May 13, 2020</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>Ratings:*</B></TD>
    <TD COLSPAN="2" STYLE="padding: 0.05in 5.75pt">[Intentionally Omitted]</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>Principal Amount:</B></TD>
    <TD COLSPAN="2" STYLE="padding: 0.05in 5.75pt">$550,000,000</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>Maturity Date:</B></TD>
    <TD COLSPAN="2" STYLE="padding: 0.05in 5.75pt">June 30, 2031</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>Issue Price (Price to Public):</B></TD>
    <TD COLSPAN="2" STYLE="padding: 0.05in 5.75pt">99.854%&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>Yield:</B></TD>
    <TD COLSPAN="2" STYLE="padding: 0.05in 5.75pt">2.815%</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>Interest Rate:</B></TD>
    <TD COLSPAN="2" STYLE="padding: 0.05in 5.75pt">2.800% per annum</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>Interest Payment Period:</B></TD>
    <TD COLSPAN="2" STYLE="padding: 0.05in 5.75pt">Semi-annual</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>Interest Payment Dates:</B></TD>
    <TD COLSPAN="2" STYLE="padding: 0.05in 5.75pt">Each June 30 and December 30, commencing December 30, 2020</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>Treasury Benchmark:</B></TD>
    <TD COLSPAN="2" STYLE="padding: 0.05in 5.75pt">1.500% due February 15, 2030</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>Spread to Benchmark:</B></TD>
    <TD COLSPAN="2" STYLE="padding: 0.05in 5.75pt">T+210 bps</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>Benchmark Yield:</B></TD>
    <TD COLSPAN="2" STYLE="padding: 0.05in 5.75pt">0.715%</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>Optional Redemption:</B></TD>
    <TD COLSPAN="2" STYLE="padding: 0.05in 5.75pt">Prior to March 30, 2031 (three months prior to their maturity date) (the &#8220;par call date&#8221;), the Notes will be redeemable, as a whole or in part, at the option of the Issuer, on at least 10 days, but not more than 60 days, prior notice mailed to the registered address of each holder of the Notes, at a redemption price equal to the greater of:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt">&nbsp;</TD>
    <TD STYLE="padding: 0.05in 5.75pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="padding: 0.05in 5.75pt">100% of principal amount of the Notes to be redeemed, and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt">&nbsp;</TD>
    <TD STYLE="padding: 0.05in 5.75pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="padding: 0.05in 5.75pt">the sum of the present values of the remaining scheduled payments through the par call date discounted, on a semiannual basis, assuming a 360-</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 37; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;C-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt">&nbsp;</TD>
    <TD STYLE="padding: 0.05in 5.75pt">&nbsp;</TD>
    <TD STYLE="padding: 0.05in 5.75pt">day year consisting of twelve 30-day months, at the applicable treasury rate plus 35 basis points,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0.05in 5.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">plus accrued interest to, but excluding, the date of redemption
        which has not been paid.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On or after the par call date, the Notes will be redeemable,
        as a whole at any time or in part from time to time, at the option of the Issuer, at a redemption price equal to 100% of the principal
        amount of the Notes being redeemed plus accrued interest to, but excluding, the date of redemption which has not been paid.</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>CUSIP:</B></TD>
    <TD COLSPAN="2" STYLE="padding: 0.05in 5.75pt">74834L BC3</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>ISIN:</B></TD>
    <TD COLSPAN="2" STYLE="padding: 0.05in 5.75pt">US74834LBC37</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>Joint Book-Running Managers:</B></TD>
    <TD COLSPAN="2" STYLE="padding: 0.05in 5.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Goldman Sachs &amp; Co. LLC<BR>
        J.P. Morgan Securities LLC<BR>
        Mizuho Securities USA LLC</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Morgan Stanley &amp; Co. LLC</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Wells Fargo Securities, LLC</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>Co-Managers:</B></TD>
    <TD COLSPAN="2" STYLE="padding: 0.05in 5.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Credit Agricole Securities (USA) Inc.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">MUFG Securities Americas Inc.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fifth Third Securities, Inc.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PNC Capital Markets LLC</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BNY Mellon Capital Markets, LLC</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BofA Securities, Inc.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">KeyBanc Capital Markets Inc.</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>Conflicts of Interest:</B></TD>
    <TD COLSPAN="2" STYLE="padding: 0.05in 5.75pt">The Issuer expects to use the net proceeds from this offering for general corporate purposes, which may include the redemption or repayment of indebtedness.&nbsp;&nbsp;The indebtedness the Issuer may redeem or repay with the net proceeds of this offering includes its $550 million aggregate principal amount of 4.70% Senior Notes due 2021 (the &#8220;4.70% Senior Notes&#8221;) and outstanding borrowings under its senior unsecured revolving credit facility and its secured receivables credit facility.&nbsp;&nbsp;Certain of the underwriters (or their affiliates) may hold the 4.70% Senior Notes and would receive a portion of the proceeds from this offering if such notes were to be redeemed or repaid.&nbsp;&nbsp;In addition, certain of the underwriters (or their affiliates) may be lenders under the Issuer&#8217;s senior unsecured revolving credit facility or the Issuer&#8217;s secured receivables credit facility and would receive a portion of the proceeds from this offering if outstanding borrowings under the Issuer&#8217;s credit </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0.05in 5.75pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;C-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 42%; padding: 0.05in 5.75pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 58%; padding: 0.05in 5.75pt; font: 10pt Times New Roman, Times, Serif">facilities were to be repaid.&nbsp;&nbsp;If any one underwriter, together with its affiliates, were to receive 5% or more of the net proceeds of this offering by reason of the redemption or repayment, such underwriters would be deemed to have a &ldquo;conflict of interest&rdquo; within the meaning of Rule 5121 of the Financial Industry Regulatory Authority, Inc. (&ldquo;Rule 5121&rdquo;). Accordingly, this offering will be conducted in accordance with Rule 5121. No underwriter with a &ldquo;conflict of interest&rdquo; under Rule 5121 will confirm sales to any account over which it exercises discretion without the specific written approval of the account holder.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding: 0.05in 5.75pt"><B>Global Settlement:</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.05in 5.75pt">Through The Depository Trust Company, Euroclear or Clearstream, Luxembourg.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>*Note: A securities rating is not a recommendation to buy,
sell or hold securities and may be subject to revision or withdrawal at any time.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>The Issuer has filed a registration statement (including
a prospectus and a prospectus supplement) with the Securities and Exchange Commission (the &#8220;SEC&#8221;) for the offering
to which this communication relates. Before you invest, you should read the prospectus and the prospectus supplement in that registration
statement and other documents the Issuer has filed with the SEC for more complete information about the issuer and this offering.
You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the Issuer, any underwriter
or any dealer participating in the offering will arrange to send you the prospectus and the prospectus supplement if you request
it by calling Goldman Sachs &amp; Co. LLC toll free at 1-866-471-2526; J.P. Morgan Securities LLC collect at 1-212-834-4533 or
Mizuho Securities USA LLC collect at 1-212-866-271-7403</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;C-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>SCHEDULE D &#8211; SUBSIDIARIES</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="5" STYLE="padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt"><B>Company</B></FONT></TD>
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt"><B>Registered Alternate Name</B></FONT></TD></TR>
<TR>
    <TD COLSPAN="5" STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Quest Diagnostics Holdings Incorporated (DE)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="5" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;&nbsp;<FONT STYLE="font: 10pt inherit,serif">100% Quest Diagnostics International Holding Limited (UK)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Quest Diagnostics Holdings Ltd. (UK)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Exam<I>One</I>&nbsp;Canada, Inc. (New Brunswick)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Quest Diagnostics Brasil Holdings Ltd. (UK)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">65% Quest Diagnostics Testes Forenses do Brasil Ltda. (Brazil)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">99.9% Quest Diagnostics HTAS India Private Limited (India) (0.1% Quest Diagnostics International Holdings Limited (UK)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Quest Diagnostics of Puerto Rico, Inc. (PR)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Quest Diagnostics Ireland Limited (Ireland)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Quest Diagnostics (Shanghai) Co., Ltd. (China)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Quest Diagnostics Subsidiary Holdings Ltd. (UK)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="4" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">40% Q Squared Solutions Holdings Limited (UK)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="5" STYLE="text-align: left; vertical-align: top; padding: 1.5pt"><FONT STYLE="font: 10pt inherit,serif">100% Quest Diagnostics Clinical Laboratories, Inc. (DE)</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt">
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">Advanced Toxicology</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;Network</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">Smithkline Beecham</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;Clinical Laboratories Solstas</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">Lab Partners Group Solstas Lab Partners</P></TD></TR>
<TR>
    <TD COLSPAN="5" STYLE="text-align: left; vertical-align: top; padding: 1.5pt"><FONT STYLE="font: 10pt inherit,serif">100% Lab<I>One</I>, LLC (MO)</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt">
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">LabOne, Inc. of Kansas</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">Quest Diagnostics</P></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Exam<I>One</I>&nbsp;World Wide, Inc. (PA)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="4" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% ExamOne LLC (DE)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="4" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% ExamOne World Wide of NJ, Inc. (NJ)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="4" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">&nbsp;&nbsp;51% DGXWMT JV, LLC (DE)</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt">
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">Health Check by Quest</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;Diagnostics</P></TD></TR>
<TR>
    <TD COLSPAN="4" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Mobile Medical Examination Services, LLC (CA)</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">MedXM</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="4" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Quest Diagnostics Health &amp; Wellness LLC (DE)</FONT></TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="4" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Lab<I>One</I>&nbsp;of Ohio, Inc. (DE)</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt">
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">Quest Diagnostics</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">LabOne</P></TD></TR>
<TR>
    <TD COLSPAN="5" STYLE="vertical-align: bottom; padding: 1.5pt"><FONT STYLE="font: 10pt inherit,serif">&nbsp;&nbsp;44% Mid America Clinical Laboratories (IN)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="5" STYLE="vertical-align: bottom; padding: 1.5pt"><FONT STYLE="font: 10pt inherit,serif">&nbsp;&nbsp;51% Diagnostic Laboratory of Oklahoma LLC (OK)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="5" STYLE="vertical-align: bottom; padding: 1.5pt"><FONT STYLE="font: 10pt inherit,serif">&nbsp;&nbsp;49% Sonora Quest Laboratories LLC (AZ)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="5" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;&nbsp;<FONT STYLE="font: 10pt inherit,serif">70% Quest Diagnostics Domestic Holder LLC (DE) </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">40% Q Squared Solutions Holdings, LLC (DE)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="6" STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="5" STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Quest Diagnostics do Brasil Ltda. (Brazil)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="5" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="5" STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Quest Diagnostics Incorporated (MD)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Diagnostic Reference Services Inc. (MD)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Pathology Building Partnership (MD) (gen. ptnrshp.)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="6" STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="5" STYLE="padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Quest Diagnostics Incorporated (MI)</FONT></TD>
    <TD STYLE="padding: 1.5pt">
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">Quest Diagnostics</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0"></P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 40; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;Incorporated</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Quest Diagnostics India Private Limited (India)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Quest Diagnostics Infectious Disease, Inc. (DE)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">(30%)&nbsp; Quest Diagnostics Domestic Holder LLC (DE) </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Quest Diagnostics International LLC (DE)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Quest Diagnostics Investments LLC (DE)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Quest Diagnostics LLC (IL)</FONT></TD>
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">Quest Diagnostics LLC</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Quest Diagnostics LLC (MA)</FONT></TD>
    <TD STYLE="padding: 1.5pt">
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">Quest Diagnostics LLC</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">Quest Diagnostics of</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;Connecticut LLC</P></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">81.1% Quest Diagnostics Massachusetts LLC (MA)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Quest Diagnostics LLC (CT)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Quest Diagnostics Mexico Holding Company Trust (Mexico)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Quest Diagnostics Mexico, S de RL de CV (Mexico)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Quest Diagnostics Terracotta LLC (DE)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Quest Diagnostics Nichols Institute (CA)</FONT></TD>
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">Nichols Institute</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Quest Diagnostics of Pennsylvania Inc. (DE)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">51% Quest Diagnostics Venture LLC (PA)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">53.5% Associated Clinical Laboratories of Pennsylvania, L.L.C. (PA)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">1% Associated Clinical Laboratories, L.P. (PA)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">52.97% Associated Clinical Laboratories, L.P. (PA)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Quest Diagnostics Receivables Inc. (DE)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Quest Diagnostics TB LLC (DE)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100 % Quest Diagnostics Ventures LLC (DE)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Athena Diagnostics, Inc. (DE)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% American Medical Laboratories, Incorporated (DE)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Quest Diagnostics Nichols Institute, Inc. (VA)</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">Nichols Institute</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Quest Diagnostics Incorporated (NV)</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt">
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">Quest Diagnostics</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;Incorporated of Nevada</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">Quest Diagnostics</P></TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0"></P></TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% BluePrint Genetics Oy (Finland)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Blueprint Genetics Canada Inc. (British Columbia)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Blueprint Genetics FZ-LLC (UAE)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Blueprint Genetics Inc. (DE)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Clearpoint Diagnostic Laboratories, LLC (TN)</FONT></TD>
    <TD STYLE="padding: 1.5pt">
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">Clearpoint Diagnostic</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;Laboratories</P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Cleveland HeartLab, Inc. (DE)</FONT></TD>
    <TD STYLE="padding: 1.5pt">
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">Cleveland HeartLab</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;Services, Inc.</P></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Isabella Street Urban Renewal, LLC (NJ)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Med Fusion, LLC (TN)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">med fusion</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">med fusion clin-trials</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">med fusion clin-labs</P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Nomad Massachusetts, Inc. (MA)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; width: 2%; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 69%; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Laboratorio de Analisis Biomedicos, S.A. (Mexico)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Reprosource Fertility Diagnostics, Inc. (MA)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 1.5pt; text-align: justify"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Unilab Corporation (DE)</FONT></TD>
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">Quest Diagnostics</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% AmeriPath, Inc. (DE)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% AmeriPath Cincinnati, Inc. (OH)</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt">
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">Richfield Laboratory of</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;Dermatopathology</P></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% AmeriPath Cleveland, Inc. (OH)</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt">
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">AmeriPath GI Institute</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">Dermpath Diagnostics</P></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% AmeriPath Consolidated Labs, Inc. (FL)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% AmeriPath Florida, LLC (DE)</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt">
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">AmeriPath Central Florida</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">AmeriPath Northeast</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;Florida</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">AmeriPath Southwest</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;Florida</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">Bay Area</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;Dermatopathology</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">Dermpath Diagnostics</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">Dermpath Diagnostics</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;Bay Area</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">Institute for</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;Immunofluorescence</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">Institute for Podiatric</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;Pathology</P></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% AmeriPath Hospital Services Florida, LLC (DE)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% AmeriPath Kentucky, Inc. (KY)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% AmeriPath Lubbock 5.01(a) Corporation (TX)</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt">
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">Arlington Pathology</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;Associates</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">Dermpath Diagnostics</P></TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 2%; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 69%; padding: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt">
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;Texas</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">North Arlington Pathology</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;Associates</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">Pathology Associates of</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;Texas</P></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% AmeriPath New York, LLC (DE)</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt">
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">AmeriPath East</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">AmeriPath Gastrointestinal</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;Diagnostics</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">AmeriPath Northeast</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">Dermpath Diagnostics</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">Dermpath Diagnostics</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;NE-Braintree</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">Ackerman Academy of</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;Dermatopathology</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">Dermpath Diagnostics</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;New York</P></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% AmeriPath Texas Inc. (DE)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% AmeriPath Tucson, Inc. (AZ)</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">AmeriPath Arizona</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Arlington Pathology Association 5.01(a) Corporation (TX)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Consolidated DermPath, Inc. (DE)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% DFW 5.01(a) Corporation (TX)</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt">
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">AmeriPath North Texas</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">AmeriPath Dallas</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">AmeriPath DFW 5.01(a)</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;Corporation</P></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Diagnostic Pathology Services, Inc. (OK)</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">AmeriPath Oklahoma</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Kailash B. Sharma, M.D., Inc. (GA)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;100% Nuclear Medicine and Pathology Associates (GA)</FONT></TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Institute for Dermatopathology, Inc. (PA)</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt">
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">AmeriPath Mid-Atlantic</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">Dermpath Diagnostics</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">The Dermatopathology</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;Laboratory</P></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Ocmulgee Medical Pathology Association, Inc. (GA)</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt">
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">AmeriPath Georgia</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;Gastrointestinal</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;Diagnostics</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">Dermpath Diagnostics</P></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% Specialty Laboratories, Inc. (CA)</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt">
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">Quest Diagnostics Nichols</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;Institute of Valencia, Inc.</P></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">100% TXAR 5.01(a) Corporation (TX)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt"><B>Additional Entities Consolidated for Accounting Purposes</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">A. Bernard Ackerman, M.D. Dermatopathology, PC (NY)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">AmeriPath Indianapolis, P.C. (IN)</FONT></TD>
    <TD STYLE="padding: 1.5pt">
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">AmeriPath Indianapolis,</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;PSC</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">Dermpath Diagnostics</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">AmeriPath Milwaukee, S.C. (WI)</FONT></TD>
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">AmeriPath Great Lakes</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">Colorado Pathology Consultants, P.C. (CO)</FONT></TD>
    <TD STYLE="padding: 1.5pt">
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">AmeriPath Colorado</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">Dermpath Diagnostics</P></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">Dermatopathology of Wisconsin, S.C. (WI)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">Diamond Occupational Health Services, P.S.C. (PR)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="5" STYLE="padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">Hoffman, M.D., Associated Pathologists Chartered (NV)</FONT></TD>
    <TD STYLE="padding: 1.5pt">
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">AmeriPath Nevada</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">Associated Pathologists,</P>
        <P STYLE="font: 10pt inherit,serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;Chartered</P></TD></TR>
<TR>
    <TD COLSPAN="5" STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">Kilpatrick Pathology, P.A. (NC)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="5" STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-family: inherit,serif; font-size: 10pt">PhenoPath Laboratories, PLLC (WA)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 66%">&nbsp;</TD>
    <TD STYLE="width: 30%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt/120% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/120% Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/120% Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/120% Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt/120% Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">D-5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>3
<FILENAME>ss173511_ex0402.htm
<DESCRIPTION>TWENTY-FIRST SUPPLEMENTAL INDENTURE
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 4.2</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><BR>
<BR>
<BR>
QUEST DIAGNOSTICS INCORPORATED,<BR>
<BR>
as Issuer<BR>
<BR>
and<BR>
<BR>
THE BANK OF NEW YORK MELLON,<BR>
<BR>
as Trustee<BR>
<BR>
<BR>
Twenty-First Supplemental Indenture<BR>
<BR>
<BR>
Dated as of May 13, 2020<BR>
<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">TABLE OF
CONTENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Page</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%; text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 12pt; padding-left: 0.5in">Article&nbsp;I. DEFINITIONS</TD>
    <TD STYLE="width: 10%; text-align: right; padding-top: 0in; padding-bottom: 12pt">3</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -1.25in; padding-top: 0in; padding-bottom: 12pt; padding-left: 1.75in">SECTION&nbsp;1.1.&nbsp;&nbsp;&nbsp;Certain Terms Defined in the Indenture.</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt">3</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -1.25in; padding-top: 0in; padding-bottom: 12pt; padding-left: 1.75in">SECTION&nbsp;1.2.&nbsp;&nbsp;&nbsp;Definitions.</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt">3</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -1.25in; padding-top: 0in; padding-bottom: 12pt; padding-left: 1.75in">SECTION&nbsp;1.3.&nbsp;&nbsp;&nbsp;Other Definitions</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt">6</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 12pt; padding-left: 0.5in">Article&nbsp;II. FORM AND TERMS OF THE NOTES</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt">6</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -1.25in; padding-top: 0in; padding-bottom: 12pt; padding-left: 1.75in">SECTION&nbsp;2.1.&nbsp;&nbsp;&nbsp;Form and Dating</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt">6</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -1.25in; padding-top: 0in; padding-bottom: 12pt; padding-left: 1.75in">SECTION&nbsp;2.2.&nbsp;&nbsp;&nbsp;Terms of the Notes</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt">8</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -1.25in; padding-top: 0in; padding-bottom: 12pt; padding-left: 1.75in">SECTION&nbsp;2.3.&nbsp;&nbsp;&nbsp;Application of the Article of the Indenture Regarding Redemption of Securities</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt">9</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -1.25in; padding-top: 0in; padding-bottom: 12pt; padding-left: 1.75in">SECTION&nbsp;2.4.&nbsp;&nbsp;&nbsp;Application of the Article of the Indenture Relating to a Sinking Fund</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt">9</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -1.25in; padding-top: 0in; padding-bottom: 12pt; padding-left: 1.75in">SECTION&nbsp;2.5.&nbsp;&nbsp;&nbsp;Additional Events of Default</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt">9</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -1.25in; padding-top: 0in; padding-bottom: 12pt; padding-left: 1.75in">SECTION&nbsp;2.6.&nbsp;&nbsp;&nbsp;Application of the Article of the Indenture Regarding Defeasance and Covenant Defeasance</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt">9</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -1.25in; padding-top: 0in; padding-bottom: 12pt; padding-left: 1.75in">SECTION&nbsp;2.7.&nbsp;&nbsp;&nbsp;Application of the Article of the Indenture Regarding Repayment at the Option of Holders</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt">10</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -1.25in; padding-top: 0in; padding-bottom: 12pt; padding-left: 1.75in">SECTION&nbsp;2.8.&nbsp;&nbsp;&nbsp;Limitations on Subsidiary Indebtedness and Preferred Stock</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt">10</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -1.25in; padding-top: 0in; padding-bottom: 12pt; padding-left: 1.75in">SECTION&nbsp;2.9.&nbsp;&nbsp;&nbsp;Limitations on Liens</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt">10</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -1.25in; padding-top: 0in; padding-bottom: 12pt; padding-left: 1.75in">SECTION&nbsp;2.10.&nbsp;&nbsp;&nbsp;Repurchase of Notes Upon a Change of Control</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt">10</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -1.25in; padding-top: 0in; padding-bottom: 12pt; padding-left: 1.75in">SECTION&nbsp;2.11.&nbsp;&nbsp;&nbsp;Additional Guarantees</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt">12</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -1.25in; padding-top: 0in; padding-bottom: 12pt; padding-left: 1.75in">SECTION&nbsp;2.12.&nbsp;&nbsp;&nbsp;Exempted Liens and Sale and Leaseback Transactions</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt">12</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 12pt; padding-left: 0.5in">Article&nbsp;III. MISCELLANEOUS</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt">13</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -1.25in; padding-top: 0in; padding-bottom: 12pt; padding-left: 1.75in">SECTION&nbsp;3.1.&nbsp;&nbsp;&nbsp;Governing Law</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt">13</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -1.25in; padding-top: 0in; padding-bottom: 12pt; padding-left: 1.75in">SECTION&nbsp;3.2.&nbsp;&nbsp;&nbsp;Separability</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt">13</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -1.25in; padding-top: 0in; padding-bottom: 12pt; padding-left: 1.75in">SECTION&nbsp;3.3.&nbsp;&nbsp;&nbsp;Counterparts</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt">13</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -1.25in; padding-top: 0in; padding-bottom: 12pt; padding-left: 1.75in; width: 90%">SECTION&nbsp;3.4.&nbsp;&nbsp;&nbsp;Ratification</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt; width: 10%">13</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -1.25in; padding-top: 0in; padding-bottom: 12pt; padding-left: 1.75in">SECTION&nbsp;3.5.&nbsp;&nbsp;&nbsp;Waiver of Jury Trial</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt">14</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -1.25in; padding-top: 0in; padding-bottom: 12pt; padding-left: 1.75in">SECTION&nbsp;3.6.&nbsp;&nbsp;&nbsp;Force Majeure</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt">14</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -1.25in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1.75in">SECTION&nbsp;3.7.&nbsp;&nbsp;&nbsp;Effectiveness</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">14</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 91%; padding-right: 5.4pt; padding-left: 5.4pt">EXHIBIT&nbsp;A &mdash; Form &nbsp;of 2.800% Senior Note due 2031</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">A-1</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TWENTY-FIRST SUPPLEMENTAL INDENTURE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">TWENTY-FIRST SUPPLEMENTAL INDENTURE (this
&#8220;Twenty-First Supplemental Indenture&#8221;), dated as of May 13, 2020, between QUEST DIAGNOSTICS INCORPORATED, a Delaware
corporation (the &#8220;Company&#8221;), and THE BANK OF NEW YORK MELLON, a New York banking corporation, as Trustee (the &#8220;Trustee&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">RECITALS OF THE COMPANY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">WHEREAS, the Company, the Trustee and the
Initial Subsidiary Guarantors (as defined therein) executed and delivered an Indenture, dated as of June&nbsp;27, 2001 (the &#8220;Base
Indenture&#8221;), as supplemented by the first supplemental indenture, dated as of June&nbsp;27, 2001, among the Company, the
Initial Subsidiary Guarantors (as defined therein) party thereto, and the Trustee (the &#8220;First Supplemental Indenture&#8221;),
as further supplemented by a second supplemental indenture, dated as of November&nbsp;26, 2001, among the Company, the Subsidiary
Guarantors (as defined therein) party thereto and the Trustee (the &#8220;Second Supplemental Indenture&#8221;), as further supplemented
by a third supplemental indenture, dated as of April&nbsp;4, 2002, among the Company, the Subsidiary Guarantors (as defined therein)
party thereto and the Trustee (the &#8220;Third Supplemental Indenture&#8221;), as further supplemented by a fourth supplemental
indenture, dated as of March&nbsp;19, 2003, among the Company, the Subsidiary Guarantors (as defined therein) party thereto and
the Trustee (the &#8220;Fourth Supplemental Indenture&#8221;), as further supplemented by a fifth supplemental indenture, dated
as of April&nbsp;16, 2004, among the Company, the Subsidiary Guarantors (as defined therein) party thereto and the Trustee (the
&#8220;Fifth Supplemental Indenture&#8221;), as further supplemented by a sixth supplemental indenture dated October&nbsp;31, 2005,
among the Company, the Subsidiary Guarantors (as defined therein) party thereto (the &#8220;Sixth Supplemental Indenture&#8221;),
as further supplemented by a seventh supplemental indenture dated November&nbsp;21, 2005, among the Company, the Subsidiary Guarantors
(as defined therein) party thereto and the Trustee (the &#8220;Seventh Supplemental Indenture&#8221;), as further supplemented
by an eighth supplemental indenture dated July&nbsp;31, 2006, among the Company, the Subsidiary Guarantors (as defined therein)
party thereto and the Trustee (the &#8220;Eighth Supplemental Indenture&#8221;), as further supplemented by a ninth supplemental
indenture, dated as of September&nbsp;30, 2006, among the Company, the Subsidiary Guarantors (as defined therein) party thereto
and the Trustee (the &#8220;Ninth Supplemental Indenture&#8221;), as further supplemented by a tenth supplemental indenture, dated
as of June&nbsp;22, 2007, among the Company, the Subsidiary Guarantors (as defined therein) party thereto and the Trustee (the
&#8220;Tenth Supplemental Indenture&#8221;), as further supplemented by an eleventh supplemental indenture, dated as of June&nbsp;22,
2007, among the Company, the Subsidiary Guarantors (as defined therein) party thereto and the Trustee (the &#8220;Eleventh Supplemental
Indenture&#8221;), as further supplemented by a twelfth supplemental indenture, dated as of June&nbsp;25, 2007, among the Company,
the Subsidiary Guarantors (as defined therein) party thereto and the Trustee (the &#8220;Twelfth Supplemental Indenture&#8221;),
as further supplemented by a thirteenth supplemental indenture, dated as of November&nbsp;17, 2009, among the Company, the Subsidiary
Guarantors (as defined therein) party thereto and the Trustee (the &#8220;Thirteenth Supplemental Indenture&#8221;), as further
supplemented by a fourteenth supplemental indenture, dated as of March&nbsp;24, 2011, among the Company, the Subsidiary Guarantors
(as defined therein) party thereto and the Trustee (the &#8220;Fourteenth Supplemental Indenture&#8221;), as further supplemented
by the fifteenth supplemental indenture, dated as of November&nbsp;30, 2011, among the Company, the Additional Subsidiary Guarantors
(as</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">defined therein) and the Trustee (the &#8220;Fifteenth Supplemental Indenture&#8221;), as further supplemented by the sixteenth
supplemental indenture, dated as of March 17, 2014, between the Company and the Trustee (the &#8220;Sixteenth Supplemental Indenture&#8221;),
as further supplemented by the seventeenth supplemental indenture, dated as of March 10, 2015, between the Company and the Trustee
(the &#8220;Seventeenth Supplemental Indenture&#8221;), as further supplemented by the eighteenth supplemental indenture, dated
as of May 26, 2016, between the Company and the Trustee (the &#8220;Eighteenth Supplemental Indenture&#8221;), as further supplemented
by the nineteenth supplemental indenture, dated as of March 12, 2019, between the Company and the Trustee (the &#8220;Nineteenth
Supplemental Indenture&#8221;), as further supplemented by the twentieth supplemental indenture, dated as of December 16, 2019,
between the Company and the Trustee (the &#8220;Twentieth Supplemental Indenture&#8221;) and as to be further supplemented by this
Twenty-First Supplemental Indenture (collectively, the &#8220;Indenture&#8221;), to provide for the issuance by the Company from
time to time of Securities to be issued in one or more series as provided in the Indenture;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">WHEREAS, the issuance and sale of $550,000,000
aggregate principal amount of a new series of the Company&#8217;s 2.800% Senior Notes due 2031 (the &#8220;Notes&#8221;) pursuant
to this Twenty-First Supplemental Indenture have been authorized by resolutions adopted by the Board of Directors of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">WHEREAS, the Company desires to issue and
sell $550,000,000 aggregate principal amount of the Notes pursuant to this Twenty-First Supplemental Indenture on the date hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">WHEREAS, Sections&nbsp;901(7) and 901(9) of
the Indenture provide that without the consent of the Holders of the Securities of any series issued under the Indenture, the Company,
when authorized by a Board Resolution, and the Trustee may enter into one or more indentures supplemental to the Indenture to (a)&nbsp;establish
the form or terms of Securities of any series and any related coupons as permitted by Sections&nbsp;201 and 301, including the
provisions and procedures relating to Securities convertible into or exchangeable for any securities of any Person (including the
Company) and (b)&nbsp;cure any ambiguity, to correct or supplement any provision therein which may be inconsistent with any other
provision therein, or make any other provisions with respect to matters or questions arising under the Base Indenture;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">WHEREAS, the Company desires to establish
the form and terms of the Notes;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">WHEREAS, all things necessary to make this
Twenty-First Supplemental Indenture a valid supplement to the Indenture according to its terms and the terms of the Indenture have
been done;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">NOW, THEREFORE, for and in consideration of
the premises stated herein and the purchase of the Notes by the Holders thereof, the parties hereto hereby enter into this Twenty-First
Supplemental Indenture, for the equal and proportionate benefit of all Holders of the Notes, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;I.<BR>
<BR>
DEFINITIONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">SECTION&nbsp;1.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Certain Terms Defined in the Indenture</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">All capitalized terms used but not defined
herein shall have the meanings ascribed to such terms in the Indenture, as amended through the date hereof, other than such terms
as are defined in the Second Supplemental Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">SECTION&nbsp;1.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Definitions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Except as may be provided in a Future Supplemental
Indenture, for the benefit of the Holders of the Notes, Section&nbsp;101 of the Indenture shall be amended by adding the following
new definitions or, to the extent already defined in the Indenture, replacing existing definitions with the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Change of Control&#8221; means the
occurrence of any of the following: (1)&nbsp;the consummation of any transaction (including, without limitation, any merger or
consolidation) the result of which is that any &#8220;person&#8221; (as that term is used in Section&nbsp;13(d)&nbsp;(3)&nbsp;of
the Exchange Act) (other than the Company or one of its subsidiaries) becomes the beneficial owner (as defined in Rules 13d-3 and
13d-5 under the Exchange Act), directly or indirectly, of more than 50% of the Voting Stock of the Company or other Voting Stock
into which the Voting Stock of the Company is reclassified, consolidated, exchanged or changed, measured by voting power rather
than number of shares; (2)&nbsp;the direct or indirect sale, transfer, conveyance or other disposition (other than by way of merger
or consolidation), in one or more series of related transactions, of all or substantially all of the assets of the Company and
the assets of its subsidiaries, taken as a whole, to one or more &#8220;persons&#8221; (as that term is used in Section 13(d)(3)
of the Exchange Act) (other than the Company or one of its subsidiaries); or (3)&nbsp;the first day on which a majority of the
members of the Board of Directors of the Company are not Continuing Directors. Notwithstanding the foregoing, a transaction will
not be deemed to involve a Change of Control if (1)&nbsp;the Company becomes a direct or indirect wholly-owned subsidiary of a
holding company and (2)(A)&nbsp;the direct or indirect holders of the Voting Stock of such holding company immediately following
that transaction are substantially the same as the holders of the Voting Stock of the Company immediately prior to that transaction or (B)&nbsp;immediately following that transaction no person (other
than a holding company satisfying the requirements of this sentence) is the beneficial owner, directly or indirectly, of more than
50% of the Voting Stock of such holding company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Change of Control Triggering Event&#8221;
means the occurrence of both a Change of Control and a Rating event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Comparable Treasury Issue&#8221;
means the United States Treasury security selected by an Independent Investment Banker as having a maturity comparable to the remaining
term of the Notes to be redeemed (assuming the Notes matured on the Par Call Date) that would be utilized, at the time of selection
and in accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity
to the remaining term of the Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Comparable Treasury Price&#8221;
means, with respect to any redemption date for the Notes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the average of four&nbsp;Reference Treasury Dealer Quotations for that redemption date, after excluding the highest and lowest
of such Reference Treasury Dealer Quotations; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if the Company obtains fewer than four&nbsp;Reference Treasury Dealer Quotations, the average of all quotations obtained by
the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Continuing Directors&#8221; means,
as of any date of determination, any member of the Company&#8217;s Board of Directors who (1)&nbsp;was a member of such Board of
Directors on the date the Notes were issued or (2)&nbsp;was nominated for election, elected or appointed to such Board of Directors
with the approval of a majority of the Continuing Directors who were members of such Board of Directors at the time of such nomination,
election or appointment (either by a specific vote or by approval of the proxy statement of the Company in which such member was
named as a nominee for election as a director, without objection to such nomination).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Existing Receivables Credit Facility&#8221;
means the receivables-backed financing transaction pursuant to (1)&nbsp;the Fourth Amended and Restated Receivables Sale Agreement,
dated as of October 28, 2015, between the Company and each of its direct and indirect wholly owned Subsidiaries that is a seller
thereunder, and Quest Diagnostics Receivables Inc., as the buyer, as amended, (2)&nbsp;the Sixth Amended and Restated Credit and
Security Agreement, dated as of October&nbsp;27, 2017, among Quest Diagnostics Receivables Inc., as borrower, the Company, as initial
servicer, each of the lenders from time to time party thereto, and The Bank of Tokyo-Mitsubishi UFJ, Ltd., New York Branch, as
administrative agent, as amended and (3)&nbsp;the various related ancillary documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Fitch&#8221; means Fitch Ratings,
Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Global Notes&#8221; means, individually
and collectively, each of the Global Notes, substantially in the form of <U>Exhibit&nbsp;A</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Global Notes Legend&#8221; means
the legend set forth in Section&nbsp;204 to be placed on all Global Notes issued under this Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Investment Grade Rating&#8221; means
a rating equal to or higher than Baa3 (or the equivalent) by Moody&#8217;s, BBB&#8211; (or the equivalent) by S&amp;P and BBB&#8211;
(or the equivalent) by Fitch, and the equivalent investment grade credit rating from any additional rating agency or Rating Agencies
selected by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Moody&#8217;s&#8221; means Moody&#8217;s
Investors Service, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Rating Agencies&#8221; means (1)&nbsp;each
of Moody&#8217;s, S&amp;P and Fitch; and (2)&nbsp;if any of Moody&#8217;s, S&amp;P or Fitch ceases to rate the Notes or fails to
make a rating of the Notes publicly available for reasons outside of the control of the Company, a &#8220;nationally recognized
statistical rating organization&#8221; within the meaning of Section 3(a)(62) of the Exchange Act selected by the Company (as certified
by a resolution of the Board of Directors) as a replacement agency for Moody&#8217;s, S&amp;P or Fitch, or all of them, as the
case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Rating event&#8221; means the rating
on the Notes is lowered by at least two of the Rating Agencies and the Notes are rated below an Investment Grade Rating by at least
two of the Rating Agencies on any day within the 60&#45;day period (which 60-day period shall be extended so long as the rating
of the Notes is under publicly announced consideration for a possible downgrade by any of the Rating Agencies) after the earlier
of (1)&nbsp;the occurrence of a Change of Control and (2)&nbsp;public notice of the occurrence of a Change of Control or the intention
of the Company to effect a Change of Control; <I>provided</I>, <I>however</I>, that a Rating event otherwise arising by virtue
of a particular reduction in rating will not be deemed to have occurred in respect of a particular Change of Control (and thus
will not be deemed a Rating event for purposes of the definition of Change of Control Triggering Event) if the Rating Agencies
making the reduction in rating to which this definition would otherwise apply do not announce or publicly confirm or inform the
trustee in writing at its request or the request of the Company that the reduction was the result, in whole or in part, of any
event or circumstance comprised of or arising as a result of, or in respect of, the applicable Change of Control (whether or not
the applicable Change of Control has occurred at the time of the Rating event).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Par Call Date&#8221; means March
30, 2031.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Remaining Scheduled Payments&#8221;
means, with respect to the Notes, the remaining scheduled payments of the principal thereof and interest thereon from the redemption
date through the Par Call Date; <I>provided</I>, <I>however</I>, that, if such redemption date is not an interest payment date
with respect to the Notes, the amount of the next succeeding scheduled interest payment thereon will be deemed to be reduced by
the amount of interest accrued thereon to such redemption date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;S&amp;P&#8221; means S&amp;P Global
Ratings, a division of S&amp;P Global Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Subsidiary Guarantor&#8221; means,
at any time, each existing and future domestic Subsidiary of the Company that may guarantee the Notes; <I>provided</I> that such
Subsidiary continues to guarantee the Notes at such time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Treasury Rate&#8221; means, with
respect to any redemption date for the Notes, the rate per annum equal to the semiannual equivalent yield to maturity or interpolation
(on a day count basis) of the interpolated Comparable Treasury Issue, assuming a price for the Comparable Treasury Issue (expressed
as a percentage of its principal amount) equal to the Comparable Treasury Price for such redemption date, as determined by the
Company or an Independent Investment Banker appointed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Voting Stock&#8221; means, with respect
to any specified &#8220;person&#8221; (as that term is used in Section&nbsp;13(d)(3)&nbsp;of the Exchange Act) as of any date,
the capital stock of such person that is at the time entitled to vote generally in the election of the board of directors of such
person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">SECTION&nbsp;1.3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Other Definitions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 65%; padding-right: 5.4pt; padding-left: 5.4pt"><U>Term</U></TD>
    <TD STYLE="width: 35%; padding-right: 5.4pt; padding-left: 5.4pt"><U>Defined in Section</U></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8220;Additional Notes&#8221;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">2.2(a)</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8220;Change of Control Offer&#8221;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">2.10</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8220;Change of Control Payment&#8221;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">2.10</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8220;Change of Control Payment Date&#8221;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">2.10</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8220;Depository&#8221;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">2.1(a)</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8220;Maturity&#8221;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">2.2(c)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;II.<BR>
<BR>
FORM AND TERMS OF THE NOTES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">SECTION&nbsp;2.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Form and Dating</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">The Notes and the Trustee&#8217;s certificate
of authentication shall be substantially in the form of <U>Exhibit&nbsp;A</U> attached hereto. The Notes shall be executed on behalf
of the Company by its Chief Executive Officer, the Chief Financial Officer, the Controller or the Treasurer and the Secretary.
Notwithstanding Section 303 of the Base Indenture, no corporate seal shall be reproduced thereon. The Notes may have notations,
legends or endorsements required by law, stock exchange rules or usage. Each Note shall be dated the date of its authentication.
The Notes and any beneficial interest in the Notes shall be in minimum denominations of $2,000 and integral multiples of $1,000
in excess thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">The terms and notations contained in the Notes
shall constitute, and are hereby expressly made, a part of this Indenture and the Company and the Trustee, by their execution and
delivery of this Indenture, expressly agree to such terms and provisions and to be bound thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Global Notes. The Global Notes designated herein shall be issued initially in the form of one or more fully registered global
notes, which shall be deposited on behalf of the purchasers of the Notes represented thereby with the Depository Trust Company,
New York, New York (the &#8220;Depository&#8221;) and registered in the name of Cede &amp; Co., the Depository&#8217;s nominee,
duly executed by the Company and authenticated by the Trustee. The aggregate principal amount of outstanding Notes may from time
to time be increased or decreased by adjustments made on the records of the Trustee and the Depository or its nominee as hereinafter
provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">The Global Notes may not be transferred
except by the Depository, in whole and not in part, to another nominee of the Depository or to a successor of the Depository or
its nominee. If at any time the Depository for the Notes notifies the Company that the Depository is unwilling, unable or ineligible
to continue as depository for the Global Notes and a successor depository for the Global</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Notes is not appointed by the Company
within 90&nbsp;days after delivery of such notice, then the Company shall execute, and the Trustee shall, upon receipt of a Company
Order, for authentication, authenticate and deliver, Definitive Notes in an aggregate principal amount equal to the principal amount
of the Global Notes in exchange for such Global Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Book&#45;Entry Provisions. This Section&nbsp;2.1(b) shall apply only to the Global Notes deposited with or on behalf of
the Depository.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">The Company shall execute and
the Trustee shall, in accordance with this Section&nbsp;2.1(b), authenticate and deliver the Global Notes that shall be registered
in the name of the Depository or the nominee of the Depository and shall be delivered by the Trustee to the Depository or pursuant
to the Depository&#8217;s instructions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">Depository Participants shall
have no rights either under this Indenture or with respect to any Global Notes held on their behalf by the Depository or under
such Global Notes. The Depository shall be treated by the Company, the Trustee and any agent of the Company or the Trustee as the
absolute owner of such Global Note for all purposes under this Indenture. Notwithstanding the foregoing, nothing herein shall prevent
the Company or the Trustee from giving effect to any written certification, proxy or other authorization furnished by the Depository
or impair, as between the Depository and the Depository Participants, the operation of customary practices of such Depository governing
the exercise of the rights of an owner of a beneficial interest in the Global Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Definitive Notes. Notes issued in certificated form shall be substantially in the form of <U>Exhibit&nbsp;A</U>, attached
hereto, but without including the text referred to therein as applying only to Global Notes. Except as provided above in subsection&nbsp;(a),
owners of beneficial interests in the Global Notes will not be entitled to receive physical delivery of certificated Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Transfer and Exchange of the Notes. The transfer and exchange of beneficial interests in the Global Notes shall be effected
through the Depository, in accordance with this Indenture and the procedures of the Depository therefor. Beneficial interests in
the Global Notes may be transferred to Persons who take delivery thereof in the form of a beneficial interest in the Global Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Paying Agent. The Company appoints The Bank of New York Mellon as agent of the Company for the payment of the principal
of (and premium, if any) and interest on the Notes; and that the Corporate Trust Office of The Bank of New York Mellon in the Borough
of Manhattan, the City of New York, be and hereby is, designated as the office or agency in the Borough of Manhattan where the
Notes may be presented for payment and where notices to or demands upon the Company in respect of the Notes and the Indenture pursuant
to which the Notes are to be issued may be served.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">SECTION&nbsp;2.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Terms of the Notes</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">The following terms relating to the Notes
are hereby established:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Notes shall constitute a series of Securities having the title &#8220;Senior Notes due 2031.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The aggregate principal amount of the Notes that may be initially authenticated and delivered under the Indenture (except
for Notes authenticated and delivered upon registration of, transfer of or in exchange for, or in lieu of, other Notes pursuant
to Sections&nbsp;304, 305, 306, 906 or 1107 of the Indenture) shall be $550,000,000. The Company may from time to time, without
the consent of the Holders of the Notes, issue additional Notes (&#8220;Additional Notes&#8221;) having the same ranking and the
same interest rate, maturity and other terms as the Notes. Any Additional Notes and the existing Notes will constitute a single
series under the Indenture and all references to the Notes shall include the Additional Notes unless the context otherwise requires.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The entire outstanding principal of the Notes shall be payable on June 30, 2031 (the &#8220;Maturity&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The rate at which the Notes shall bear interest shall be 2.800% per annum, and the date from which interest shall accrue
on the Notes shall be May 13, 2020, or the most recent Interest Payment Date to which interest has been paid or provided for; the
Interest Payment Dates for the Notes shall be June 30 and December 30 of each year, beginning December 30, 2020; the interest so
payable, and punctually paid or duly provided for, on any Interest Payment Date, will be paid, in immediately available funds,
to the Persons in whose names the Notes (or one or more Predecessor Securities) is registered at the close of business on the Regular
Record Date for such interest, which shall be June 15 or December 15, as the case may be, next preceding such Interest Payment
Date. Interest on the Notes will be computed on the basis of a 360-day year of twelve 30-day months. Any such interest not punctually
paid or duly provided for shall forthwith cease to be payable to the Holders on such Regular Record Date, and such Defaulted Interest,
may be paid to the Persons in whose names the Notes (or one or more Predecessor Securities) is registered at the close of business
on a Special Record Date for the payment of such Defaulted Interest to be fixed by the Trustee, notice whereof shall be given to
Holders of Notes not less than ten days prior to such Special Record Date, or may be paid at any time in any other lawful manner
not inconsistent with requirements of any securities exchange on which the Notes may be listed, and upon such notice as may be
required by such exchange, all as more fully provided in said Indenture. Payment of principal and interest on the Notes will be
made at the Corporate Trust Office of the Trustee or such other office or agency of the Company as may be designated for such purpose,
in such coin or currency of the United States of America as at the time of payment is legal tender for payment of public and private
debts; <I>provided</I>, <I>however</I>, that each installment of interest and principal on the Notes may at the Company&#8217;s
option be paid in immediately available funds by transfer to an account maintained by the payee located in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Notes shall be issuable in whole in the registered form of one or more Global Notes (without coupons), and the Depository
for such Global Notes shall be The Depository Trust Company, New York, New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The references to &#8220;30 days&#8221; in the first sentence of Section 1104 shall be replaced with &#8220;10 days.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The words &#8220;prior to the Par Call Date&#8221; shall be inserted in the first sentence of Section 1108, immediately
following the phrase &#8220;At any time and from time to time&#8221; and immediately preceding the phrase &#8220;, the Securities
of any series.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The following sentence shall be inserted immediately following clause (b) of the first sentence of Section 1108: &#8220;On
or after the Par Call Date, the Notes may be redeemed, as a whole at any time or in part from time to time, at the option of the
Company, on at least 10 days, but not more than 60 days, prior notice mailed to the registered address of each holder of the Notes,
at a redemption price equal to 100% of the principal amount of the Notes being redeemed.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Redemption Amount of Basis Points applicable to the Notes used to calculate the Redemption Price pursuant to Section&nbsp;1108
of this Indenture shall be 35&nbsp;basis points.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">SECTION&nbsp;2.3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Application of the Article of the Indenture Regarding Redemption of Securities</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Except as may be provided in a Future Supplemental
Indenture, the provisions of Article&nbsp;Eleven of the Indenture, as amended (including as amended hereby), shall apply to the
Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">SECTION&nbsp;2.4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Application of the Article of the Indenture Relating to a Sinking Fund</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Except as may be provided in a Future Supplemental
Indenture, the Notes shall not be entitled to the benefit of any sinking fund, and the provisions of the Indenture relating to
a sinking fund, including Article&nbsp;Twelve and Subsection&nbsp;(3) of Section&nbsp;501 of the Indenture, shall not apply to
the Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">SECTION&nbsp;2.5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Additional Events of Default</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Except as may be provided by a Future Supplemental
Indenture, for the benefit of the holders of the Notes, Section&nbsp;501(7)(A) of the Indenture shall be amended by deleting the
words &#8220;$100 million&#8221; in the second line thereof and, in their place, adding the words &#8220;$200&nbsp;million&#8221;;
and Section&nbsp;501(7)(B) of the Indenture shall be amended by deleting the words &#8220;$100&nbsp;million&#8221; in the sixth
line thereof and, in their place, adding the words &#8220;$200&nbsp;million.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">SECTION&nbsp;2.6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Application of the Article of the Indenture Regarding Defeasance and Covenant Defeasance</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Except as may be provided by a Future Supplemental
Indenture, the provisions of Article&nbsp;Fourteen of the Indenture, including the provisions relating to defeasance and covenant
defeasance of the Securities under Sections&nbsp;1402 and 1403, respectively, of the Indenture shall apply to the Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">SECTION&nbsp;2.7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Application of the Article of the Indenture Regarding Repayment at the Option of Holders</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Except as may be provided by a Future Supplemental
Indenture, the provisions of Article&nbsp;Thirteen of the Indenture shall not apply to the Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">SECTION&nbsp;2.8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Limitations on Subsidiary Indebtedness and Preferred Stock</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except as may be provided by a Future Supplemental Indenture, for the sole benefit of the holders of the Notes, Section&nbsp;1011(a)
of the Indenture shall be amended by deleting the words &#8220;First Supplemental Indenture&#8221; in the second line thereof and,
in their place, adding the words &#8220;Twenty-First Supplemental Indenture.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except as may be provided by a Future Supplemental Indenture, for the sole benefit of the holders of the Notes, Section&nbsp;1011
of the Indenture shall be amended by adding a new subsection&nbsp;1011(k) and subsection&nbsp;1011(l) as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&#9;(k)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any guarantee of Indebtedness
of the Company by any Subsidiary of the Company in anticipation of such Subsidiary becoming a Subsidiary Guarantor pursuant to
Article&nbsp;Sixteen of the Indenture; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&#9;(l)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of Preferred
Stock held by the Company or a subsidiary of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">SECTION&nbsp;2.9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Limitations on Liens</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Except as may be provided by a Future Supplemental
Indenture, for the sole benefit of the holders of the Notes, Section&nbsp;1008(a) of the Indenture shall be amended by deleting
the words &#8220;First Supplemental Indenture&#8221; in the first and second line thereof and, in their place, adding the words
&#8220;Twenty-First Supplemental Indenture.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">SECTION&nbsp;2.10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Repurchase of Notes Upon a Change of Control</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Except as may be provided by a Future Supplemental
Indenture, for the benefit of the holders of the Notes, a new Section&nbsp;315 shall be added to the Indenture as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">Section&nbsp;315&#9;Repurchase
of Notes Upon a Change of Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If a Change of Control Triggering Event occurs, unless the Company has exercised its option to redeem the Notes as described
in Section&nbsp;1108, the Company shall make an offer to repurchase all or any part&nbsp;(equal to $2,000 or an integral multiple
of $1,000 in excess thereof) of the Notes pursuant to the offer described below (the &#8220;Change of Control Offer&#8221;) on
the terms set forth in the Notes. In the Change of Control Offer, the</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Company shall offer payment in cash equal to 101% of the
aggregate principal amount of Notes repurchased, plus accrued and unpaid interest, if any, on the Notes repurchased to, but excluding,
the date of repurchase (the &#8220;Change of Control Payment&#8221;). Within 30&nbsp;days following any Change of Control Triggering
Event or, at the option of the Company, prior to any Change of Control, but after the public announcement of the transaction that
constitutes or may constitute the Change of Control, the Company shall mail a notice to holders of Notes describing the transaction
that constitutes or may constitute the Change of Control Triggering Event and offering to repurchase the Notes on the date specified
in the notice, which date will be no earlier than 30&nbsp;days and no later than 60&nbsp;days from the date such notice is mailed
(the &#8220;Change of Control Payment Date&#8221;). The notice shall, if mailed prior to the date of consummation of the Change
of Control, state that the offer to purchase is conditioned on the Change of Control Triggering Event occurring on or prior to
the Change of Control Payment Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company shall comply with the requirements of Rule&nbsp;14e&#45;1 under the Exchange Act, and any other securities laws
and regulations thereunder to the extent those laws and regulations are applicable in connection with the repurchase of the Notes
as a result of a Change of Control Triggering Event. To the extent that the provisions of any such securities laws or regulations
conflict with the Change of Control provisions of the Notes, the Company will comply with the applicable securities laws and regulations
and will not be deemed to have breached its obligations under the Change of Control provisions of the Notes by virtue of any such
conflict.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>On the Change of Control Payment Date, the Company shall, to the extent lawful:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>accept for payment all Notes or portions of Notes properly tendered pursuant to the Change of Control Offer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>deposit with the Paying Agent an amount equal to the Change of Control Payment in respect of all Notes or portions of Notes
properly tendered; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>deliver or cause to be delivered to the Trustee the Notes properly accepted together with an Officers&#8217; Certificate
stating the aggregate principal amount of Notes or portions of Notes being purchased.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company shall not be required to make a Change of Control Offer upon the occurrence of a Change of Control Triggering
Event if a third party makes such an offer in the manner, at the times and otherwise in compliance with the requirements for an
offer made by the Company and the third party repurchases all Notes properly tendered and not withdrawn under its offer. In addition,
the Company shall not repurchase any Notes if there has occurred and is continuing on the Change of Control Payment Date an event
of default under this Indenture, other than a default in the payment of the Change of Control Payment upon a Change of Control
Triggering Event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">SECTION&nbsp;2.11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Additional Guarantees and Release of Guarantees</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Except as may be provided by a Future Supplemental
Indenture, for the sole benefit of the holders of the Notes, Section 1604 and Section 1605 of the Indenture shall be amended by
deleting each in its entirety and, in their place, adding the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">SECTION 1604 Additional Guarantees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">If any future domestic Subsidiary
of the Company or any Subsidiary Guarantor which has been released and discharged from its obligations under its Subsidiary Guarantee
of the Notes pursuant to Section 1605 guarantees any of the following series of Securities of the Company pursuant to a requirement
to guarantee such Securities under the Indenture: 4.70% senior notes due 2021, 4.25% senior notes due 2024, 3.50% senior notes
due 2025, 3.45% senior notes due 2026, 4.20% senior notes due 2029, 6.95% senior notes due 2037, 5.75% senior notes due 2040 or
4.70% senior notes due 2045, then the Company will cause such Subsidiary to execute and deliver to the Trustee a supplemental indenture
pursuant to which it will become a Subsidiary Guarantor under the Twenty-First Supplemental Indenture in a substantially consistent
manner for so long as such Subsidiary guarantees any such series of Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">SECTION 1605 Release of Guarantees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">The Subsidiary Guarantees of the
Subsidiary Guarantors with respect to the Notes will remain in effect with respect to each Subsidiary Guarantor until the entire
amount of principal of, premium, and interest on the Notes shall have been paid in full or otherwise discharged in accordance with
the provisions of the Indenture; provided, however, that if</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">(a) all outstanding Indebtedness of
such Subsidiary Guarantor would have been permitted to be incurred pursuant to Section 1011 measured at the time of the release
and discharge as described in this Section 1605,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">(b) the Notes are defeased and discharged
pursuant to Article Fourteen hereof,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">(c) all or substantially all of the
assets of such Subsidiary Guarantor or all of the capital stock of such Subsidiary Guarantor is sold (including by issuance, merger,
consolidation or otherwise) by the Company or any of its Subsidiaries, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">(d) the Subsidiary Guarantees of the
Securities referred to in Section 1604 have been released,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">then in each case of (a), (b), (c),
or (d) above, such Subsidiary Guarantor or the corporation acquiring such assets (in the event of a sale or other disposition of
all or substantially all of the assets or capital stock of such Subsidiary Guarantor) shall be released and discharged from its
obligations under its Subsidiary Guarantee of the Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">SECTION&nbsp;2.12.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exempted Liens and Sale and Leaseback Transactions</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Except as may be provided by a Future Supplemental
Indenture, for the sole benefit of the holders of the Notes, Section 1010 shall be amended by deleting &#8220;5%&#8221; and, in
its place, adding &#8220;10%&#8221;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;III.<BR>
<BR>
MISCELLANEOUS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">SECTION&nbsp;3.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Governing Law</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">This Twenty-First Supplemental Indenture and
the Notes shall be governed by and construed in accordance with the laws of the State of New York, without regard to principles
of conflicts of laws. This Twenty-First Supplemental Indenture is subject to the provisions of the Trust Indenture Act that are
required to be part of this Indenture and shall, to the extent applicable, be governed by such provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">SECTION&nbsp;3.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Separability</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">In case any provision in this Twenty-First
Supplemental Indenture or in any Securities, including the Notes, shall be invalid, illegal or unenforceable, the validity, legality
and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">SECTION&nbsp;3.3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Counterparts</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">This Twenty-First Supplemental Indenture may
be executed in any number of counterparts, each of which so executed shall be deemed to be an original, but all such counterparts
shall together constitute but one and the same Supplemental Indenture. The words &#8220;execution,&#8221; signed,&#8221; &#8220;signature,&#8221;
and words of like import in this Twenty-First Supplemental Indenture or in any other certificate, agreement or document related
to this Twenty-First Supplemental Indenture shall include images of manually executed signatures transmitted by facsimile or other
electronic format (including, without limitation, &#8220;pdf&#8221;, &#8220;tif&#8221; or &#8220;jpg&#8221;) and other electronic
signatures (including, without limitation, DocuSign and AdobeSign). The use of electronic signatures and electronic records (including,
without limitation, any contract or other record created, generated, sent, communicated, received, or stored by electronic means)
shall be of the same legal effect, validity and enforceability as a manually executed signature or use of a paper-based record-keeping
system to the fullest extent permitted by applicable law, including the Federal Electronic Signatures in Global and National Commerce
Act, the New York State Electronic Signatures and Records Act, and any other applicable law, including, without limitation, any
state law based on the Uniform Electronic Transactions Act or the Uniform Commercial Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">SECTION&nbsp;3.4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Ratification</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">The Base Indenture, as supplemented and amended
by the First Supplemental Indenture, the Second Supplemental Indenture, the Third Supplemental Indenture, the Fourth Supplemental
Indenture, the Fifth Supplemental Indenture, the Sixth Supplemental Indenture, the Seventh Supplemental Indenture, the Eighth Supplemental
Indenture, the Ninth Supplemental</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indenture, the Tenth Supplemental Indenture, the Eleventh Supplemental Indenture, the Twelfth
Supplemental Indenture, the Thirteenth Supplemental Indenture, the Fourteenth Supplemental Indenture, the Fifteenth Supplemental
Indenture, the Sixteenth Supplemental Indenture, the Seventeenth Supplemental Indenture, the Eighteenth Supplemental Indenture,
the Nineteenth Supplemental Indenture, the Twentieth Supplemental Indenture and this Twenty-First Supplemental Indenture is in
all respects ratified and confirmed. The Base Indenture, the First Supplemental Indenture, the Second Supplemental Indenture, the
Third Supplemental Indenture, the Fourth Supplemental Indenture, the Fifth Supplemental Indenture, the Sixth Supplemental Indenture,
the Seventh Supplemental Indenture, the Eighth Supplemental Indenture, the Ninth Supplemental Indenture, the Tenth Supplemental
Indenture, the Eleventh Supplemental Indenture, the Twelfth Supplemental Indenture, the Thirteenth Supplemental Indenture, the
Fourteenth Supplemental Indenture, the Fifteenth Supplemental Indenture, the Sixteenth Supplemental Indenture, the Seventeenth
Supplemental Indenture, the Eighteenth Supplemental Indenture, the Nineteenth Supplemental Indenture, the Twentieth Supplemental
Indenture and this Twenty-First Supplemental Indenture shall be read, taken and construed as one and the same instrument. All provisions
included in this Twenty-First Supplemental Indenture supersede any conflicting provisions included in the Base Indenture unless
not permitted by law. The Trustee accepts the trusts created by the Indenture, as supplemented by this Twenty-First Supplemental
Indenture, and agrees to perform the same upon the terms and conditions of the Indenture, as supplemented by this Twenty-First
Supplemental Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">SECTION&nbsp;3.5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Waiver of Jury Trial</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">EACH OF THE COMPANY AND THE TRUSTEE HEREBY
IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING
ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE NOTES OR THE TRANSACTION CONTEMPLATED HEREBY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">SECTION&nbsp;3.6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Force Majeure</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">In no event shall the Trustee be responsible
or liable for any failure or delay in the performance of its obligations hereunder arising out of or caused by, directly or indirectly,
forces beyond its control, including, without limitation, strikes, work stoppages, accidents, acts of war or terrorism, civil or
military disturbances, nuclear or natural catastrophes or acts of God and interruptions, loss or malfunctions of utilities, communications
or computer (software and hardware) services; it being understood that the Trustee shall use reasonable efforts which are consistent
with accepted practices in the banking industry to resume performance as soon as practicable under the circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">SECTION&nbsp;3.7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Effectiveness</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">The provisions of this Twenty-First Supplemental
Indenture shall become effective as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">SECTION&nbsp;3.8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Submission to Jurisdiction</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Each party to this Twenty-First Supplemental
Indenture hereby irrevocably submits to the jurisdiction of any New York State court sitting in the Borough of Manhattan in the
City of New York or any federal court sitting in the Borough of Manhattan in the City of New York in respect of any suit, action
or proceeding arising out of or relating to the Indenture and the Notes, and irrevocably accepts for itself and in respect of its
property, generally and unconditionally, jurisdiction of the aforesaid courts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Remainder of page intentionally left blank.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">IN WITNESS WHEREOF, the parties hereto have
caused this Twenty-First Supplemental Indenture to be duly executed as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">QUEST DIAGNOSTICS INCORPORATED</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 39%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 6%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 55%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">/s/ Sandip Patel</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Name:&nbsp;&nbsp;Sandip Patel</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Title:&nbsp;&nbsp;Vice President &amp; Treasurer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Page to Twenty-first Supplemental
Indenture</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 19; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">THE BANK OF NEW YORK MELLON,<BR>
as Trustee</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 39%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 6%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 55%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">/s/ Shannon Matthews</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Name:&nbsp;&nbsp;Shannon Matthews</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Title: &nbsp;&nbsp;&nbsp;Agent</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Page to Twenty-First Supplemental
Indenture</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">EXHIBIT&nbsp;A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form of 2.800% Senior Note due 2031</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">[<I>The following legends apply only if the
Note is a Global Note</I>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">THIS NOTE IS A GLOBAL NOTE WITHIN THE MEANING
OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITORY OR A NOMINEE THEREOF. THIS NOTE MAY NOT
BE EXCHANGED IN WHOLE OR IN PART FOR A NOTE REGISTERED, AND NO TRANSFER OF THIS NOTE IN WHOLE OR IN PART MAY BE REGISTERED, IN
THE NAME OF ANY PERSON OTHER THAN SUCH DEPOSITORY OR ITS NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE
OF THE DEPOSITORY TRUST COMPANY TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT AND SUCH CERTIFICATE
ISSUED IN EXCHANGE FOR THIS CERTIFICATE IS REGISTERED IN THE NAME OF CEDE &amp; CO., OR SUCH OTHER NAME AS REQUESTED BY AN AUTHORIZED
REPRESENTATIVE OF THE DEPOSITORY, ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL,
SINCE THE REGISTERED OWNER HEREOF, CEDE &amp; CO., HAS AN INTEREST HEREIN.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">QUEST DIAGNOSTICS INCORPORATED</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2.800% Senior Note due 2031</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; padding-right: 5.4pt"><B>No. 0 (Specimen) </B></TD>
    <TD STYLE="width: 51%; padding-left: 5.4pt; text-align: right"><B>$[_________]</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CUSIP: </B>74834L BC3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Quest Diagnostics Incorporated, a Delaware
corporation (herein called the &#8220;Company,&#8221; which term includes any successor Person under the Indenture hereinafter
referred to), for value received, hereby promises to pay to Cede &amp; Co., or registered assigns, the principal sum of $[_________]
on June 30, 2031 (the &#8220;Stated Maturity&#8221;) (except to the extent redeemed or repaid prior to the Stated Maturity) and
to pay interest thereon from May 13, 2020 or from the most recent Interest Payment Date to which interest has been paid or duly
provided for semi&#45;annually at the rate of 2.800% per annum, on June 30 and December 30, commencing with December 30, 2020,
on the Stated Maturity and on any Redemption Date (each such date, an &#8220;Interest Payment Date&#8221;) until the principal
hereof is paid or made available for payment. All capitalized terms used but not defined herein shall have the meanings ascribed
to such terms in the Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><U>Payment of Interest</U>. The interest so
payable, and punctually paid or made available for payment, on any Interest Payment Date, will, as provided in the Indenture, be
paid, in immediately available funds, to the Person in whose name this Note (or one or more Predecessor Securities) is registered
at the close of business on June 15 or December 15 (whether or not a Business Day, as defined in the Indenture), as the case may
be, next preceding such Interest Payment Date (the &#8220;Regular Record Date&#8221;). Any such interest not punctually paid or
duly provided for (&#8220;Defaulted Interest&#8221;) will forthwith cease to be payable to the Holder on such Regular Record Date,
and such Defaulted Interest, may be paid to the Person in whose name this Note (or one or more Predecessor Securities) is registered
at the close of business on a special record date (the &#8220;Special Record Date&#8221;) for the payment of such Defaulted Interest
to be fixed by the Trustee, notice whereof shall be given to Holders of Notes not less than ten days prior to such Special Record
Date, or may be paid at any time in any other lawful manner not inconsistent with requirements of any securities exchange on which
the Notes may be listed, and upon such notice as may be required by such exchange, all as more fully provided in said Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><U>Place of Payment</U>. Payment of interest
on this Note will be made at the Corporate Trust Office of the Trustee or such other office or agency of the Company as may be
designated for such purpose, in such coin or currency of the United States of America as at the time of payment is legal tender
for payment of public and private debts; <I>provided</I>, <I>however</I>, that each installment of interest and payment of principal
on this Note may at the Company&#8217;s option be paid in immediately available funds by transfer to an account maintained by the
payee located in the United States. Payment of the principal of this Note on the Stated Maturity will be made against presentation
of this Note at the office or agency of the Company maintained for that purpose in the Borough of Manhattan, The City of New York,
in such coin or currency of the United States of America as at the time of payment is legal tender for the payment of public and
private debts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><U>Time of Payment</U>. In any case where
any Interest Payment Date, Redemption Date or Stated Maturity shall not be a Business Day at any Place of Payment, then (notwithstanding
any other provision of the Indenture or this Note), payment of principal or interest, if any, need not be made at such Place of
Payment on such date, but may be made on the next succeeding Business Day at such Place of Payment with the same force and effect
as if made on the Interest Payment Date, Redemption Date, or at Stated Maturity; <I>provided</I> that no interest shall accrue
on the amount so payable for the period from and after such Interest Payment Date, Redemption Date, Repayment Date, or Stated Maturity,
as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><U>Legends</U>. The statements set forth in
the restrictive legends above are an integral part of the terms of this Note and by acceptance hereof each Holder of this Note
agrees to be subject to and bound by the terms and provisions set forth in such legend.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><U>General</U>. This Note is one of a duly
authorized issue of securities (herein called the &#8220;Securities&#8221;) of the Company, issued and to be issued in one or more
series under an indenture, dated as of June&nbsp;27, 2001 (the &#8220;Base Indenture&#8221;), between the Company and The Bank
of New York, Trustee (herein called the &#8220;Trustee,&#8221; which term includes any successor trustee under the Indenture with
respect to a series of which this Note is a part), to which Base Indenture and all indentures supplemental thereto, including the
supplemental indenture dated May 13, 2020 (the &#8220;Supplemental Indenture&#8221;) (the Base Indenture, as so supplemented, the
&#8220;Indenture&#8221;), reference is hereby made for a statement of the respective rights, limitations of rights, duties and
immunities thereunder of the Company, the Trustee and the Holders of the Securities, and of the terms upon which the Securities
are, and are to be, authenticated and delivered. This Note is one of a duly authorized series of Securities designated as &#8220;2.800%
Senior Notes due 2031&#8221; (collectively, the &#8220;Notes&#8221;), initially limited in aggregate principal amount to $550,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><U>Further Issuance</U>. The Company may from
time to time, without the consent of the Holders of Notes of this series, issue additional Notes (the &#8220;Additional Notes&#8221;)
of this series having the same ranking and the same interest rate, maturity and other terms as the Notes of this series. Any Additional
Notes of this series and the Notes of this series will constitute a single series under the Indenture and all references to the
Notes of this series shall include the Additional Notes unless the context otherwise requires.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><U>Book&#45;Entry</U>. This Note is a Global
Note representing $[_________] of the Notes. This Note is a &#8220;book entry&#8221; Note and is being registered in the name of
Cede &amp; Co. as nominee of The Depository Trust Company (the &#8220;Depository&#8221;), a clearing agency. Subject to the terms
of the Indenture, this Note will be held by a clearing agency or its nominee, and beneficial interest will be held by beneficial
owners through the book&#45;entry facilities of such clearing agency or its nominee in minimum denominations of $2,000 and integral
multiples of $1,000 in excess thereof. As long as this Note is registered in the name of the Depository or its nominee, the Trustee
will make payments of principal and interest on this Note by wire transfer of immediately available funds to the Depository or
its nominee. Notwithstanding the above, the final payment on this Note will be made after due notice by the Trustee of the pendency
of such payment and only upon presentation and surrender of this Note at its Corporate Trust Office or such other offices or agencies
appointed by the Trustee for that purpose and such other locations provided in the Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><U>Events of Default</U>. If an Event of Default
with respect to the Notes shall have occurred and be continuing, the principal of the Notes of this series may be declared due
and payable in the manner and with the effect provided in the Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><U>Optional Redemption</U>. The Notes of this
series are not subject to any sinking fund. Prior to March 30, 2031 (three months prior to their maturity date), the Notes of this
series will be redeemable at any time, at the option of the Company, in whole or from time to time in part, upon not less than
10 nor more than 60&nbsp;days&#8217; prior notice, at a Redemption Price, calculated pursuant to the Indenture, together with accrued
interest thereon, if any, to, but excluding, the Redemption Date (subject to the rights of holders of record on the Regular Record
Date that is prior to the Redemption Date to receive interest on the relevant Interest Payment Date). On or after March 30, 2031
(three months prior to their maturity date), the Notes of this series will be redeemable at any time, at the option of the Company,
in whole or from time to time in part, upon not less than 10 nor more than 60 days&#8217; prior notice, at a redemption price equal
to 100% of the principal amount of the Notes being redeemed, together with accrued interest thereon, if any, to, but excluding,
the Redemption Date (subject to the rights of holders of record on the Regular Record Date that is prior to the Redemption Date
to receive interest on the relevant Interest Payment Date). If less than all of the Notes of this series are to be redeemed, and
such Notes are at the time represented by one or more global security certificates, then the Notes to be redeemed shall be selected
in accordance with the procedures of the Depository. If less than all of the Notes of this series are to be redeemed, and such
Notes are not represented by one or more global security certificates, the Notes to be redeemed shall be selected by the Trustee
by such method as the Trustee in its sole discretion shall deem fair and appropriate. If any Note is to be redeemed in part only,
the notice of redemption relating to such Note shall state the portion of the principal amount thereof to be redeemed. A new Note
in principal amount equal to the unredeemed portion thereof will be issued in the name of the Holder thereof upon cancellation
of this Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><U>Redemption upon a Change of Control Triggering
Event</U>. Upon the occurrence of a Change of Control Triggering Event, the Company shall be required to make an offer to repurchase
the Notes on the terms set forth in the Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><U>Defeasance and Covenant Defeasance</U>.
The Indenture contains provisions for defeasance at any time of (a) the entire indebtedness of the Company on this Note and (b)
certain restrictive covenants and the related Defaults and Events of Default, upon compliance by the Company with certain conditions
set forth therein, which provisions apply to this Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><U>Modification and Waivers; Obligations of
the Company Absolute</U>. The Indenture permits, with certain exceptions as therein provided, the amendment thereof and the modification
of the rights and obligations of the Company and the rights of the Holders of the Securities of each series. Such amendment may
be effected under the Indenture at any time by the Company and the Trustee with the consent of the Holders of not less than a majority
in aggregate principal amount of the Outstanding Notes of each series affected thereby. The Indenture also contains provisions
permitting the Holders of not less than a majority in aggregate principal amount of the Securities at the time Outstanding, on
behalf of the Holders of all Outstanding Securities, to waive compliance by the Company with certain provisions of the Indenture.
Furthermore, provisions in the Indenture permit the Holders of not less than a majority in aggregate principal amount of the Outstanding
Securities of individual series to waive on behalf of all of the Holders</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">of Securities of such individual series certain past defaults
under the Indenture and their consequences. Any such consent or waiver shall be conclusive and binding upon the Holder of this
Note and upon all future Holders of this Note and of any Note issued upon the registration of transfer hereof or in exchange hereof
or in lieu hereof, whether or not notation of such consent or waiver is made upon this Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">No reference herein to the Indenture and no
provision of this Note or of the Indenture shall alter or impair the obligation of the Company, which is absolute and unconditional,
to pay the principal of and interest on this Note at the time, place, and rate, and in the coin or currency, herein prescribed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><U>Limitation on Suits</U>. As set forth in,
and subject to, the provisions of the Indenture, no Holder of any Note of this series will have any right to institute any proceeding
with respect to the Indenture or for any remedy thereunder, unless such Holder shall have previously given to the Trustee written
notice of a continuing Event of Default with respect to this series, the Holders of not less than 25% in principal amount of the
Outstanding Notes of this series shall have made written request, and offered reasonable indemnity, to the Trustee to institute
such proceedings as trustee, and the Trustee shall not have received from the Holders of a majority in principal amount of the
Outstanding Notes of this series a direction inconsistent with such request and shall have failed to institute such proceeding
within 60 days; <I>provided</I>, <I>however</I>, that such limitations do not apply to a suit instituted by the Holder hereof for
the enforcement of payment of the principal of or interest on this Note on or after the respective due dates expressed herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><U>Authorized Denominations</U>. The Notes
of this series are issuable only in registered form without coupons in denominations of $2,000 or any integral multiple of $1,000
in excess thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><U>Registration of Transfer or Exchange</U>.
As provided in the Indenture and subject to certain limitations herein and therein set forth, the transfer of this Note is registrable
in the Security Register upon surrender of this Note for registration of transfer at the office or agency of the Company in any
place where the principal of and interest on this Note are payable, duly endorsed by, or accompanied by a written instrument of
transfer in form satisfactory to the Company and the Security Registrar duly executed by, the Holder hereof or his attorney duly
authorized in writing, and thereupon one or more new Notes, of authorized denominations and for the same aggregate principal amount,
will be issued to the designated transferee or transferees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">As provided in the Indenture and subject to
certain limitations herein and therein set forth, the Notes are exchangeable for a like aggregate principal amount of Notes of
different authorized denominations, as requested by the Holders surrendering the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><U>This Note is a Global Security</U>. If
the Depository is at any time unwilling, unable or ineligible to continue as depository and a successor depository is not appointed
by the Company within 90 days or an Event of Default under the Indenture has occurred and is continuing, the Company will issue
Securities in certificated form in exchange for each Global Security. In addition, the Company may at any time determine not to
have Securities represented by a Global Security and, in such event, will issue Securities in certificated form in exchange in</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">whole for the Global Security representing such Security. In any such instance, an owner of a beneficial interest in a Global Security
will be entitled to physical delivery in certificated form of Securities equal in principal amount to such beneficial interest
and to have such Securities registered in its name. Securities so issued in certificated form will be issued in denominations of
$2,000 or any amount in excess thereof which is an integral multiple of $1,000 and will be issued in registered form only, without
coupons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">No service charge shall be made for any such
registration of transfer or exchange, but the Company may require payment of a sum sufficient to cover any tax or other governmental
charge payable in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Prior to due presentment of this Note for
registration of transfer, the Company, the Trustee and any agent of the Company or the Trustee may treat the Holder as the owner
hereof for all purposes, whether or not this Note be overdue, and neither the Company, the Trustee nor any such agent shall be
affected by notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><U>Defined Terms</U>. All terms used in this
Note, which are defined in the Indenture and are not otherwise defined herein, shall have the meanings assigned to them in the
Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B><U>Governing Law</U>. This Note shall be
governed by and construed in accordance with the laws of the State of New York.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Unless the certificate of authentication hereon
has been executed by the Trustee by manual or electronic signature, this Note shall not be entitled to any benefit under the Indenture
or be valid or obligatory for any purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">IN WITNESS WHEREOF, the Company has caused
this instrument to be duly executed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">QUEST DIAGNOSTICS INCORPORATED</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 4%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 46%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">Name:</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Sandip Patel</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Attest:</TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">Title:</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Vice President &amp; Treasurer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By: ___________________________________<BR>
Name: William J. O&#8217;Shaughnessy, Jr.<BR>
Title: &nbsp;&nbsp;Deputy General Counsel and Corporate Secretary</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TRUSTEE&#8217;S CERTIFICATE OF AUTHENTICATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">This is one of the Notes of the series designated
and referred to in the within&#45;mentioned Indenture, as such is supplemented by the within&#45;mentioned Twenty-First Supplemental
Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">THE BANK OF NEW YORK MELLON,<BR>
as Trustee</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 43%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 4%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 53%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Name:&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Title:&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>ss173511_ex0501.htm
<DESCRIPTION>OPINION OF SHEARMAN & STERLING LLP
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Exhibit 5.1</B></FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 6pt; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; padding-bottom: 6pt"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 11px; width: 248px"></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt/10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">599
        Lexington Avenue<BR>
        New York, NY 10022-6069</FONT></P>
        <P STYLE="font: 10pt/10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt/10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt/10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">+1.212.848.4000</FONT></P>
        <P STYLE="font: 10pt/10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-align: right">May 13, 2020</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0">The Board of Directors<BR>
Quest Diagnostics Incorporated<BR>
500 Plaza Drive<BR>
Secaucus, New Jersey 07094<BR>
<BR>
</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0"><BR>
Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in">We have acted as counsel to Quest Diagnostics Incorporated,
a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), in connection with (i) the purchase and sale of $550,000,000 aggregate
principal amount of the Company&rsquo;s 2.800% Senior Notes due 2031 (the &ldquo;<U>Notes</U>&rdquo;), pursuant to the Underwriting
Agreement, dated as of May 11, 2020 (the &ldquo;<U>Underwriting Agreement</U>&rdquo;), among the Company and Goldman Sachs &amp;
Co. LLC, J.P. Morgan Securities LLC and Mizuho Securities USA LLC, as representatives of the several underwriters named therein;
(ii) the preparation and filing by the Company with the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;)
under the Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;), of the automatic registration statement
on Form S-3 (File No. 333-232138) filed by the Company under the Securities Act with the Commission on June 14, 2019 (such automatic
registration statement, including the information deemed to be a part thereof at the time of effectiveness pursuant to Rule 430B
under the Securities Act and documents incorporated by reference therein, being hereinafter referred to as the &ldquo;<U>Registration
Statement</U>&rdquo;); (iii) the preparation and filing with the Commission of the prospectus, dated June 14, 2019, relating to
the debt securities generally contained in the Registration Statement (the prospectus, including the documents incorporated by
reference therein, being hereinafter referred to as the &ldquo;<U>Base Prospectus</U>&rdquo;), the preliminary prospectus, dated
May 11, 2020, with respect to the Notes, including the Base Prospectus, the preliminary prospectus supplement and all documents
incorporated or deemed incorporated therein by reference (in the form in which it was filed with the Commission pursuant to Rule
424(b), the &ldquo;<U>Preliminary Prospectus</U>&rdquo;), the pricing term sheet, dated May 11, 2020, relating to the Notes, in
the form filed with the Commission pursuant to Rule 433 under the Securities Act (the &ldquo;<U>Pricing Term Sheet</U>&rdquo;),
and the final prospectus, dated May 11, 2020, with respect to the Notes, including the Base Prospectus, the final prospectus supplement
and all documents incorporated or deemed incorporated therein by reference (in the form in which it was filed with the Commission
pursuant to Rule 424(b) under the Securities Act, the &ldquo;<U>Final Prospectus</U>&rdquo;).</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in">The Notes have been issued in one or more series pursuant
to an indenture, dated as of June 27, 2001 (the &ldquo;<U>Base Indenture</U>&rdquo;), among the Company, the Subsidiary Guarantors
(as defined therein) and The Bank of New York Mellon (formerly, &ldquo;The Bank of New York&rdquo;), as trustee (the &ldquo;<U>Trustee</U>&rdquo;),
as supplemented by a first supplemental indenture, dated as of June 27, 2001, among the Company, the Initial Subsidiary Guarantors
(as defined therein) and the Trustee, as further supplemented by a second supplemental indenture, dated as of November 26, 2001,
among the Company, the Subsidiary Guarantors (as defined therein) and the Trustee, as further supplemented by a third supplemental
indenture, dated as of April 4, 2002, among the Company, the Additional Subsidiary Guarantors (as defined therein) and the Trustee,
as further supplemented by a fourth supplemental indenture, dated as of March&nbsp;19, 2003, among the Company, the Additional
Subsidiary Guarantor (as defined therein) and the Trustee, as further supplemented by a fifth supplemental indenture, dated as
of April 16, 2004, among the Company, the Additional Subsidiary Guarantor (as defined therein) and the Trustee, as further supplemented
by a sixth supplemental indenture, dated as of October 31, 2005, among the Company, the Subsidiary Guarantors (as defined therein)
and the Trustee, as further supplemented by a seventh supplemental indenture, dated as of November 21, 2005, among the Company,
the Additional Subsidiary Guarantors (as defined therein) and the Trustee, as further supplemented by an eighth supplemental indenture,
dated as of July 31, 2006, among the Company, the Additional Subsidiary Guarantors (as defined therein) and the Trustee, as further
supplemented by a ninth supplemental indenture, dated as of September&nbsp;30, 2006, among the Company, the Additional Subsidiary
Guarantors</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt; width: 100%; font: bold 10pt Arial Narrow, Helvetica, Sans-Serif">SHEARMAN.COM</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt/8pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-size: 7pt">Shearman &amp; Sterling LLP is a limited
    liability partnership organized in the United States under the laws of the state of Delaware, which laws limit the personal
    liability of partners.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in">(as defined therein) and the Trustee, as further supplemented
by a tenth supplemental indenture, dated as of June 22, 2007, among the Company, the Subsidiary Guarantors (as defined therein)
and the Trustee, as further supplemented by an eleventh supplemental indenture, dated as of June 22, 2007, among the Company, the
Additional Subsidiary Guarantors (as defined therein) and the Trustee, as further supplemented by a twelfth supplemental indenture,
dated as of June 25, 2007, among the Company, the Additional Subsidiary Guarantors (as defined therein) and the Trustee, as further
supplemented by a thirteenth supplemental indenture, dated as of November 17, 2009, among the Company, the Subsidiary Guarantors
(as defined therein) and the Trustee, as further supplemented by a fourteenth supplemental indenture, dated as of March 24, 2011,
among the Company, the Subsidiary Guarantors (as defined therein) and the Trustee, as further supplemented by a fifteenth supplemental
indenture, dated as of November 30, 2011, among the Company, the Additional Subsidiary Guarantors (as defined therein) and the
Trustee, as further supplemented by a sixteenth supplemental indenture, dated as of March 17, 2014, between the Company and the
Trustee, as further supplemented by a seventeenth supplemental indenture, dated as of March 10, 2015, between the Company and the
Trustee, as further supplemented by an eighteenth supplemental indenture, dated as of May 26, 2016, between the Company and the
Trustee, as further supplemented by a nineteenth supplemental indenture, dated as of March 12, 2019, between the Company and the
Trustee, as further supplemented by a twentieth supplemental indenture, dated as of December 16, 2019, between the Company and
the Trustee, and as further supplemented by a twenty-first supplemental indenture, dated May 13, 2020, between the Company and
the Trustee (collectively, as so supplemented, the &ldquo;<U>Indenture</U>&rdquo;).</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in">In that connection, we have reviewed originals or copies
of the following documents:</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 91.5pt; text-indent: -19.5pt"><FONT STYLE="font-family: Proxima Nova A">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Proxima Nova A">The Indenture (including the supplemental indentures referred to above); and </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 91.5pt; text-indent: -19.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 91.5pt; text-indent: -19.5pt"><FONT STYLE="font-family: Proxima Nova A">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Proxima Nova A">The Notes in global form as executed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 91.5pt; text-indent: -19.5pt">&nbsp;</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in">The documents described in the foregoing clauses (a) and
(b) of this paragraph are collectively referred to herein as the &ldquo;<U>Opinion Documents</U>.&rdquo;</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0">We have also reviewed the following:</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Proxima Nova A; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>The Registration Statement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Proxima Nova A">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Proxima Nova A; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>The Base Prospectus.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Proxima Nova A">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Proxima Nova A; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>The Preliminary Prospectus.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Proxima Nova A">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Proxima Nova A; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD>The Pricing Term Sheet.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Proxima Nova A">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Proxima Nova A; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD>The Final Prospectus.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Proxima Nova A">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Proxima Nova A; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD>Originals or copies of such other corporate records of the Company, certificates of public officials and of officers of the
Company and agreements and other documents as we have deemed necessary as a basis for the opinions expressed below.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Proxima Nova A">&nbsp;</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0">In our review of the Opinion Documents and other documents, we have assumed:</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Proxima Nova A; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>The genuineness of all signatures.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Proxima Nova A">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Proxima Nova A; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>The authenticity of the originals of the documents submitted to us.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Proxima Nova A">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Proxima Nova A; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>The conformity to authentic originals of any documents submitted to us as copies.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Proxima Nova A">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Proxima Nova A; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD>As to matters of fact, the truthfulness of the representations made in the Opinion Documents and in certificates of public
officials and officers of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Proxima Nova A">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Proxima Nova A; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD>That each of the Opinion Documents is the legal, valid and binding obligation of each party thereto, other than the Company,
and is enforceable against each such party, other than the Company, in accordance with its terms.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Proxima Nova A">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Proxima Nova A; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD>That:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Proxima Nova A">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Proxima Nova A; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD>The Company is duly organized and validly existing under the laws of the jurisdiction of its organization.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Proxima Nova A">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Proxima Nova A; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD>The Company has the full power to execute, deliver and perform, and the Company has duly executed and delivered (except to
the extent Generally Applicable Law is applicable to such execution and delivery), the Opinion Documents.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Proxima Nova A">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Proxima Nova A; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD>The execution, delivery and performance by the Company of the Opinion Documents to which it is a party do not and will not:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Proxima Nova A">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Proxima Nova A; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>contravene its certificate or articles of incorporation, by-laws or other organizational documents; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Proxima Nova A">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Proxima Nova A; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>except with respect to Generally Applicable Law, violate any law, rule or regulation applicable to it.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Proxima Nova A">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Proxima Nova A; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD>That the execution, delivery and performance by the Company of the Opinion Documents to which it is a party do not and will
not result in any conflict with or breach of any agreement or document binding on it.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Proxima Nova A">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Proxima Nova A; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD>Except with respect to Generally Applicable Law, no authorization, approval, consent or other action by, and no notice to or
filing with, any governmental authority or regulatory body or any other third party is required for the due execution, delivery
or performance by the Company of any Opinion Document or, if any such authorization, approval, consent, action, notice or filing
is required, it has been duly obtained, taken, given or made and is in full force and effect.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Proxima Nova A">&nbsp;</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0">We have not independently established the validity of the foregoing assumptions.</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0"></P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in">&ldquo;<U>Generally Applicable Law</U>&rdquo; means the federal
law of the United States of America, and the law of the State of New York (including in each case the rules or regulations promulgated
thereunder or pursuant thereto), that a New York lawyer exercising customary professional diligence would reasonably be expected
to recognize as being applicable to the Company, the Opinion Documents or the transactions governed by the Opinion Documents, and
for purposes of assumption paragraphs (f) and (h) above and our opinions below, the General Corporation Law of the State of Delaware.
Without limiting the generality of the foregoing definition of Generally Applicable Law, the term &ldquo;Generally Applicable Law&rdquo;
does not</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in">include any law, rule or regulation that is applicable to
the Company, the Opinion Documents or such transactions solely because such law, rule or regulation is part of a regulatory regime
applicable to the specific assets or business of any party to any of the Opinion Documents or any of its affiliates.</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in">Based upon the foregoing and upon such other investigation
as we have deemed necessary and subject to the qualifications set forth below, we are of the opinion that:</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Proxima Nova A; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">1.</TD><TD>The Indenture is the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with
its terms.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Proxima Nova A">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Proxima Nova A; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">2.</TD><TD>The Notes, when authenticated by the Trustee in accordance with the Indenture and delivered and paid for as provided in the
Underwriting Agreement, will be the legal, valid and binding obligations of the Company, enforceable against the Company in accordance
with their terms and entitled to the benefits of the Indenture.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Proxima Nova A">&nbsp;</P>



<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in">Our opinions expressed above are subject to the following
qualifications:</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Proxima Nova A">(a)</FONT></TD><TD><FONT STYLE="font-family: Proxima Nova A">Our opinions are subject to the effect of any applicable bankruptcy, insolvency,
reorganization, moratorium or similar laws affecting creditors&rsquo; rights generally (including without limitation all laws relating
to fraudulent transfers).</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Proxima Nova A">(b)</FONT></TD><TD><FONT STYLE="font-family: Proxima Nova A">Our opinions are also subject to the effect of general principles of equity, including
without limitation concepts of materiality, reasonableness, good faith and fair dealing (regardless of whether considered in a
proceeding in equity or at law).</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Proxima Nova A">(c)</FONT></TD><TD><FONT STYLE="font-family: Proxima Nova A">Our opinions are limited to Generally Applicable Law, and we do not express any opinion
herein concerning any other law.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in">This opinion letter speaks only as of the date hereof. We
expressly disclaim any responsibility to advise you of any development or circumstance of any kind, including any change of law
or fact, that may occur after the date of this opinion letter and which might affect the opinions expressed herein.</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in">We hereby consent to the filing of this opinion letter as
an exhibit to your Current Report on Form 8-K, dated May 13, 2020, and incorporated by reference into the Registration Statement
and to the use of our name under the heading &ldquo;Legal Matters&rdquo; in the prospectus constituting a part of such Registration
Statement. In giving this consent, we do not hereby admit that we are in the category of persons whose consent is required under
Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder.</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in">Very truly yours,</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in">/s/ Shearman &amp; Sterling LLP</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0; text-indent: 0in">LN/dy/mp/pp</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0">RA</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Proxima Nova A; margin: 0pt 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>ss173511_ex9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="text-align: right; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white; color: #63666A"><FONT STYLE="font-size: 10pt; color: Black"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white; color: #63666A">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white; color: #63666A">SECAUCUS, N.J.,&nbsp;May
11, 2020&nbsp;/PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information
services, announced today the pricing of a public offering of&nbsp;$550 million aggregate principal amount of its 2.800% senior
notes due&nbsp;2031 under Quest Diagnostics' shelf registration statement.&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white; color: #63666A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; color: #35792A"><IMG SRC="image_002.jpg" ALT="Quest Diagnostics Incorporated logo. (PRNewsFoto|Quest Diagnostics Incorporated)" STYLE="height: 190px; width: 400px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white; color: #63666A">Quest Diagnostics expects
to receive the net offering proceeds upon closing on&nbsp;May 13, 2020, subject to customary closing conditions. The company intends
to use the net proceeds from the offering for general corporate purposes, which may include the repayment of indebtedness. The
indebtedness the company may repay with the net proceeds of the offering includes the company's&nbsp;$550 million&nbsp;aggregate
principal amount of 4.70% senior notes due 2021 and outstanding borrowings under the company's senior unsecured revolving credit
facility and secured receivables credit facility.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white; color: #63666A">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white; color: #63666A">This press release shall
not constitute an offer to sell or a solicitation of an offer to purchase any of these securities and shall not constitute an offer,
solicitation or sale in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful. This offering
may be made only by means of a prospectus supplement and accompanying base prospectus, copies of which or information concerning
this offering may be obtained by calling Goldman Sachs &amp; Co. LLC, collect at 1 (212) 902-1171, J.P. Morgan Securities LLC,&nbsp;collect
at 1 (212) 834-4533 or Mizuho Securities&nbsp;USA&nbsp;LLC, toll-free at 1 (866) 271-7403.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white; color: #63666A">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: #63666A"><B>About
Quest Diagnostics<BR>
</B>Quest Diagnostics empowers people to take action to improve health outcomes.&nbsp;Derived from the world's largest database
of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and
improve health care management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals
in&nbsp;the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic
insights can inspire actions that transform lives.&nbsp;</FONT><FONT STYLE="color: #35792A"><U>www.QuestDiagnostics.com</U></FONT><FONT STYLE="color: #63666A">.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white; color: #63666A"><B>About COVID-19 Testing
by Quest Diagnostics<BR>
</B>Quest Diagnostics is at the forefront of response to the COVID-19 pandemic, working to broaden access to laboratory insights
to help us all lead healthier lives. We provide both</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white; color: #63666A">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #63666A"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #63666A">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white; color: #63666A">molecular diagnostic
and antibody serology tests to aiding the diagnosis of COVID-19 and immune response. Our COVID-19 test services are based on tests
that have received or are expected to receive FDA emergency use authorization and which also meet our high standards for quality.
We provide data on COVID-19 testing to various federal and state public health authorities, including the Centers for Disease Control
and Prevention, and participate in studies with government and private institutions, aiding COVID-19 public health response and
research. Through our team of dedicated phlebotomists, couriers, air fleet team, and laboratory professionals, Quest Diagnostics
won't stop until quality testing is broadly available to patients and communities across the United States.&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white; color: #63666A">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: #63666A">For more
information about the latest developments with our COVID-19 testing, visit:&nbsp;</FONT><FONT STYLE="color: #35792A"><U>newsroom.questdiagnostics.com/COVIDTestingUpdates</U></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white; color: #63666A">The statements in this
press release which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance
on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates,
projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to
be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited
to, impacts of the COVID-19 pandemic and measures taken in response, adverse results from pending or future government investigations,
lawsuits or private actions, the competitive environment, the complexity of billing, reimbursement and revenue recognition for
clinical laboratory testing, changes in government regulations, changing relationships with customers, payers, suppliers or strategic
partners and other factors discussed in the company's most recently filed Annual Report on Form 10-K and in any of the company's
subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the &quot;Business,&quot;
&quot;Risk Factors,&quot; &quot;Cautionary Factors that May Affect Future Results&quot; and &quot;Management's Discussion and Analysis
of Financial Condition and Results of Operations&quot; sections of those reports.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white; color: #63666A">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white; color: #63666A">SOURCE Quest Diagnostics</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white; color: #63666A">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white; color: #63666A">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white; color: #63666A">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white; color: #63666A">For further information:
For further information: Denny Moynihan, Quest Diagnostics (Media): 973-520-2800, Shawn Bevec, Quest Diagnostics (Investors): 973-520-2900</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  . 38# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P!!#H__  DF
MI6_CYM1M-5ENW-G?F5TB6//R>6PX7'N,5ZW=*(]'F5'9E6!@K%LDC;USW^M>
M9>)];US5WN?"&H6.D27-TY2.Z$C[8P3P=I4G<!WS7HUMIYT_PQ'I_F&1H+00
M[V_B(3&: /,?#OCG2[/X5_V7<37AOS:3QY%O(PW-OV_.!CN.<\5W_P /V9_
M6BLY+,;5,DG)-9'AC39[;X/&P=HS-]BN$R"=N27QSC/?TK<\$6KV7@K2+>0J
M7CME4E>E 'E6D2>$GEU;_A)FU![P:C.%\DW!41[N!\G'7->W1F..W4J<1J@P
M3V&*\HT77-8\)MJ=I;V5A<QS7\UP'>X=2-QZ8"'TKN_&-Q=#P1?M:[$N9H/+
M4L3A2^%)SCL": //_#NHW<?C&Q\4S32_8=?O;BS",3M5!@0G\2I'X5Z-XR)7
MP7K14D$64N"#@CY37!ZO\-GL/!$4MIK-^US9K%/%#-/FW60$$E5QD=3BNXU[
MS=3\!WV BRW.GL<9.T%D]?3F@#RB&72K32/#UQX8U&X?Q/)+"LT$5P\F[(_>
M!U)P!7JGC]F3P%K3*2K"T<@@X(XKD3H4NA:?X1UZP%O'=6L:6UXH^43QLO/(
M')&#@GUKLO&UL][X+U>WC*AY;9U!;ITH \]\/^([S1_AQJFE22,^I1&*.SR2
M2RW(!C([\%F_*NB^#\4MOX6OK>>1I)(-1FB+%B>5"CO]*KP>#!<^(O"&I2/&
M!;6""= 3\[Q*/+(XYP6/7T%:_P .K"73]+U1)F0F35)Y!L)/!(]NM &)\2HK
MKQ'K-IX?T^:6-[>SFU"4QD@Y VQ@X]6S^==CX2U@:_X4TW4<Y>:%?,_WQPWZ
M@UR%GX4F\2>+M?U6[U2]LB)EMH183^6WEJ,88X]@<?6M/X<Z=/H2:QHTDHEM
M[6\9K=\Y;8W9N!SQGCU- '*:AK=[X=^+&L:L"[Z5 ]O!?IDD(DB *^/9A^N.
M]=-X!E,OB?QB?,+I]O4H=V1@J3Q[4ZPT%+WQKXO2^6.2SOX8(R@)SC9@YXX]
MJK?"[P]<>&YM>M+B9)@+E51U)R0 0,Y'!QB@#T"O(K2#2?%GQ!UNRU74K@WZ
MSAM,NK:Y*B-%Y9(^VX=^#WKUF:/SH)(]Q7>I7<O49%>)'0]2FCM_ @BT];NR
MG:6WU-9'5T4DD\!>I!P><=/3- 'LNEZE9ZK8I<Z?<K=09*"53D,1P>>_-0>)
M$U"3PWJ*Z.Q74# X@(.#NQQCW]/>LSX?.P\(VMH]O# ]E_H["%B48C^(9 /.
M<GWS6UJQO1I5R=+,"WHC)A,^=@;WQS0!YEX"A\+3:E8HSZEIWB:WYN(KF:1'
MN7Q\V<\,,\XX-=QXR\/V&MZ/++?)*SV<,LD)CF9,-M[[2,]!UKA[>\U#XA^*
M-+CN+2PLGTBX%Q-/%(S/)M/W4RHP"?4UZ;J\9ET:^C7&Y[>11GIRIH X_P"%
M6A64'ABPUI1,;Z[MRLKO,[ C?_=)P/NCH*PO&DFCCXH[/$377V#^S5*K 9,^
M9O..$YZ9KMOA]9R6'@32K:8J7CB()4Y'WC7,^)[C4-#^)/\ ;%E!:W ;3EM_
M+FE9/XR<\*?2@#K/!HTC_A'XSH'G_83(Y7SM^[=GG[_/6O,I5\-2Z]XN?Q%J
M,MM=17C_ &39<NC@8_A4'!YKU/PSJMSK.CK=WD$,$I=EV12%UP#ZD#^5<0?!
MJZS#XUCG$ GGO#-:S 9:)@,CG&1R.<>IH ZGX>W&HW7@;3)=7,ANVC.6E^^R
M[CM)]RN*S?AL[O/XHWNS8UF8#)S@<5T'A6_N=2\-65Q?;/M1CVRE#D,PX)'U
MQG\:\]TS6-7\*:IKD-O9V-S'=:C+<!I+AT(R<8P$/I0!U/Q6=H_AQJC(S*P$
M>"IP?]8M;TY/_",2')S]C//_  "L?XCV<NI^ -0MX2BR2"/&XG ^=3Z5M31,
M?#TD7&XVI7VSLQ0!Y!X.U^\LO!.HZ-J<C;+W3)[O3I6<G.%8.@/J""<?7U%>
MA^&M0;3_ (565^V9&M],\[#'.XJF?Z5S$G@LZI\'-.MV>)-0T]'FAE!.W[S;
MESC."OMU KLO"VFAO &GZ==[65K(0R;3P05P<4 <%9Z3H-QX8LM<\6:Y/;ZU
MJBM/#>FX96B.<@1@<  $<>]>IZ7-%<:5:RP71NXGB4K<'&91C[W'KUKRFYDU
M?0;,^!I+?3;XNCPV=Y*S QQOG&X;3\PSV/I7J'A[3&T7P]I^G22"5[6!(F=1
M@,0,9% ',_$EW27PQL=ESK,(.TXR.:[>N(^)\-PUGHUS:K$SVFHI<;96*AMH
M)QD UI>$/$=]X@^U_;K.VM_)V;/)F9]V<YSE1CH* ,[P([OXE\8AF9@NI8 )
MSCCM4/Q;:,:%I0N)6CMVU2%9F#E<1X;=DCVS6)%K6J>%/$_B(VMG97,=Y>F7
M,D[H5P,8P%-=%X_LY=7T;0N(@?[1MY9%8DKC!R.G/7O0!R"W1L/%7D?#6[EO
FH6M"]U%YS31(V\ $%B?FHKUVVLK:S#"UMX8 WWA&@7/Y44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_[0(L4&AO=&]S:&]P(#,N,  X0DE-! 0
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M%A86%A86%A86%O_  !$( +X!D ,!(@ "$0$#$0'_Q  =  $  @(# 0$
M        !@@%!P$#! D"_\0 41   00! @,%! 8%!P<*!P   0 " P0%!A$'
M$B$($S%!42)A<8$4%3)2D:$)0F)R@B,D,SACL;)35G62HK.T%A<8)30U-W1V
MP4-SE*/"T>'_Q  : 0$  @,!                 @,!! 4&_\0 ,1$  @("
M 0,!!@0& P        $" P01(1(Q0043(C)187&AL='P%#-"@<'A%9'Q_]H
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M,S#-QYO49HVXBZ,=<J7J<=JE9ALP2CFCEAD#V/'J'#H0N]7&T$1$ 1$0!$1
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MBSG]1T<)5#I+&3MQUH_,ETC@W<_CNMSU"]=2J7?R<_U2S<54O)?3LS8]^-X
M:0JR-+7C#PO(/ESMY_\ \E.EYL-3AQV)JX^L-H:D+(8QZ-:T-'Y!>E=.*U%(
MZL(],%'Y!$4-[0>H\GI'@WJ#4F&=$V]C:9F@,T?.P.YFCJWSZ$K,FHIMB<E&
M+D_!+;=:"U7?!9ACFBD&SXY&AS7#T(/0J'W^$'"Z[:-BSH'3SY"=R[ZOC;O\
M@ %'Z6"XY6*D5AO$;3 $L;7AITR[IN =OZ;WKJR&NN('#U[)^)F'QF0T^7!D
MVH, ) *.YV#K%9Y+FLW\7L) \U5*47\42B4X/F<./JO_ $V+IK36G]/0&# X
M3'XR,C8MIU61!WQY0-_FNS-X'"9D1C,8BCD!#OW0MUF3!F_CMS [;]/!>AD[
M+F-$]&>.1LT0?!,T\S' C=K@1XCJ#\%C] 5]25M)U8=6WJ-W,-YOI-BC"8H7
M^T>7E:>H]GE!]X*LX[:+]+X=<'&/TAI2A=CN4=-8>K9A.\<T%"*.1AVVW#@T
M$=%Z\_A<1G*#J.9QE3(57'=T%J!LK"?79P(7N#@4W"SI#ICK6B,::X<:"T]D
M!?P>C\+0M-.[9X*,;9&_!VVX^2RF7TWI[+6Q:RF#QMZ<-#!+:IQRN#1Y N:3
MMU/190G9<<P]_P""*,5QH*$4M)<'3C:53'THZ=&K#6KQ#:.&&,,8P>@:  %V
M31QRQNCD8US7CE<UPW!'H0OUNG,%DSP0W)<).&-^X;=O06GY)B=R_P"KXQN?
M4@ !233^#PV"H_0\+BJ6.K^/<U*[8F?@T!>[F'O_  7._3=148KE(C&$(O:1
MQL%C-1Z;T_J" 0YW"8_)Q@;!MRJR8#X<P.WR63YAZ'\$W&VZSI,DTFN2+X'A
MMP_PET7,3HS!4[#3NV:+'QA[3Z@[;CY*4  )S#W_ (+@G<=$22[&%&,>R/%J
M#"8?.T32S6+IY&L3N8;<#96;^NS@>JQ>F] :(T_;%O":2PV/L#PFK48V2#X.
M W'R7EX3ZLLZJBU"ZU4AK_4VHK>*B[IQ/>,A+0'NW\">;J!T61X@5]4VL$R/
M2&0Q]+(?28G.EOP.EC,(=_*-#1UYBW< ^14?=:ZM$?<DNM+9G BX;X=4YAZ'
M\%,L.47 ((W"<PW\_P $!RBAW$S4.=P>4P\>*BQTE>]).R?Z2V0O9W=>2?=O
M*=NHB+>OF0?<L+P4XEY/6^9DIW,#]6BOB8)IRXNW^EESFS1MW'5C?8V=Y\Q]
M%#VD=Z*_:QZ^GR;+1$4RP(B( B(@"(B +IOUH+E*:I9B;+#/&Z.6-W@]KAL0
M?<02NY$!C=(8H8+2^/PS9W3LQ]6.LR1PV+FL:&MW]^P"R,@W800#OY'S7*+"
M6EHPEI:* <;]%V=!<4<CAI(G-IR2NLXZ0CV9:[W$MV/JWJT^]OO6*QK^@5Z>
M+7#W3O$/3XQF=KNYXB7U;<1Y9JSSYL/H?-IZ'\%7/4W9NUSB;;OJ.S0S5;?V
M#WOT>7;]IK_9W^#EYO/]-M4G*M;1R+,.=<VX+:('C)1T4@QU@ #JLE0X*\3P
M\-=IQK/>Z]#L/]I3?2' /4L[F/SF5I4(_P!9E?>>3_V:/Q*\[;Z1EW/4:W^7
MYEU4;/D17 9B[C\C!:Q\TD=J-X[IT?5V_IMY[^&WFK/Z*OY/):;K6\OCG4+D
MC/Y2 GP]^WEOX['J%BM"</=-:5#9:-0S6P-C;LGGE^7DW^$!2I>E]!]'N]/4
MG.??^E=OO]SH132Y"X<=AT0D!<KT1(I/VH]0Y[.<3;L>=J34?J\F"I3D_P#A
M1;[AVXZ$O^US#H>@\EF.PYHA^;XCS:OMP[TL TM@+AT?:>-AM^ZPD_%S58#C
M[PLQ?$C3W=ES*>8JM/T&_P N_+^Q(!U=&?3Q!ZCSWSO"K1^.T+H>EIS&CF96
M9O+*1LZ>4]7R.]Y/X#8>2Y%6!..4[)O:[G/6))Y'7+E=R1-^RN41=<Z 6M^U
MY_5LU?\ Z-=_C:MD+6_:\_JVZP_T:?\ &U5V_P N7V*K_P"5+[,GN"_[EJ?^
M7C_PA?O*4ZV0Q\]&Y"R:O9C=%-$\;MD8X;.:1Z$$A?C!G_J:H-C_ -GC\OV0
MHCQ>XDXK1]'Z#4VRFIKH,>*P=5P?8M3'[.[1U8P'JY[M@ "I-I+DE*48PW(P
M/9,EGBX4WL!+,Z:/3.<R&(K2..Y,,,I[L;^YK@/DLIV5K]W*< -.7LG=L7+4
MT,IEGL2F21Y$\@&[CU/0 ?)>S@3I"SHKA=5Q&1G;8RDKI;N3F9]F2U,XR2$>
MX%VP]P6O.'F8R^G^P8W-8%I.2HX6W-6(9S%CA-+[8'GRC=WR5,=QUOPG_@UX
M-UJ/5XB_\&?S'#C3#+)DUGQ)U+;O3$N:ZSJ4T6LW.X$<,18UH'P*YX87LIIC
MBT_05G4MG4>$R6(=E,+=N3B>S7[N5L<L#Y1_2-]MKFN/4=0O1PNX6<,;&B\?
MDS@,7J.7(U8[$^7R4+;L]U[F@ND=))S'J2>@V \-NBBNEL;H3#=L6IB-%8RA
M0=6TU<^M(Z$8;&V8RPEK"![(>&]2!X<PW6--:D0TXN,M);:\_/\ ,E&N<AJ'
M7'%:?AUI_,VL%B\-2BN:@R-(AMN1TQ/=5H7D'N]VM+G/VWVV 79-P:IXV V]
M(:MU1A<M&-V6I<Q-=BE=_;0S.<R1I\P-CZ$+%ZHR)X6\=LGK#-0RC2FKZ=6&
MYDHXR]F,MP L89M@2V-['?;\ 1U4JSO&#ASC\<R>'5./RD]@;5:.)G;;M6W'
MP9'%&2XD^'78#S("S[KVY]R2]FW+VCY_>M& [+V6U)EY=<.U4YS,A5U/)7?6
M$[I(JW+!%NR'F\(R=W >CE'>&>$U)K_4.LJ.<U-F*VFL5JR_!#!2O/BGNNYP
M>[?,#SL@C;L&L81N7'<[ !9OLI6<M<M\0+>=J,IY&;5DC[%9D@>*Y->$B/F'
M0EK>4$CS!64[-0_F^M__ %UE?\;%&*ZE%/ZD8+J4$]^?VR/<0-/V.#L-/6VD
MLUF78>O?@@S>%OY&6Y!-7ED;&98S*7.CD8Y[3T.Q'0J5\:]4YVE=P>B](R0Q
M:BU1/)'!:FC#V8^O$WFFLEOZQ:" UIZ%Q&_@O-VOOZO6>_?I_P#%PK&\;K+-
M)<9M$\0LCNW!UV6L-D[)'L4OI'(8I7GR9SLY2?+<*4O=;2[<?[)3]QR4>%Q_
M;;Y/8W@E@Y:O?W-5:TLY<CF.6.HK#)@_[S6-(C;U_5Y-O)?OA#J#4>-UUE>&
M6LKXR>0QM5E_%Y8QAC\E2<[DWD:.@EC=[+B.AZ%;*BGCD@;-&0]CVAS7-.X(
M/@01XA:GTC:AUEVG\GJC$N$V'TQ@SA'78SO'8N23"61C'>#A&UH!(Z G92<5
M%KI)RC&$H]/=O_LPF@<72XKZCU+9UAJ;,C(8S-6:4. I9>6DW&01OY8WF.)S
M7/<\>WSNW!WV'@MF<.-(VM)OMUSJS.9FC*YIJU\M,V=]/8'F#9=@]X/3[1.V
MRQ6HM"<,N)@;GS4I7[()CBS.)MF.PTM.VPGA<"=B-MB3LL-PCLYS3W&3-\.;
M.I+FHL31Q,&2JV<@\26Z#I)',^CRR #GW#>=I=[6RC%=+6U_<C!=$EU+>_/Z
M_MD>X0\/Z.I\KK?*3Y_4]"6/6V1C;%C,W-5A]E["'&-IY2[KU)\=@ICVFKE[
M$<+*TN/R%JO.,WBXG3Q2EDCVNN1-<"6[?:!((\#N5T]FJ5C9-?5BX=]%KG(N
MDC_68'=VYI(\MQU"=K0@\*8-O\X,3_QT2))5-HPDECMKY,R7'#5F6P5+$X#2
M\<#]1ZHO?0<8ZPTNBK;-+Y;#Q^LV-@)V\R0%BX^"6(L5>_S6K-8Y+,.&[\I]
M?3UWA_K''&X1L&_@WE('O7G[0TSM-ZVT/Q&LQO=B=/7[%;+2-:7?18+4?=B<
M@?JM>&[GR!6TZ=JO;J1VJLS)H9F!\<L3@YCVD;@M(Z$'U4DE*34B:C&<Y*?C
MP1;A_C-7:;TQ?I:ASPU*^J][L98,'=VI80S=K)R/9=)S;CF:!N-B>JUGP6TO
MB>*FAX-7ZCUEJ"_GKG,^W%0SDU1F(EYC_-V01. 9R; >T"3X^:W!C=7::R#,
ML^GFJ<T>#E,62E;*.[JO#.=P>_[(V;U/7IY]0HGJ#A9PZUE,W5-"L:E^XT2Q
MYO 7759I=^H?WD1Y7_%P*2CO6N4)PWKIY2\-_OL2;A]IZ[IW#/QU[4N4SX$[
MG06,F6.FBC.VT9>UHY]NOM.ZG=9]K&M\!LM:=GK+YV3*ZMTIF<T[/QZ6RD=.
MIEY&M$MACXFR&.4M]ETD9/*2/'<;]5LU3@TX[1;4TX+01$4RP(B( B(@"(B
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>dgx-20200511.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +qs5w7xRiXgOn8uGaH9cOaGNCaPtzJJ9qZkhsmd7bYl6fywrs5lKKife04IGwUsI -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:DGX="http://DGX/20200511" elementFormDefault="qualified" targetNamespace="http://DGX/20200511">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://DGX/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="dgx-20200511_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="dgx-20200511_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>dgx-20200511_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>dgx-20200511_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://DGX/role/Cover" xlink:href="dgx-20200511.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://DGX/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>12
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ss173511_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "ss173511_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "dgx-20200511_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dgx-20200511_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "dgx-20200511.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "DGX",
   "nsuri": "http://DGX/20200511",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ss173511_8k.htm",
      "contextRef": "From2020-05-11to2020-05-11",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://DGX/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ss173511_8k.htm",
      "contextRef": "From2020-05-11to2020-05-11",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The start date of the period covered in the document, in CCYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r11": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r12": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r13": {
   "Name": "Forms 10-K, 20-F, 40-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d-1"
  },
  "r14": {
   "Name": "Forms 20-F, 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220 and 240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6630076544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 11, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 11,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Quest Diagnostics Incorporated<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001022079<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">16-1387862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">500 Plaza Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Secaucus<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(973)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">520-2700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 Par Value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DGX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>14
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M @  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSK9)!"H,P$ "_(GE
M5VWIH:BG7KRV_4#0U8B:A.R6ZN^;>E%!H0<O"6'#S$"2/+"3W!A-JK$4#'VG
M*16*V=X J%#82SH9B]I/*N-ZR?[H:K"R:&6-$(?A%=R2(;)DR0SR,A4N+R,1
MO*2KD5,!0P<?XUI2B$PP;=')"_R5T>(_>E-538%W4[Q[U+Q1,0L$; ?%<Q I
MZ;!\LFMT34>'K.![,>=%#(\='E\Q4??TEUG/7H(PK8>_R43]-<#JUV5?4$L#
M!!0    ( #>(K5 +C]@#(0$  %<$   3    6T-O;G1E;G1?5'EP97-=+GAM
M;+5434_#, S]*U.O:,W@P %MNP!7F 1_("1N&S5?LKW1_7O<;D-B*F)HVR6)
M\^SW7A(K\_=M!IITP4=:% US?E"*3 -!4YDR1$&JA$&SA%BKK$VK:U!WL]F]
M,BDR1)YRSU$LYT]0Z;7GR>-NOZ=>%#IG[XQFEZ+:1'M$.MT3E@A^R*'&9;J1
MA&+RW D+R=ZB$)0*=8+"<6$?2]WK!A"=A7]92U7E#-ADUD%*2LH(VE(#P,&7
MU&@$^\;H8KWWN]+(+SH(L>J\^I%07L\';SV,&QB02RJSM 6,20W ;KP]2_#0
M#28A3#,*BNQ&CB>65H*2ZA,O>43H6\>"/4E<J*_WL)\)VV$]=N'?(*EA.N_6
M_VATF<N@7?S-R$=*[4%?#?_)\@M02P$"% ,4    "  WB*U0'R// \     3
M @  "P              @ $     7W)E;',O+G)E;'-02P$"% ,4    "  W
MB*U0)^B'#H(   "Q    $               @ 'I    9&]C4')O<',O87!P
M+GAM;%!+ 0(4 Q0    ( #>(K5!=.0.A[0   "L"   1              "
M 9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( #>(K5"97)PC$ 8
M )PG   3              "  ;4"  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ -XBM4((SFO>= @  DPL  !@              ( !]@@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( #>(K5#%UV*E20(
M -X%   4              "  <D+  !X;"]S:&%R9613=')I;F=S+GAM;%!+
M 0(4 Q0    ( #>(K5"ZH3F*UP$  #(&   -              "  40.  !X
M;"]S='EL97,N>&UL4$L! A0#%     @ -XBM4# #][XW 0  (@(   \
M         ( !1A   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( #>(K5#_
MP"8(O0   (4"   :              "  :H1  !X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( #>(K5 +C]@#(0$  %<$   3
M      "  9\2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     *  H @ (
' /$3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0000947871-20-000458-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000947871-20-000458-xbrl.zip
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MK72#R_6&ZD2QF:-3@W='":1\BDJYPAL*[/6OZ8E.F.NUZY"[\E)W,#Q2>(H
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M]W&<35P>HN(5 QR5ZE<OT+U*PV4C(F-04\=*8SPYL@@E03::G* ;I//C_^K
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MY@JMA-D4& ,J&S=1F<\.=]!-"P&*<00<9Y>HO"Y2,')'425""NVV?].R#[3
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M&C#DEROJD]1D4O0P:@W3S,[Y+[ZO1I'TC6GN4\/6!&F,2PVXG,/%4F&4H:3
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M9?0@K4ASKC/:76<T!2OK6<'$7\YM'S1G#AFSGL_%F -<?6#9 ]Y::/!3J1Y
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M4R7I=1Z.9K?.;6C-RAR377\SP%4:;DP:#YTF3/.2AM%=G!X]6;OB[!2U+$^
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M?W@1A1>KB,)=1A2V5A&%AW<[YXTHZ+:83L-'X8PP>L"%]-()4;= ))<@NLN
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MH0+>(QH61Q),%UO-9/DXFK8?[$*;B=AFH=CT2GU6B[57!-;" )M5L-L]#E!
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M=XO?N^NZ>%?<*CN608[\*R%Q!MCU,&GQAX**:%?YZK>0<U#?-,*C(\-5DOI
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M,.\^-VEW8(M$^7>U ]I(4# !UA+S6@\0]WAV.8+> .!)U4GV9CD#(=?HFQ)
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M**U9\2+L4["\]D3(LRVO A'R9 OK,80\S\K*"&'/%URD(.19EM<+B/W*:GU
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M,/E:55<B"\>)PRV2V/"%.7\>N=;-VQ_Y%(W<GX*R8H4@]^\'BIX>TRP0@88
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M^;1/!3A1&F=Y(=L1\N+R1VH]AM/ BX1C7TY&O:!@]8<ZX(26D127]KCS^O&
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M8&%E\BD?#8*@JB3I-OP5>W+;P"<3XZZU+RENF;F3>9@G-6P4:,C$C7((VR,
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MNVA,/H,DSB^OBAI_0ZH1H/5&UEAD5O8PJL:]DJ4QAL_^BDJ5V5<)59R*Y&N
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MIJWI\'@27WLAQTX7S#R5QAK:+"W2L@$MF*@DK>!C<A.X\'I-[<%:.HEB6WY
MMBS.Z@?>B;5=T2))-C3\UEHX!PO%W^8<*32U(E.U-4/9LF@)\G+@2.NUR)MR
M H/'*_-]YW#YE['<D3&5Q\._Y /JG,V^'J\PT1,(.FWEC>GY(S^X1HDG%4?
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M#WNP0O[WK--'0M3JML\_]U=NZ3^;^>[O_&P7V7)N_!'$PH0:')]Z-VN1V#U
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M% +ED5Z]FD^-JPBB\3@5S032H:A>(-HV0H@+PXHHK'60DRQZ0[OUQ)$,.IT
M+Z#VEMBV]_+23RC4@81>EJ0^JS;-4J*5;3>7C\!2<\-QO%G]MF68*MPE&6$\
M!!89H0<XEP.;]%+?CH-U.D4[SMNU$VE!S?"]E!M6 AH?Q7"22/W-]W0O]=K
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M@[-$7;FL9V],?K4Q)F^,R<_$F/SB@QM4H_QI9?35Y,A+*7&7Y*!Z;5%$ AN
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M9[0[S<87T+YA$IL3VFDMO6V 5BMO=,Y*IO&1Q5L%(0:KN"S;+KK3\FNSX86
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M4EU4SKL@_X&H#\ B->$=PW)'07IKZ\G*2*/A8RNVGZR3"H#1*JMVU11?JOQ
MC):IHK9;CG5P(*YDK+Q9K@RIO5??M%GNHB<?D^%#*3='M_2'U(Q/V.\14Z;@
MUQXC,;UMCQ4%Y#XB92&7MC+JIZP,9=VL.P7[8-VCUQC73T0G]>[U)5S^JR%E
M;% UYB@HUE(85\>H!,8FY/2,3=,E',8Z!B^IN?$CW"MV<?V[ D':K^,X3U0%
ME!UQC3Q9K2!:HAS%"2H6J)!!ADX\&RJJ)67?N2JG!"$W-%CI)P@\MJLF"&?#
M 5*Z0EV4!$ONZ&7N9B;3O_IRG1,XU_&H$PSZ YHV0* 9H%=P\I<9=?U@\0Y5
M"369S48-:JG4(N'6#E"@^UQFV@"S)RKDX0!W3<X/!WB 6-1$A414?+>*=KU4
MXPG'G^<_]!47&H/$0?/>&C=4L"5T%%_)I)+  5V[XZ+).M""(KE&F:(.RY*J
MS4%_/_?+?/=&H-DJ;;C*6VNB5NF-:SM<*8E6D5HO.-5TQJIS2L8\:$5O'O"<
M+)U%"N%F8FT==U!H-7 J8I:)240ZITW^!+4,""5/D!<A&(S3>IB?FXV%29["
M7Q#<*-><CDHC56:  W*213DIYU)'-#?@%A?FAR)\!8<J"3Y9M+8!>CT_+%DK
M%/_20]4_H=<Y@P?& %:J8U?=KN1JBI0520[=$.X8F31FW;+7F0_#&V9IB;FV
MVNW_H0(7/8G-C(D[[\@/PO4J=Y-9%-7<?1J2-/7*]QLN:FE\6<W^K>]2M*7Y
M77TV5( <8))&-EB "..V<((6Q);#"5AV <!K1\9PC;JBVQ&W*#L)BXA&(!DO
M$!U$C>()=1'-8F@:");HP0)J/Y-/4"PGHS9%VO83&EF-+\F 15,T4TOAN\90
MU? :13>/15;-)#K@(,\RPC?R@YC[.]*#>>/+0+#T.4+ZI@LN/8:L:F)K='5"
M8TCJYNQ;?Y_>!64TM&& 8*$"GCY!"Y9;.(!.V5J78U!NV*$9=!8D.E!<<U,;
M:IH'<>M[^RD.9!")I4'19.0NSU3%I-#2:FK-,]Z6&",:2QM'.B;\HO:A11,%
MMG.Q\4%;PF+$\!1PL3R.X'E<B?> YA#)PZXDX.%#JORH%XHL!*SE&"B2S##U
MRH8A(KFP.;WXPO(R^<C2,.5Q$!B.$K=*YAI-%5%:/8S4>P)W'&*L>7+6@CPZ
M'N>0K,IKG!'9#0,S37C(3U[8;-0G(66*J0 I0$,_51P^M3-D:HHBJ!"1E]!Q
MX>#^WDRG!<KY-PR<U%*YY$^>*E*>XYDEO:534RJB*$4G*BL\!4?+. 9I8A)J
M"T)4[Q2SAM6X/ ;6<563.'C11$=8-.!)"0(S-9FC*N2,9@>];OM'7VDEM0'N
MBE2S8?.QY4)\1>JG'%*I#->>FJV3^XG)G12Q]>&"E^T?U\L68]7#DWSW+C?N
MX#BWFMYHM/QEL^$_*1+$F5="\:C8<.*!AE[=%,]]>-"KGH$/CS/O>;?>,8O=
M)+#_>EG'AZ$7JZS\!B@LEI; $DHZTPE0"U%*%99_.<2+;E<Q=YTJ_[*U9&,+
M8/%*-AP?K)UO>"CZR&O]Z_O;D]-'YB?_0SKXWV-\QJB?,8#5:L+]9N-C3\10
M)0"D2[-,](Q>6C\<JSV[1-<@G^^+O=VM]HM^M]U_V>U"WIE<).(8R!X\NNN<
M<PW0H;YSK]O];._0/_MO&_Y/\",_W_(CI[7?;_TN)G["TWUDPL.CG/YG/,9C
M@\C;/%+M<ACTL2GCUB/2\;W:\&]C;7=]$%@;1S*U![/(4KTTJBK^UD=5:R)^
M$8ORL-S_/N]PL_A)WW\!4$L! A0#%     @ -XBM4)76(08_ P  <0P  !
M             ( !     &1G>"TR,#(P,#4Q,2YX<V102P$"% ,4    "  W
MB*U0NWUYW_P*  #?AP  %               @ %M P  9&=X+3(P,C P-3$Q
M7VQA8BYX;6Q02P$"% ,4    "  WB*U0+HD#75 '   A60  %
M    @ &;#@  9&=X+3(P,C P-3$Q7W!R92YX;6Q02P$"% ,4    "  WB*U0
M"J&^=IT7   <DP  #P              @ $=%@  <W,Q-S,U,3%?.&LN:'1M
M4$L! A0#%     @ -XBM4,B699">D    %\$ !,              ( !YRT
M '-S,3<S-3$Q7V5X,#$P,2YH=&U02P$"% ,4    "  WB*U0:0>/.C!5  "C
M2P( $P              @ &VO@  <W,Q-S,U,3%?97@P-# R+FAT;5!+ 0(4
M Q0    ( #>(K5!\T6&VZQ,  (%Y   3              "  1<4 0!S<S$W
M,S4Q,5]E># U,#$N:'1M4$L! A0#%     @ -XBM4,841<\J#   VR<  !,
M             ( !,R@! '-S,3<S-3$Q7V5X.3DP,2YH=&U02P4&      @
,"  # @  CC0!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ss173511_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://DGX/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="ss173511_8k.htm">ss173511_8k.htm</File>
    <File>dgx-20200511.xsd</File>
    <File>dgx-20200511_lab.xml</File>
    <File>dgx-20200511_pre.xml</File>
    <File>ss173511_ex0101.htm</File>
    <File>ss173511_ex0402.htm</File>
    <File>ss173511_ex0501.htm</File>
    <File>ss173511_ex9901.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>ss173511_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="dgx-20200511.xsd" xlink:type="simple"/>
    <context id="From2020-05-11to2020-05-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
        </entity>
        <period>
            <startDate>2020-05-11</startDate>
            <endDate>2020-05-11</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2020-05-11to2020-05-11">0001022079</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-05-11to2020-05-11">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2020-05-11to2020-05-11">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2020-05-11to2020-05-11">2020-05-11</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2020-05-11to2020-05-11">Quest Diagnostics Incorporated</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2020-05-11to2020-05-11">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2020-05-11to2020-05-11">001-12215</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2020-05-11to2020-05-11">16-1387862</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2020-05-11to2020-05-11">500 Plaza Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2020-05-11to2020-05-11">Secaucus</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2020-05-11to2020-05-11">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2020-05-11to2020-05-11">07094</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2020-05-11to2020-05-11">(973)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2020-05-11to2020-05-11">520-2700</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2020-05-11to2020-05-11">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2020-05-11to2020-05-11">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2020-05-11to2020-05-11">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2020-05-11to2020-05-11">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2020-05-11to2020-05-11">Common Stock, $0.01 Par Value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2020-05-11to2020-05-11">DGX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2020-05-11to2020-05-11">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2020-05-11to2020-05-11">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
